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Background: The role of P2X7R in the immune response has been investigated and 
this receptor clearly has important roles in inflammation. However, the mechanisms 
which integrate P2X7R activation with biochemical changes in T lymphocytes such 
as: proliferation, migration and regulation of adhesion molecule expression are less 
well understood. Many of these processes are controlled by the PI3K pathway, which 
is an important signalling cascade involved in development and immunity that it is 
frequently altered in disease. This study sought to investigate if PI3K was responsible 
for integrating P2X7R dependent signalling in primary human T lymphocytes, with an 
emphasis on regulation of the adhesion molecule CD62L. 
Results: Whole cell patch clamp electrophysiology is an important technique for 
characterising ion channel expression. This technique was optimised for the first time 
in primary human naïve CD4
+
 T lymphocytes and used to show P2X7R expression in 
this study. The pharmacology of ATP in the process of CD62L down-regulation in 
these cells was explored using new P2X7R antagonists with improved selectivity over 
previous compounds. Remarkably, PI3K/mTOR, MAPK and PKC signalling was 
shown to be dispensable for this down-regulation of cell surface CD62L expression. 
However, while investigating novel mechanisms for ATP induced CD62L down-
regulation, it was revealed that pharmacological modulation of mitochondrial complex 
I or III, but not inhibition of NADPH oxidase, enhanced P2X7R dependent CD62L 
down-regulation by increasing ATP potency. The mechanism for this was further 
explored and this effect may arise from enhanced superoxide generation in the 
mitochondria of rotenone and antimycin A treated cells. Crucially, although ATP alone 
did not cause apoptosis of cell, perturbation of the mitochondria of cell with these 
compounds followed by ATP treatment, revealed P2X7R exposure of phosphatidyl 
serine. 
Discussion: This major new finding may have implications for the clearance of naïve 
CD4
+
 T lymphocytes which have undergone mitochondrial damage. A novel protective 
mechanism for the potential removal of cells with damaged mitochondria is presented, 
whereby, P2X7R dependent PS exposure occurs only when cells have enhanced 
mitochondrial ROS generation. Given the potential role of P2X7R in a number of 
diseases with a mitochondrial element, the findings of this thesis are of great 
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1.1. The Immune System 
The immune system exists as an evolved mechanism to protect organisms from 
infection. It comprises organs, tissues, cells and small soluble factors which 
interact to maintain a homeostatic healthy organism. Some factors are relatively 
static, for instance skin and epithelial cells act as barriers to infection, whereas 
others are induced and act rapidly such as the recruitment of cells to sites of 
infection. The response of immune cells to pathogens is termed inflammation 
(Figure 1.1). Inflammation is heavily regulated and de-regulation can result in poor 
immunity and susceptibility to pathogens, or over reactive immunity which can 
lead to chronic inflammation and auto-immune disorders. Resolution of 
inflammation is therefore critical and involves the suppression of the immune 
response and the remodelling and repair of damaged tissue and vasculature (1). 
At this stage “memory” of previous infections can also be acquired through the 
maintenance of a pool of specially developed memory cell subsets. This process 
is exploited by pharmaceutical companies and medical professionals to produce 
vaccinations against diseases (2). In addition, the immune system plays a critical 
role in immune surveillance to detect the presence of transformed cancerous cells 
and tissues in the body (3). Cells of the immune system themselves are, however, 
susceptible to forming cancers such as leukaemia and lymphomas; as well as 
infection by viruses including Human Immunodeficiency Virus (HIV) (4, 5). 
1.1.1. Innate Immunity 
The first line of defence against pathogens is innate immunity which consists of 
anatomical barriers to disease, such as the skin and the epithelial cells lining the 
lungs and gut. Additional to barrier function, these cells are also able to actively 
release a number of factors including cytokines, chemokines and can activate the 
complement system. These cells, when damaged by pathogens, can also release 
their contents including reactive oxygen species (ROS) and damage associated 
molecular patterns (DAMPs). One such DAMP is the molecule Adenosine 
Triphosphate (ATP). Resident macrophages and mast cells, which reside in the 
surrounding connective tissue, express receptors called Toll Like Receptors 
(TLRs) on their surface. TLRs are able to recognise DAMPs along with pathogen 
associated molecular patterns (PAMPs) (6). Fc receptors, which can recognise 
PAMPs in complex with antibodies, are also expressed on these cells. Receptor 




ligation activates macrophages, which opsonise pathogens by a process termed 
phagocytosis, and mast cells, which can undergo de-granulation to release their 
inflammatory contents. This latter process by mast cells is largely responsible for 
allergic responses in mammals (7, 8). Macrophages and mast cells can also 
release cytokines and soluble chemokines into the surrounding tissue and 
vasculature. Chemokines can also be expressed on the surface of epithelial cells 
or released from these cells following activation of TLRs (9). Chemokines act to 
recruit cells of the innate immune system including neutrophils, eosinophils, 
basophils and further monocytes/macrophages; this process of cell migration 
termed chemotaxis will be described further in following sections (10). Cytokines 
activate and cause the differentiation and proliferation of these infiltrating cells. 
Once neutrophils encounter pathogens they employ phagocytosis, produce 
elastase and generate ROS, as part of the respiratory burst to destroy bacteria 
and resolve infection (11). Infiltrating macrophages can develop along multiple 
distinct lineages but can be broadly defined as being classically activated (MI) or 
alternatively activated (MII). Pro-inflammatory MI macrophages differentiate to 
produce cytokines including: Interferon γ (IFNγ), Interleukin 6 (IL-6), IL-12 and 
Tumour Necrosis Factor (TNF); whereas, MII macrophages are anti-inflammatory 
and promote wound healing through the production of IL-10 and Tumour Growth 
Factor β (TGF-β) (12). Macrophages, along with dendritic cells, are an important 
bridge between the innate and adaptive immune system. These cells express 
major histocompatability (MHC) molecules on their cell surface which allows 
presentation of antigenic components of bacteria to T lymphocytes (13). Once 
antigen has been immobilised on their surface, dendritic cells migrate into the 
lymphatic system through draining lymph nodes where they encounter resting 
(naïve) cells of the adaptive immune system (14, 15). Antigen is presented and, if 
the cognate receptor specific for that pathogen is present on the adaptive immune 
cell, the cell becomes activated, clonally expands and an adaptive immune 
response is initiated. 
1.1.2. Adaptive Immunity 
The adaptive immune response by lymphocytes can be broadly divided into 
cellular and humoral responses. B lymphocytes are involved in humoral immunity, 
whereas, specific T lymphocyte subsets (which will be discussed in detail in the 




following section) can act as mediators of cellular or humoral immunity. B 
lymphocytes are produced in the bone marrow and mature in situ. Mature, but un-
activated, naïve B lymphocytes circulate through the lymphatic system, until they 
encounter antigen specific for membrane bound antibody also termed the B cell 
receptor (BCR). Activation of B lymphocytes in response to antigen induces 
proliferation, maturation and class switching of cell surface antibodies. The type of 
antibody expressed, or released by B lymphocytes, as well as their interaction with 
T lymphocytes and macrophages, helps to determine the specific adaptive 
immune response. Antibodies released by B lymphocytes have multiple roles in 
the adaptive immune response including activation of the complement system, 





























Figure 1.1: Innate and Adaptive Immunity. 1. Skin provides an essential barrier 
to infection, but when broken pathogens such as bacteria can enter and cause 
infection. 2. Resident tissue macrophages and mast cells recognise antigenic 
components, they then release chemokines and cytokines to recruit and activate 
circulating phagocytes. 3. Phagocytes opsonise bacteria and release factors such 
as elastase, leukotriene and histamine, which is also released by mast cells. 4. 
Dendritic cells are professional antigen presenting cells (APCs) which opsonise 
bacteria and travel through draining lymph to secondary lymphoid organs (SLOs). 
5. Here, dendritic cells present antigenic bacterial components to lymphocytes 
expressing cognate receptors. 6. These cells become activated, clonally expand 
and enter the vasculature where they migrate to peripheral sites of infection. 7. 
Lymphocytes are part of the adaptive arm of the immune response and can bring 
about cell mediated (cytotoxic) or humoral (B cell antibody mediated) killing of 
bacteria and bacterially infected cells. Finally, the infection is resolved and the 
wound (1) is repaired. 




1.2. T Lymphocytes 
1.2.1. T lymphocyte maturation 
T lymphocyte precursors are produced in the bone marrow and migrate to the 
thymus, where they mature from double negative (CD4-/CD8-) to either single 
positive CD4+ or CD8+ cells expressing the αβ T cell receptor (TCR) (Figure 1.2). 
The CD4 and CD8 molecules aid binding of T lymphocytes to class II and class I 
MHC molecules respectively. Double negative cells may also form a 
subpopulation of γδ T cells, named due to their expression of only the γ and δ 
chains of the TCR. Somatic gene rearrangement of the V, D and J components of 
the TCR by the enzymes RAG1 and RAG2 in the thymus is essential for 
production of a plethora of structurally distinct TCRs. These TCRs are specific 
only for one antigenic component, and the naïve T lymphocytes produced are only 
activated once they encounter this specific antigen presented by an APC.  
Naïve T lymphocytes have a distinct phenotype characterised by high levels of 
surface L-selectin (CD62L) expression, expression of the RB isoform of protein 
tyrosine phosphatase receptor type C (CD45RB) and low levels of the glycoprotein 
CD44 (16). Naïve cells exist in this CD62Lhigh, CD45RBhigh, and CD44low state and 
survey the lymphatic system for antigen (17, 18). Prior to antigen presentation, 
naïve CD4+ cells undergo homeostatic proliferation in response to IL-7. Naïve 
CD8+ cells respond more robustly to IL-7 and, while the cytokines IL-4 and IL-15 
also enhance proliferation, IL-7 is indispensable (19, 20). IL-7 can also drive the 
transition of naïve (independent of antigen) and effector T cells into a memory 
phenotype (16, 21). IL-7 levels are carefully controlled to maintain proliferation of 
naïve T cells, however, acting as a co-stimulant IL-7 can drive T cell autoimmune 
disease (22).  
















Figure 1.2: T lymphocyte maturation. 1. T lymphocytes originate from 
hematopoietic stem cells (HSCs) which are produced in the bone marrow and 
develop into common lymphoid precursor cells (CLPs). 2. CLPs migrate to the 
thymus where they develop into committed T-cell precursors (TCPs). These 
thymocytes are double negative (DN) as they do not express either the CD4 or 
CD8 co-receptors on their cell surface. C-Kit+, CD44high, CD25- D1 thymocytes 
develop into DN2 cells which gain CD25 expression and lower the levels of cell 
surface CD44. 3. At the DN2 stage, the TCR components begin to rearrange 
forming either DN3 thymocytes or T lymphocytes which eventually express the γδ 
TCR (4). C-Kit-, CD44-, CD25+ DN3 cells, in contrast, express TCRβ and pre-
TCRα in complex with CD3. 5. CD25 expression is lost at the DN4 stage and, as 
both the CD4 and CD8 co-receptors are expressed, cells become double positive 
(DP). 6. Positive selection allows the progression of DP cells which can bind MHC 
expressed by epithelial cells 7. DP cells that bind MHC too readily are removed by 
apoptosis through the process of negative selection. 8. Finally, single positive 
CD4+ or CD8+ cells are produced and leave the thymus. 




1.3. T cell activation 
1.3.1. TCR 
As described above, the TCR is assembled in a RAG1/2 dependent manner from 
V, D, and J elements by somatic gene rearrangement. Once mature, the TCR 
forms a membrane complex with constant cell surface CD3γ, δ and two ε co-
receptors as well as two intracellular CD3 ζ elements. These form a complete TCR 
complex as described in the figure below (Figure 1.3). Activation of a T cell is a 
two signal system, it requires formation of an immunological synapse involving 
both presentation of cognate peptide to the TCR by the MHC of an APC, and the 
co-stimulation of CD28 by B7 family ligands expressed on the surface of the APC 
(Figure 1.4). Super-antigens such as staphylococcal enterotoxin B (SEB) act 
independent of MHC to activate a large number of αβTCR T lymphocytes, 
irrespective of the antigen specificity of these cells (23). As well as co-stimulatory 
signals, co-inhibitory receptors expressed by T lymphocytes can respond to 
ligands expressed on the surface of APCs (Figure 1.4). If co-stimulation is absent, 
T lymphocytes become anergic (24). Activated T cells up-regulate CTLA-4 which 
also acts as a co-receptor for B7 family ligands; ligation of CTLA-4 results in 
inhibition of T cell function and this is an important step in resolution of adaptive 
immunity (25). This inhibition of T cell function by CTLA-4 forms a strategy for the 
treatment of auto-immune disorders and cancer (26–28). Antigen presentation and 
co-stimulation of T lymphocytes induces activation by initiating a complex 
signalling cascade involving multiple kinases, increases in free intracellular 
calcium levels followed by changes in gene transcription and finally global 






















Figure 1.3: Signalling mechanisms down-stream of T lymphocyte activation. 1. 
Following engagement of the TCR with antigen presented by an APC and presentation 
of co-stimulatory ligands the sequential activation of a number of signalling pathways 
occurs. 2. CD3 subunits contain ITAMs which are phosphorylated by Fyn and p56Lck 
allowing the recruitment of ZAP70. 3. ZAP70 becomes tyrosine phosphorylated and 
phosphorylates SLP76 and LAT. 4. These act as linkers to recruit PLCγ brings it into 
close proximity with its substrate PI(4,5)P2 which is hydrolysed into IP3 and DAG. 5. IP3 
acts on IP3 receptors on the ER which allow release of calcium. 6. Raised intracellular 
calcium levels, along with DAG in the plasma membrane, activate PKC. 7. Calcium 
release from the ER also causes association of STIM with ORAI channels in the plasma 
membrane which allow influx of calcium, further raising intracellular levels. 8. Free 
calcium (Ca2+) also acts through Calcineurin to activate the transcription factor Nuclear 
Factor of Activated T cells (NFAT) leading to IL-2 synthesis. 9. PKC and GRB2/SOS 
activate the Ras/Erk1/2 pathway. 10. Activation of the TCR/CD3 complex, as well as 
engagement of the co-stimulatory receptor CD28 by B7 family ligands on the APC 
surface, recruits the class I PI3Kδ (as well as PI3Kγ). 11. The PI3K signalling cascade 
is important for proliferation and survival of T lymphocytes and can feed into the mTOR 
pathway which controls protein synthesis (12) 


















Figure 1.4: Role of co-stimulatory, co-inhibitory receptors and cognate 
ligands on antigen presenting cells. The TCR is engaged by antigen presented 
by MHC molecules on an APC and T cell activation is initiated. The ultimate fate of 
the T cell depends on the mechanism of co-stimulation provided by the APC. 
Activation of CD28 and ICOS expressed by T lymphocytes promotes the activation 
of these cells (black arrows) whereas activation of CTLA-4, PD-1 or BTLA causes 
inhibition of T lymphocyte activation and eventual anergy (red arrows). 




1.3.2. Signalling down-stream of the TCR 
1.3.2.1. ITAMs 
CD3 and CD28 co-receptors contain immunoreceptor tyrosine-based activation 
motifs (ITAMs) on their intracellular tails, these have the common sequence:   
YxxLx(7-12)YxxL. This sequence becomes phosphorylated by p56Lck and Fyn 
following engagement of peptide-MHC with TCR. These ITAMs act to recruit a 
number of signalling components. The first of these is ZAP70 which is tyrosine 
phosphorylated and in turn phosphorylates SLP76 and LAT; these act as linkers to 
recruit a complex of signalling molecules including: VAV1, ITK, GRB2, SOS and 
PLCγ.  
1.3.2.2. PLC and PKC 
PLCγ recruitment to the membrane brings it into close contact with its substrate 
phosphatidylinositol(4,5)bisphosphate (PI[4,5]P2), which is hydrolysed by PLCγ to 
form the membrane anchored substrate diacylglycerol (DAG) and 
inositol(1,4,5)trisphosphate (IP[1,4,5]P3). These second messengers activate 
conventional α, β and γ isoforms of the Protein Kinase C (PKC) family. DAG 
anchors PKC at the inner leaflet of the plasma membrane and IP[1,4,5]P3 acts to 
open calcium release channels on the endoplasmic reticulum. Two ions of free 
Ca2+ bind to each PKC protein in a region that is revealed by a conformational 
change in the protein following DAG binding. Recently the novel PKC isoforms θ, ε 
and η (but not δ), which are activated by Ca2+ alone, were shown to be required 
for re-localisation of the microtubule-organising centre (MTOC) to the 
immunological synapse after T lymphocyte activation (29, 30). GRB2 and SOS, 
along with PKCθ, activate the GTPase Ras which has multiple roles in cell growth 
(31, 32). Other PKC substrates include PKD1 which associates with a complex 
containing adhesion and degranulation promoting adaptor protein (ADAP) and 
SLP76 and RAPL which is responsible for integrin activation (33). Integrin 
activation allows the adhesion of T cells to APCs during activation and/or the 
surface of the endothelium.  
1.3.2.3. PI3K and mTOR 
The phosphoinositide 3-kinase (PI3K) family of lipid kinases has four distinct 
classes: I, II, III and IV. Little is known about class II and III PI3Ks in T lymphocyte 




activation but the class I and mammalian Target of Rapamycin (mTOR), a class IV 
enzyme, have been extensively studied. Class IA PI3K isoforms are composed of 
regulatory subunits p85α, p55γ, p50α, p85β, or p55γ in complex with catalytic 
p110 α, β or δ subunits (Figure 1.5). The single class IB p110γ catalytic subunit is 
associated with p84/p87 or p101 regulatory subunits. Classically class IA PI3Ks 
are activated down-stream of a number of cell surface receptor tyrosine kinases 
(RTKs) including: antigen and co-stimulatory receptors, Fc receptors, adhesion 
molecules, TLRs and cytokine receptors (34) (Figure 1.6). Whereas, the p110γ 
catalytic subunit is activated by chemoattractant receptors including those for the 
ligands C5a, N-formylmethionyl-leucyl-phenylalanine (fMLP), chemokines and 
sphingosine-1-phosphate (S1P) (14). Promiscuity between Class I PI3Ks and 
receptor types is a new concept, growing evidence has shown that p110β can be 
activated through G-Protein Coupled Receptors (GPCRs) and p110γ can be 
activated via the TCR complex (35, 36). 
In the context of TCR signalling, regulatory p85 subunits are recruited to the 
membrane along with the p110δ catalytic subunit, by the LAT, TRIM and other 
adaptors (37). PI3K can also be directly activated by the co-stimulatory CD28 and 
ICOS molecules (38). In T lymphocytes p110δ is largely responsible for integrating 
signalling downstream of the TCR (39, 40) although there is increasing evidence 
that p110γ may also play a role (35). Both p110δ and γ have distinct and 
overlapping roles in T lymphocyte function which will be mentioned briefly in the 
























Figure 1.5: Class IA and IB PI3K isoforms. The genes PIK3C1, PIK3C2, 
PIK3C3 and PIK3CG encode the catalytic p110 α, β, δ and γ isoforms of the 
class I PI3K family. These catalytic subunits contain a number of important 
structural domains including: an N-terminal adaptor binding domain (ABD), a 
Ras binding domain (RBD) and a core structure comprising the C2, helical and 
kinase domains. Class IA PI3K catalytic subunits can associate with either p85α, 
p55α or p50α all encoded by PIK3R1 or p85β (PI3KR2) or p55γ (PI3KR3). 
These regulatory proteins have two proline rich SH3 domains, one Sh2 domain 
and a p110 binding domain. The single class IB p110γ associates with p101 
encoded by PI3KR5 or the PIK3R6 proteins p84 or p87.  





Upon activation of class I PI3K, the substrate PI(4,5)P2 is phosphorylated at the 
D3 position to produce the product phosphatidylinositol(3,4,5)trisphosphate 
(PI[3,4,5]P3). An increase in PI(3,4,5)P3 levels in the cell membrane is observed 
following T cell activation and PI(3,4,5)P3 acts to recruit signalling molecules which 
contain the pleckstrin homology (PH) domain to the plasma membrane (41). 
These PH domain containing proteins include Phosphoinositide-dependent 
kinase-1 (PDK1) which, along with mammalian Target Of Rapamycin complex 2 
(mTORC2), activates Akt/Protein Kinase B (PKB). Akt is one of the most 
commonly studied substrates of PI3K and controls cell survival, growth, 
proliferation and processes such as migration (42). There are three isoforms of 
Akt: 1, 2 and 3 encoded by distinct genes; Akt 1 and 2 are ubiquitously expressed 
but Akt 3 has a more restricted expression profile (43). It is becoming increasingly 
apparent that these Akt isoforms have differing substrate profiles and may 
regulate cellular processes by different mechanisms. For example, in a model of 
invasive carcinoma siRNA targeting Akt1 results in increased migration, whereas, 
targeting Akt2 decreases migration (44, 45). Substrates phosphorylated only by 
Akt1 include: P21 cip1, SKP2 (46, 47) and paladin; Akt2 phosphorylates MDM2 
and AS160 however a large number of substrates, such as BAD and GSK3β, are 
phosphorylated by both Akt1 and 2. 
Full activation of Akt generally requires phosphorylation of both Ser473 by 
mTORC2 and Thr308 by PDK1. However, this may not be true for all Akt isoforms 
in all cell types (48). A recent study has also demonstrated that Akt can be 
phosphorylated and activated independently of PI3K by Inhibitor of NFκ-B Kinase 
subunit ε (IKBKE) (49). The Ser473 residue can also be de-phosphorylated by a 
family of PH domain leucine-rich repeat protein phosphatases (PHLPP) (50). PI3K 
signalling can also be terminated by the actions of phosphatase and tensin 
homolog(PTEN), which dephosphorylates PI(3,4,5)P3 to PI(4,5)P2. The Src 
homology 2 domain-containing inositol-5-phosphatase-1 (SHIP-1) 
dephosphorylates PI(3,4,5)P3 at the 5’ position to give the alternative PIP2, 
PI(3,4)P2
 and this may act to recruit PH domain containing proteins with a different 
specificity to PI(3,4,5)P3 (51, 52). 




mTOR is responsible for regulation of cell metabolism and protein synthesis and 
mTOR activity is important for T lymphocyte proliferation (53). mTOR can form two 
signalling complexes mTORC1 and mTORC2 which have different substrate 
specificities and sensitivities to inhibitors. Akt, through phosphorylation of TSC2 
and release of inhibition by Rheb, leads to activation of the protein complex 
mTORC1. mTORC1 activates S6Kinase which in turn inhibits 4EBP1 to promote 
cellular growth and proliferation. Much of what is known about mTORC1 has been 
garnered from the use of a naturally occurring compound called Rapamycin, an 
immunosuppressant. Rapamycin blocks the interaction between Raptor and 
mTOR in mTORC1, whereas mTORC2 contains Rictor in place of Raptor and is 






























Figure 1.6: PI3K/mTOR signalling. 1. Ligands activate cell surface receptors such 
as RTKs and GPCRs. 2. Classically class IA PI3K isoforms are activated down-
stream of RTKs and the single class IB PI3K isoform is activated down-stream of 
GPCRs. 3. Class I PI3Ks catalyse the addition of a phosphate group to the 3’ region 
of the inositol ring of PI(4,5)P2 to produce PI(3,4,5)P3. PIP3 acts as a membrane 
anchor for proteins with a PH domain. 4. The increased proximity of two such 
proteins PDK and Akt/PKB at the membrane leads to phosphorylation of T308 on 
Akt by PDK. 5. The kinase mTOR can form one of two signalling complexes: 
mTORC1 and mTORC2 the latter of which phosphorylates S473 on Akt leading to 
its activation. This residue can be de-phosphorylated by PHLPP. 6. Akt through its 
inhibition of TSC2 (an inhibitor of mTOR signalling) leads to activation of mTORC1. 
The PIP3 product of PI3K function can also be de-phosphorylated to PI(4,5)P2 and 
PI(3,4)P2 by the lipid phosphatases PTEN (7) and SHIP1 (8) respectively. PI(3,4)P2, 
in contrast to PI(4,5)P2, can also act as an anchor for PH domain containing 
proteins including several which PIP3 cannot bind. 




1.3.3. Inhibition of PI3K/mTOR pathway for the treatment of 
inflammatory and autoimmune disease 
As mentioned previously, deregulation of PI3K signalling can lead to the 
development and progression of diseases such as inflammatory and autoimmune 
disease and malignancies (54). The p110δ and γ isoforms of PI3K are expressed 
predominantly in cells of the immune system and control leukocyte activation, 
differentiation, migration and a whole host of other biochemical processes. Isoform 
and cell specific roles for PI3K have been investigated intensively using animal 
mouse models, where p110δ and/or γ have been knocked out or inactivated (55). 
The important role of these PI3K isoforms in disease has led to the development 
of PI3K inhibitors as novel therapeutics. Early efforts to target PI3K involved the 
natural compound Wortmannin and the first synthesised PI3K inhibitor LY294002 
(56, 57). These were both useful pharmacological tools; however multiple off 
target effects and toxicity limited their use as drugs (58, 59). Wortmannin and 
LY294002 are examples of Pan-isoform PI3K inhibitors, in that they target all four 
PI3K isoforms. Recently a large number of Pan-isoform PI3K inhibitors have been 
developed for the treatment of cancer, a number of these can be seen in Table 1.1 
below. However, the targeting of PI3K in inflammation and autoimmunity may 
require a more selective approach. While isoform specific PI3K inhibitors were 
initially thought impossible to achieve, a number of p110δ and γ selective (as well 
as dual p110δ/γ) inhibitors have been reported in the literature (Table 1.1). 
Recently the structure of p110δ in complex with PI3K inhibitors has been solved; 
this has provided insight into how isoform selectivity of compounds can be 
obtained (60). 
PI3K is not the only point of intervention in the signalling cascade to provide 
therapeutic potential. The mTORC1 inhibitor Rapamycin was one of the first 
immunosuppressive drugs developed and has been joined more recently by active 
site inhibitors of both mTORC1 and mTORC2 (61, 62). The PI3K effector molecule 
Akt can also be directly inhibited and this may overcome novel PI3K independent 
Akt activation mechanisms such as IKBKE (63–65). 
 




Compound Company Ref IC50 (µM) Structure 
   p110α p110β p110δ p110γ mTOR  
Wortmannin N/A (66) 0.0042  
 








(68) 0.003 0.033 0.003 0.075  
 
PIK-75  (69) 0.0058 1.3 0.51 0.076  
 
TGX-221  (70) n/a 0.005 n/a n/a  
 








(73) 0.06 0.27 0.3 0.008  
 
TG-100-115 TargeGen (74) 1.3 1.2 0.235 0.083  
 




(76) 0.356 0.736 3.225 1.774 1.06 
 
AZD8055 AstraZeneca (77) 3.59 18.9 3.2 >14.79 0.0008 
 
   Akt1 Akt2 Akt3  










Table 1.1 PI3K Inhibitors 
Details for inhibitors of the PI3K/mTOR pathway are given including: the 
companies responsible for their development, the IC50 values against Class I PI3K 
isoforms, mTOR or Akt as well as their chemical structure. Colour coding indicates 
the selectivity of compounds: Orange = Pan-PI3K, Blue = Isoform selective, Grey 
= Dual p110δ/γ selective, Purple = Pan-PI3K/mTOR, Green = mTOR and Red = 
Akt. 
1.4. Role of T lymphocyte subsets in adaptive immunity 
and inflammation 
After exiting the thymus and becoming activated, CD4+ T lymphocytes can 
differentiate into a number of different T helper (Th) subsets (Figure 1.7). This 
differentiation depends on the cytokine environment surrounding the cells during 
activation. Two distinct types of Th cell were initially described in the lab of Robert 
L Coffman, based upon the how they reacted to specific stimuli and the proteins 
they produced in response (78, 79). From this point, Th cells were either Th1 cells 
which facilitated cell based immunity or Th2 cells which were responsible for 
humoral immunity. This paradigm existed for almost 20 years before the discovery 
of a lineage of Th cells which responded to IL-23 and produced, among others, 
the cytokine IL-17. Each CD4+ sub group produces signature cytokines, which 
have specific roles in supporting the cell mediated or humoral arms of the adaptive 
immune response. For example, IL-4 produced by Th2 cells supports B 
lymphocytes whilst inhibiting the generation of Th1 cells. Unrestrained production 
of cytokines by Th cells can also drive inflammation; indeed, high levels of IL-17 
are observed in patients with inflammatory and auto-immune disorders including 
Rheumatoid Arthritis (RA). More recently several other Th subsets have been 
discovered including Th9 and Th22 cells (80–83). A suppressive T cell subset, 
regulatory T cells (Tregs), are characterised by the expression of the transcription 
factor FOXP3, high surface expression of CD25 and secretion of IL-10. Tregs help 
control tolerance to self-antigens and therefore play a key role in preventing 
autoimmune disease. There is on-going debate about the plasticity of these cell 




subsets, how they arise and whether they are terminally committed to a specific 
lineage (84–86). 
Naïve CD8+ T lymphocytes differentiate into cytotoxic T lymphocytes (CTLs) when 
they are activated. CTLs are responsible for detecting pathogen infected cells and 
survey for signs of cancerous cells. These infected cells, like most cells of the 
body, are capable of displaying antigen through MHC class I on their surface. 
Killing of infected cells by CTLs requires tight cell to cell contact followed by 
release of granules from the CTL. These granules contain perforin (a pore forming 
protein) and granzymes (serine proteases responsible for lysis of infected cells). 
CTLs also express Fas ligand (FasL) on their cell surface which, when in contact 
with Fas Receptor on the surface of infected cells, initiates the programmed cell 




Figure 1.7: T helper subsets generated following activation of naïve 
CD4+ (Th0) T lymphocytes. Cytokines required to “skew” to a specific 
subset in vitro are given in red. The signature chemokine receptor 
expression patterns are given in orange boxes and the typical cytokines 
released by these subsets are written in black. Abbreviations: Follicular T 
helper cell (Tfh) and regulatory T cell (Treg), 




1.5. T cell migration 
1.5.1. Circulation of T cells 
The trafficking of T lymphocytes is crucial for all stages of their development, 
activation and subsequent role as effectors of adaptive immunity, described in the 
previous sections (Figure 1.8). Stem cell precursors of thymocytes migrate from 
the bone marrow to the thymus for maturation. After maturation, naïve T 
lymphocytes constantly move through the circulatory and lymphatic systems 
where they survey resident and non-resident APCs for cognate antigen (87).  
SLOs have high levels of the chemokines CXCL13, which attracts naïve B 
lymphocytes and CXCL19 and CXCL21 which attract naïve T lymphocytes. The 
architecture of SLOs is specifically designed to facilitate the process of antigen 
surveillance (17) (Figure 1.9). There are two distinct areas of antigen presentation: 
in B cell follicles follicular dendritic cells present antigen; in the T cell zone it is 
dendritic cells originating from the bone marrow that are the primary APCs. 
Dendritic cells can circulate throughout the body, migrating through SLOs, or 
remain resident in SLOs (88). Naïve T lymphocytes first enter SLOs through high 
endothelial venules (HEVs) and then move into the T zone to survey antigen. If 
antigen is presented to cognate TCR on the T cells then they become activated in 
the manner described in the sections above. These activated T lymphocytes then 
undergo rapid proliferation by a process termed clonal expansion. A small number 
of T lymphocytes remain the SLO and aid B lymphocyte activation, proliferation 
and differentiation in germinal centres (GCs). Activated T lymphocytes down-
regulate surface expression of the adhesion molecule CD62L and sphingosine-1-
phosphate receptor 1 (S1P1), this allows their egress back into the vasculature 
(14). Up-regulation of chemokine receptors specific for ligand expressed by 
peripheral tissues allows the final migration into infected tissues. After resolution of 
inflammation the memory cells generated migrate either into the blood (effector 
memory) or to Spleen and SLOs (central memory) (89). 




 Figure 1.8: Circulation of T cells. T lymphocyte precursors are 
produced by haematopoiesis in the bone marrow and migrate to the 
thymus, where they mature from thymocytes into naïve T 
lymphocytes. Naïve T lymphocytes enter the blood and circulate 
through secondary lymphoid organs such as the spleen and lymph 
nodes, as well as extra lymphoid tissue including Peyer’s patches. 
Naïve T lymphocytes survey for APCs with cognate antigen to allow 
their activation and subsequent migration to the periphery. 
















Figure 1.9: Architecture of secondary lymphoid organs. 1. 
Dendritic cells drain into SLOs through the afferent lymphatic vessel. 
These cells migrate into the T cell zone where naïve T lymphocytes 
enter through the HEVs (2). 3. T lymphocytes become activated 
following antigen presentation and co-stimulation by dendritic cells. 4. A 
number of T lymphocytes enter specialised GCs where they aid the 
activation, proliferation and differentiation of B lymphocytes. 5. 
Activated T lymphocytes down-regulate CD62L and S1P1 to allow their 
egress through the medulla into circulation. 




1.5.2. Trans Endothelial Migration (TEM) 
Leukocytes are highly motile cells which can infiltrate into tissues; this is crucial to 
both the innate and adaptive immune response. However, un-restrained cell 
migration can contribute heavily to inflammatory and autoimmune diseases; 
therefore, the signalling mechanisms which underpin this process have been 
explored in great detail with therapeutic intervention in mind.  
Entry of naïve lymphocytes into SLOs requires the key migratory processes 
termed “capture and roll” and TEM. These processes are delicately orchestrated 
by chemokines, integrins and other adhesion molecules (Figure 1.10). Molecules 
with chemo-attractant properties can be expressed on the surface of cells, such as 
on the epithelium and endothelium, or secreted from cells. Leukocytes moving 
rapidly through blood vessels often come into contact with the endothelial wall 
under shear flow. Contact allows adhesion molecules to bind to their ligands. For 
example CD62L binds to its ligands which include peripheral node addressin 
(PNAD) which is a group of glycoproteins including CD34 (90) and glycosylation 
dependent cell adhesion molecule 1 (Glycam-1) (91), as well as mucosal vascular 
addressin cell adhesion molecule 1 (MAdCAM-1) (91). This rolling causes 
chemokine receptors such as CCR7 (highly expressed on naive CD4+ T 
lymphocytes) to become activated by their cognate ligands expressed on the HEV 
(CCL21 for CCR7 (92)). Activation allows binding of leukocyte function-associated 
antigen 1 (LFA-1) to intracellular adhesion molecule 1 (ICAM1) bringing about firm 
arrest of cells on the endothelium. Cells spread out and crawl across the 
endothelium searching for routes to cross the endothelial cell layer.  
During crawling, a cell will form a polarised morphology with a leading edge 
moving towards the source of chemokine and a trailing end termed the uropod. 
This allows reorganisation of the MTOC, as in formation of the immune synapse, 
and the mitochondria. In addition there is an organised distribution of signalling 
molecules within the cell, which occurs through mechanisms including plasma 
membrane lipid metabolism. This is achieved, in part, by the formation of a 
network of actin filaments at the leading edge of the cell which is driven by a 
signalling pathway which includes a number of Rho GTPases. Briefly, the 
guanine-nucleotide-exchange factors (GEFs) DOCK2 and Tiam1 as well as Cdc42 




activate Rac1. PIP3 accumulation catalysed by PI3K at the leading edge of cells 
and PTEN accumulation at the uropod is observed early on in cell migration (93, 
94). PI3K is indispensable for most leukocyte migration, but, for T lymphocytes it is 
only require for migration during a naïve and not activated state (95). The 
recruitment of Akt facilitates F-actin organisation through Rac1. Rac1, along with 
RhoA and the GEF Vav1, is also responsible for activation of LFA-1 through 
inside-out signalling (96). Activation of LFA-1 allows its interaction with ICAM-1 
and facilitates firm adhesion of cells to the endothelium. Finally cells cross the 
endothelium by transendothelial migration through a para or transcellular route, 
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Figure 1.10: Transendothelial migration of leukocytes. Leukocytes circulate 
through the blood under shear stress. 1. Selectins such as CD62L bind ligands 
expressed on endothelial cells and are captured onto the vessel wall. 2. Leukocytes 
then begin to slowly roll across the endothelial cells which express further selectin 
ligands as well as chemokines. This activates the leukocytes and causes up-
regulation of integrins on the surface. 3. These integrins LFA-1 and VLA-4 interact 
with the endothelial ligands ICAM-1 and VCAM-1 respectively. 4-5 Intracellular 
signalling mechanisms facilitate the spread and crawling of leukocytes across the 
endothelium. 6. Leukocytes finally cross the endothelium through either para- or 
trans-cellular routes, involving interaction between endothelial junction proteins or 
cytoskeleton respectively.  





As described above in section 1.2.1, CD62L, along with CCR7, expressed on 
naive CD4+ T lymphocytes have essential roles in homing of cells to and entry into 
SLOs. This is underscored by observations from the CD62L knockout mouse, 
which shows impaired rolling and homing of leukocytes (98–100). Consequently 
these mice show altered humoral immune responses (101), reduced skin allograft 
rejection (102) and impaired responses to inflammatory stimuli (99, 100). The 
inability of leukocytes to migrate via HEVs results in almost complete loss of 
leukocytes from the peripheral SLOs, and an increase in the number of these cells 
in the spleen (100). 
Use of an antibody (MEL-4), which blocked leukocyte adherence to HEV (103) led 
to the identification and cloning of mouse and human CD62L (104, 105); CD62L 
has since been cloned from a number of other organisms (106). The gene SELL 
on chromosome 1q23-q25 encodes the 372 amino acid protein CD62L; this is 
transcribed and translated into a protein of predicted molecular weight 42.19 KDa. 
Once trafficked to and expressed on the cell surface, CD62L can undergo 
extensive post-translational modification. As a consequence, when analysed by 
western blotting, the leukemic T cell line Jurkat showed CD62L banding of ~72 
KDa under non-reducing and 80 KDa under reducing conditions (107). Human 
lymphocytes isolated from serum show CD62L to be 74 kDa in size (108). In 
contrast, human neutrophils express a 70-120 KDa CD62L protein (107, 108). 
CD62L contains several structural domains with homology to other protein 
domains including: a low affinity IgE receptor like (C-lectin) domain, epidermal 
growth factor (EGF) like domain, two tandem short consensus repeats (SCRs), a 
trans-membrane domain and an intracellular portion (104) (Figure 1.11).  
1.5.4. Mechanisms of CD62L down-regulation 
Upon T lymphocyte activation levels of cell surface CD62L are down-regulated 
(109). T lymphocyte activation by antibodies against CD3 cause loss of surface 
CD62L expression; the cytokine IL-2 also causes CD62L loss (109, 110). 
Mitogens such as phytohaemagglutinin (PHA) (109) as well as polysaccharides 
(111), antibody (IgE) (112), peptide hormone (113), and phorbol 12-myristate 13-
acetate (PMA) can also cause CD62L down-regulation. CD62L down-regulation 




occurs via direct cleavage of CD62L from the cell surface and the silencing of 
CD62L gene expression (114, 115). The signalling mechanism regulating these 
processes involves serine/threonine kinases and these will be discussed in this 
section (Figure 1.13).  
The cleavage of CD62L from leukocytes was shown to be matrix 
metalloproteinase (MMP) dependent (116, 117) and the “sheddase” responsible 
for this, tumour necrosis factor-α converting enzyme (TACE/ADAM17), was first 
cloned in 1997 (118–120). A disintegrin and metalloproteinases (ADAMs) are a 
group of membrane bound proteins which possess a disintegrin-like domain 
(Figure 1.11) which can be involved in cell adhesion and a metalloproteinase 
domain which can cleave a variety of substrates shown in Figure 1.12. ADAM17 is 
the principle “sheddase” for CD62L; however, there is conflicting evidence that 
suggests ADAM10 may have an overlapping role in this process (121–124). 
ADAM protein is produced by the endoplasmic reticulum and inactive ADAM is 
trafficked to the cell surface where it becomes activated. A number of ADAMS 
including ADAM17 possess a motif which binds Zinc through cysteine thiol groups, 
when this is disrupted, for instance by ROS, Zinc binding ADAMs become 
activated (125). A number of signals can either influence ADAM trafficking or 
initiate their activation at the cell surface leading to processing of their substrates. 
Down-regulation of ADAM10/17 substrates by PMA is largely dependent on 
ADAM17 (122, 126). Increases in intracellular calcium can induce ADAM10 
activity and calcium ionophores such as Ionomycin cause substrate processing 
(122, 126, 127). Observations that PMA causes rapid and significant CD62L 
down-regulation from leukocytes led to the investigation of PKC as a mediator of 
CD62L loss. Indeed, PKC regulates CD62L down-regulation (111, 128) through 
direct phosphorylation of ADAM17 (129). The mitogen activated protein kinase 
(MAPK) p38 can also phosphorylate threonine residues in ADAM17 in response to 
the poison cantharidin (130). Activation of p38 results in increased ADAM17 
protein at the cell surface, the MAPK Erk1/2 also increases ADAM17 trafficking 
though threonine phosphorylation (131, 132). Inhibition of MAPK activity with the 
MEK-1 inhibitor PD98059 causes inhibition of CD62L loss in mouse T 
lymphocytes following treatment with antibody against CD3 (114).  




The same study by Sinclair et al. also highlighted important roles for the 
PI3K/mTOR pathway in CD62L down-regulation following CD4+ and CD8+ T 
lymphocyte activation by antibody, TCR peptide and cytokines (114). Using 
transgenic mouse CD8+ T lymphocytes which all recognise the peptide gp33-41, it 
was shown that CD62L down-regulation in response to TCR stimulation is Erk1/2 
dependent; whereas, IL-2 mediated CD62L loss is mTOR mediated. PI3K, 
specifically the p110δ catalytic subunit, is required for both TCR and IL-2 induced 
CD62L down-regulation. The lipid phosphatase PTEN negatively regulates PI3K 
signalling, loss of PTEN decreases, and gain of PTEN increases, cell surface 
CD62L expression (114, 133). As mentioned previously, Akt acts down-stream of 
PI3K, is regulated by mTOR and phosphorylates a broad range of substrates 
involved in migration and cell survival. Akt substrates include members of the 
transcription factor forkhead box subfamily O (FOXO). FOXO1 exists in an active 
state within the nucleus of naïve T lymphocytes and promotes CD62L expression 
through the transcription factor KLF2 (133–135). FOXO1 can be phosphorylated 
by activated Akt and this causes its re-localisation to the cytosol (136). Thus 
activation of the PI3K/mTOR signalling pathway can switch off transcription of 
CD62L as well as other KFL2 regulated genes, importantly CCR7 and S1P1 (115). 
It has therefore been suggested, that the immunosuppressant actions of 
Rapamycin may be, in part, due to maintained KLF2 mediated gene expression 
and retention of naïve T lymphocytes in SLOs (114, 137). 
Patients with acute myeloid leukaemia (AML) and B cell chronic lymphoid 
leukaemia (B-CLL) show increased soluble CD62L (sCD62L) in their serum (138, 
139). sCD62L retains ligand binding function and can prevent the binding of 
lymphocytes to endothelial cells (108). Myeloid-Derived Suppressor Cells 
(MDSCs) play a key role in suppressing the immune response to cancer. Immuno-
surveillance for tumours requires T lymphocyte homing as described above and 
MDSCs may interrupt this by causing down-regulation of CD62L on T lymphocytes 
(140). Primed anti-tumour antigen T cells expressing CD62L and CCR7 are a 
possible immunotherapy for tumours (141); in contrast the down-regulation of 
CD62L from the surface of anti-tumour antigen T cells was observed to be 
required for tumour lytic activity (142).  
 
















Figure 1.11: Structure of ADAMs 10/17 and their substrate CD62L. 
Both ADAM10/17 and their substrate CD62L are membrane bound 
proteins with trans-membrane domains (TMDs) and short intracellular 
portions. ADAM 10 and 17 both possess the same basic tertiary structure 
(498). A metalloproteinase domain is responsible for the cleavage of 
substrates such as CD62L, which has a cleavage site proximal to its TMD. 
ADAM10 and 17 possess a disintegrin-like domain (DLD) which has 
shoulder (S) and arm (A) portions, a wrist domain (W), a hyper variable 
region (HVR) which may be important for substrate binding and a cysteine 
rich hand (CRH) which is shorter in ADAM10 and 17 compared to other 
ADAMs. ADAM10 and 17 also do not have calcium binding sites found in 
the DLD of other ADAMs and have an increased number of disulphide 
bonds. CD62L has a C-lectin domain which is responsible for substrate 
binding, an EGF like domain which has calcium binding properties and 2 
SCRs, which are also possessed by complement proteins.  












Figure 1.13: Mechanisms of CD62L down-regulation following T 
lymphocyte activation through TCR or PMA. 1. Under resting 
conditions, the transcription factor FOXO1 promotes the transcription of 
the gene Sell to produce CD62L mRNA in naïve T lymphocytes. 2. Upon 
activation of the T lymphocytes, or antibody induced activation of CD3, the 
p110δ isoform of PI3K is activated (3). 4. PI3K along with mTOR, which is 
activated down-stream of the IL-2 receptor (5), activate Akt. 6. Akt 
phosphorylates FOXO1 promoting its removal from the nucleus which 
turns off transcription of CD62L mRNA (7). 8. p110δ can also activate the 
Erk1/2 signalling pathway, Erk1/2 phosphorylate ADAM17 facilitating its 
trafficking to the cell surface. 9. PMA, which activates PKC, also promotes 
this trafficking. 10. Activated ADAM10 and 17 cleave cell surface CD62L 
close to the outer cell membrane. 
Figure 1.12: Substrate 
specificity of ADAM10 and 
ADAM17. Venn diagram displaying 
the substrates specific for ADAM10 
or ADAM17 and the substrates for 
which both ADAMs can process. 




1.6. Requirement for cytosolic ATP and calcium in T cell 
activation 
As mentioned previously, activation of some signalling molecules including PKC 
and the transcription factor NFAT require large increases in the concentration of 
free intracellular calcium. The phosphorylation of substrates by kinases requires 
the hydrolysis of ATP and this high energy requirement must be maintained during 
T cell activation (143). The mechanisms of calcium release by intracellular stores 
and influx through ion channels and the generation of ATP by respiration will be 
discussed in this section. 
1.6.1. Calcium 
As previously mentioned, the activation of the TCR signalling complex causes the 
hydrolysis of PI[4,5]P2 by PLCγ to DAG and IP[1,4,5]P3. The receptor for 
IP[1,4,5]P3, IP3R, is expressed as a tetramer on the surface of the endoplasmic 
reticulum (ER) (144). Multiple molecules of IP[1,4,5]P3 bind to these receptors 
which open to release Ca2+ from the ER (Figure 1.3). Store operated calcium 
release is rapid but transient, whereas T cell activation requires a sustained 
intracellular Ca2+ increase for several hours (145–147). Early electrophysiological 
evidence revealed an inward current in response to T cell activation and this 
current was dependent on the rise in intracellular Ca2+ from ER release (148). 
Thapsigargin, which blocks sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 
resulting in rapid store Ca2+ depletion, causes activation of this inward current. 
The inward current was attributed to the calcium release activated channel 
(CRAC) which has now been shown to comprise a membrane channel (ORAI) and 
stromal interaction molecules (STIM) that are calcium sensors expressed on the 
ER (149–154). Sustained Ca2+ influx activates calcineurin which dephosphorylates 
NFAT, this allows NFAT translocation to the nucleus where it promotes 
transcription of IL-2, IL-4 and INF-γ (146) (Figure 1.3). 
1.6.2. ATP and the mitochondria 
Hydrolysis of ATP to ADP and the transfer of a phosphate group to substrates is 
the basis for the enzymatic action of kinases and an important post-translational 
modification of substrates. This process of phosphorylation controls protein 
activation and localisation. ATP is produced by a complex series of biochemical 




processes which occur first in the cytosol and then in a specialised organelle 
called the mitochondria; these processes will now be briefly described. Glucose is 
the initial input into a process called glycolysis which ends in the oxidation of 
pyruvate to Acetyl-CoA; this enters the citric acid cycle. Both processes provide 
NADPH and ADP as substrates to the electron transport chain where oxidative 
phosphorylation produces ATP (155). These processes are heavily regulated and 
respond to the energy demands of the cell (143). 
Current evolutionary theory describes the mitochondria as a simple prokaryotic 
organism which may have fused with the cells of simple eukaryotic organisms 
(156). This produced a symbiotic relationship whereby the mitochondria received 
nutrients within the eukaryotic cell and the growing need for energy within the 
eukaryotic cell was met by the production of ATP by the mitochondria. This theory 
is supported by the observation that mitochondria have genomic DNA distinct to 
that of the nucleic DNA of the cells in which they reside (157). Mitochondria have a 
double membrane structure with multiple folds within the inner membrane. 
Expressed in the membrane are components of the mitochondrial electron 
transport chain which is responsible for the final process of respiration that 
produces ATP. This chain consists of five complexes: NADH dehydrogenase 
(complex I), succinate dehydrogenase (II), cytochrome b-c1 (III), cytochrome c 
oxidase (IV) and ATP synthase (V). These complexes serve to facilitate the 
passage of electrons while pumping hydrogen ions into the mitochondrial inter-
membrane space. This creates a proton gradient which allows complex V to pump 
hydrogen ions back into the mitochondrial matrix, a process which drives ATP 
synthesis (Figure 1.14). 
During normal ATP synthesis a small number of electrons may leak out from these 
complexes and, through their reactivity with H2O in the matrix, form a number of 
ROS (158–160). In pathological conditions where the mitochondrial DNA (mtDNA) 
becomes damaged these complexes may leak a greater number of electrons and 
mitochondrial ROS can noticeably increase. This results in a phenomenon where 
further damage to mtDNA and increased ROS generation occur in a cyclical 
manner; increased mitochondrial ROS can lead to cell death through apoptosis 
(161–164). A number of diseases exist where mtDNA is damaged or mitochondrial 




ROS is increased, for example: TNFR1-associated periodic syndrome (TRAPS) 












Figure 1.14: The complexes of the mitochondrial electron transport 
chain. A. The electron donors NADH and Succinate pass electrons 
through flavin and iron based electron carriers in complex I and II to 
Quinone (Q) in the mitochondrial membrane. Q shuttles electrons to 
complex III which is a dimer of subunits containing heme and iron electron 
carriers. Electrons are passed from complex III to complex IV by soluble 
cytochrome c in the membrane. Heme and copper carriers in complex VI 
are the final carrier through which the electrons are passed to oxygen to 
form water. These reactions allow the passage of protons out of the 
mitochondrial matrix by complexes I, III and VI. This creates a proton 
gradient which allows complex V (FoF1) to form ATP from ADP and 
organic phosphate (Pi). B. The basic path of electrons from NADH to O2 is 
given with the complexes that facilitate this passage. Agents which 
uncouple this pathway: DPI, Rotenone and Antimycin A are shown at the 
complexes which they target. 




1.7. Purinergic receptors 
1.7.1. P1 and P2 family in inflammation 
While investigating novel neurotransmitters, Geoffrey Burnstock discovered that 
ATP could act as a neurotransmitter, this observation was contrary to opinions 
held at the time (167). ATP can be released from cells in an autocrine or pancrine 
manner and is released from dying cells. ATP can be rapidly hydrolysed to 
adenosine monophosphate (AMP) by cell surface ectonucleoside triphosphate 
diphosphohydrolase-1 (ENTPD1/CD39) (168, 169) this can be further hydrolysed 
to adenosine by ecto-5′-nucleotidases such as CD73 (170). CD39 is expressed on 
cells of the immune system, and in combination with CD73 is important for the 
function of Treg cells (171, 172). ATP and its metabolites: adenosine diphosphate 
(ADP), AMP and adenosine, as well as the Uridine based molecules Uridine 
triphosphate (UTP)  and Uridine diphosphate (UDP), stimulate the activation of a 
class of receptors termed purinergic receptors (Table 1.2).  
The P1 adenosine receptor family consists of the A1, A2a, A2b and A3 receptors 
which are all activated endogenously by adenosine. P1 receptors are GPCRs, the 
A2a and A2b receptors couple to stimulatory Gs α subunits whereas the A1 and 
A3 receptors couple to inhibitory Gi/o α subunits (Figure 1.15). The P2 receptor 
family is subdivided into the P2Y GPCRs and P2X ligand gated ion channels. 
There are multiple P2Y GPCRs with broad tissue and cellular expression patterns 
which couple to either: Gs, Gi/o or Gq11 α subunits. The majority of P2Y receptors 
couple to Gq11 α subunits to activate PLCγ and bring about an increase in 
intracellular calcium through ER Ca2+ release. P2Y receptors respond to a wide 
variety of purine nucleotides including: ADP, ATP, UDP, UTP and UDP-glucose 
with differing sensitivities (Table 1.2). P2XRs are a family of 7 ion channels which 
share sequence homology and all are activated endogenously by ATP. Using 
electrophysiology a distinct fingerprint for each channel can be elucidated which 
are shown in Table 1.2. While ATP is the endogenous ligand for P2X receptors, a 
number of synthetic agonists have been developed as tools to investigate the 
pharmacology and function of these receptors (Figure 1.16). 
 




 Agonists Selective 
Agonists 
Selective Antagonists Tissue Distribution Signall
ing 
P1 Receptors 
A1 Adenosine CPA, CCPA, S-
ENBA, 
GR79236 




A2A Adenosine CGS21680, 
HENECA, ATL-
146e 






A2B Adenosine Bay60-6583 MRS1754, MRS1706, 
PSB1115  
Vasculature Gs 















































ATP, ARL66096 Glial cells, spinal 
cord, platelets 
Gi/o 
P2Y13 ADP>>ATP  MRS2211 Spleen, brain, lymph 





















P2X2 ATP   Sensory neurones, 
brain, pancreas 
 





P2X4 ATP   Brain, testis, colon 
 
P2X5 ATP   Heart, adrenal 
medulla 
 
P2X6 ATP   Brain 
 
P2X7 ATP  KN62, KN04,           





cells, microglia, T 
and B lymphocytes 
 
 
Table 1.2: The purinergic receptor family 
The endogenous agonists, selective agonists, antagonists, tissue distribution and 
function of the purinergic receptor family are given. The signalling pathways which 
P1 and P2Y receptors couple to are highlighted. For P2X receptors example 
traces of rat P2X7R expressed in HEK293 cells are reproduced. Cells treated with 
0.03 (P2X1-4,6) or 1 mM (P2X7) the black bar above each current represents ATP 
treatment  (173). 





















Figure: 1.15: The purinergic receptor family. P1 adenosine receptors are 
GPCRs activated by adenosine which couple to either Gs (A2A and A2B) or 
Gi (A1 and A3) subunits. Gs coupled receptors stimulate the activation of 
adenylyl cyclase which forms cAMP from ATP; whereas, Gi coupled 
receptors inhibit this process (red arrows). P2Y receptors are also GPCRs 
which are activated by a number of adenine and uracil based nucleotides to 
couple to Gs, Gi or Gq11 subunits. The Gq11 subunit promotes calcium 
release from intracellular stores via PLC activation. P2X receptors are 
activated by ATP and act as cation channels raising levels of intracellular 
calcium and sodium, as well as effluxing potassium ions. 




1.7.2. Expression of Purinergic receptors by cells of the immune 
system 
A1 receptors are not expressed by T lymphocytes; both A2a and A2b receptors 
are expressed and may have roles in activation (174, 175). A3 receptors are 
expressed at low levels on resting T lymphocytes but up-regulated upon activation 
with PHA (176) and are expressed by the leukemic T cell line Jurkat (177). Tregs 
express high levels of CD39 and CD73 on their cell surface and, therefore, have 
the potential to hydrolyse ATP and then AMP to generate large amounts of 
adenosine (170, 172). This adenosine can act upon Tregs in an autocrine manner 
or on effector T cells in a paracrine manner. A2a receptor is broadly anti-
inflammatory and is the pre-dominant adenosine receptor expressed by activated 
T lymphocytes. Adenosine acting on effector T lymphocytes reduces the 
production of pro-inflammatory cytokines and up-regulates production of the 
immune-suppressant IL-10 (178). CD8+ CTLs express A2a and A2b receptors and 
adenosine inhibits FasL expression and degranulation, significantly impairing the 
cytotoxic response (179). Inhibition of Natural Killer cells by adenosine is an 
important feature to consider in the context of tumour surveillance (180). APCs, 
especially dendritic cells, are also influenced by adenosine. Immature dendritic 
cells express mostly A2b receptors but upon activation switch to an A2a+ 
phenotype, this alters their response to adenosine. The immunosuppressive 
action of adenosine through A2a receptors is mediated by Gs coupled cyclic 
adenosine monophosphate (cAMP) generation (179, 181). 
Messenger RNA (mRNA) for all P2YR is detected in leukocytes: monocytes 
express highest levels of P2Y2 and P2Y13 whereas lymphocytes expressed 
highest levels of P2Y12 (182) as well as P2Y2 (183). Little is known about the role 
of P2Y receptors in T lymphocyte function. Activation of P2Y12 receptors 
expressed by dendritic cells has the indirect effect of enhancing T lymphocyte 
activation (184). T lymphocytes express the fast gated P2X1 receptor which is 
highly sensitive to ATP, responding to low micromolar concentrations but rapidly 
desensitising (185). P2X4 receptors which respond to 10 -100 μM ATP with a 
slower current, which is enhanced by the molecule Ivermectin, are also expressed 
by T lymphocytes (186–188). Finally, the P2X7 receptor (P2X7R, although 




originally named P2Z) is also expressed and responds to millimolar concentrations 
of ATP with a slow inward current (189). B lymphocytes also express these three 
P2X receptors as well as P2X2 (190). P2X7R is the focus of this work and its 
structural features, activation and the current understanding of its role in T 
lymphocyte function will be described in detail in the following sections. 
1.7.3. P2X7R activation by ATP 
Before cloning of the P2X7R, the subsequent use of molecular techniques and 
development of antibodies against the receptor, expression of the P2Z/P2X7R 
channel was explored by the ability of high millimolar concentrations ATP to 
induce biochemical changes in cells. Activation of P2X receptors causes a rapid 
increase in intracellular Ca2+ levels, unlike P2Y receptors this does not occur 
through release from intracellular stores, Ca2+ and Na+ influx and K+ efflux occurs 
through the trimeric complex (191). This has been measured through 
electrophysiology or using ion specific fluorescent dyes (192). ATP is the 
endogenous agonist of all P2X receptors as well as some P2Y receptors, a 
number of synthetic ligands for P2X receptors have also been developed and they 
are detailed in Figure 1.16. 
The regions and residues of P2X receptors which contribute to ATP binding have 
been investigated in a number of elegant molecular experiments and most of 
these findings can be applied to the binding of ATP to P2X7R.The ectodomain of 
P2X7R is thought to be solely responsible for agonist binding, as highlighted by a 
study of HEK293 cells expressing rat P2X7R (rP2X7R) (193). Study of P2X2R 
expressed in HEK293 cells with specific residues sequentially changed to alanine 
revealed a number of residues in a region proximal to TMD1, which were 
hypothesised to be important for activation of the receptor by ATP (194). Of these, 
four lysine residues Lys69, Lys71, Lys188 and Lys308, could have a role in co-
ordinating the binding of α and γ phosphates of ATP due to their positive charge 
(194). Lys193 and Lys311 are essential for binding of ATP to human P2X7R 
(hP2X7R) expressed in Xenopus oocytes (195); Ile67 was also identified as being 
required for ATP binding by rat P2X2R. A polymorphism in hP2X7R, which results 
in the substitution of the charged Arg307 residue of P2X7R for an uncharged 
glutamine, revealed that Arg307 present in the ATP binding region of P2X7R is 




important for activation of the receptor (196). It was determined through studies of 
human P2X2/3 heterotrimers expressed in HEK293 cells, that lysine residues from 
adjacent receptor subunits were required for ATP binding (197). The crystal 
structure of a zebrafish P2X4R homotrimer confirms the close proximity of 
residues from two P2X4 subunits forming the putative ATP binding pocket (198). 
This binding pocket contains a unique ATP binding motif, comprised of highly 
conserved basic and polar residues, homologous to those described above (199). 
Comparison of the closed state and ATP-bound open state revealed important 
features of P2XR activation. Upon ATP binding, the subunits undergo 
conformational changes to open the receptor in an “iris-like” manner; this may 
allow entry of cations laterally into the pore (199). 
An analogue of ATP 2’,3’-O-(4-benzoyl-benzoyl) ATP (BzATP) is often used to 
activate and study P2X7R. This is in part due to the observations that it is 
marginally more selective than ATP; of rat P2XRs it has only been reported to 
activate rP2X1R, rP2X2R and rP2X7R (185). BzATP is more potent than ATP at 
rP2X7R but less potent than ATP at rP2X1 and rP2X2 (185). Mouse P2X7R 
(mP2X7R) is also more sensitive to BzATP than ATP but this agonist difference is 
less significant than at rP2X7R due to differences in amino acid residues between 
the two species (193). BzATP is also more potent than ATP at the recombinant 
hP2X7R (200). 
ATP is required in its deprotonated ATP4- state for activation of P2X7R (201) and 
a number of divalent cations have been suggested to inhibit P2X7R activation 
through both quenching ATP4- and allosteric modulation of the receptor. In dye 
uptake experiments, extracellular Ca2+ or Mg2+ reduce the potency of BzATP at 
the hP2X7R (cDNA expressed in HEK293 cells) (202). Experiments involving 
HEK293 cells expressing rP2X7R assessed a larger range of divalent cations and 
demonstrated that they inhibited P2X7R with varying potencies (203). Zinc (Zn2+), 
which inhibits rP2X7R expressed in HEK293 cells potentiates ATP responses and 
inhibits BzATP responses in HEK293 cells expressing mP2X7R (203, 204). 
Extracellular Mg2+ blocks a number of P2X7R dependent processes including: 
ATP induced activation of PKD (205), cell shrinkage (206) (also blocked by Cu2+ 
and partially by Zn2+) and CD62L (207) and CD23 shedding (208) (also blocked by 
Mn2+, Ca2+ and Ba2+). 









Figure 1.16: P2X agonists. ATP is the endogenous ligand of P2X receptors. Apyrases 
catalyse the hydrolysis of ATP: grade VI apyrase preferentially converts ATP to ADP 
whereas grade VII apyrase preferentially converts ADP to AMP. These are compounds 
extracted from potato; however, cell membrane bound ATPases are found in the body. 
CD39 hydrolyses ATP to AMP and CD73 further hydrolyses this to adenosine. A methyl 
group can be introduced into ATP between the α and β phosphates to create the 
synthetic ligand αβ-meATP. A sulphur atom can also be introduced to the γ phosphate to 
give ATPγS. 2’,3’-O-(4-benzoyl-benzoyl) ATP (BzATP) is a potent agonist for P2X7 
receptors but can also activate other P2X receptors. NAD is a substrate for ART2, which 
in mice can be used to ADP ribosylate P2X7R. 




1.7.4. P2X7R antagonists 
The progress of P2X7R antagonist development has been relatively slow. 
Periodate-oxidized 2′,3′-dialdehyde ATP (oATP) was the first P2X7R antagonist 
described in 1993 from its ability to prevent pore formation in response to ATP in 
the J774 murine macrophage cell line (209) (Figure 1.17). The actions of oATP 
are very slow (1-2 hour incubation required), the inhibition is irreversible and off 
target effects were observed soon after its synthesis (209, 210). Nevertheless, 
oATP was a key tool in early pre cloning experiments with P2Z/P2X7R (207, 211). 
Other compounds such as Suramin and PPADS are broad spectrum P2X 
antagonists which inhibit P2X7R activation, but at much higher concentrations 
than other P2XRs (185, 200). KN-62 is an isoquinoline derivative first reported for 
its ability to inhibit calmodulin-dependent kinase II; however, it was subsequently 
discovered to inhibit P2X7R (200, 212, 213). Coomassie Brilliant Blue G (BBG) 
was also identified as an inhibitor of the rat P2X7R (214). 
Until the mid-2000s these compounds represented the core pharmacological tools 
for the study of P2X7R and their lack of selectivity, coupled with non-selective 
agonists, hampered research efforts. Pharmaceutical companies were keen to 
investigate P2X7R antagonism as a novel therapeutic intervention for a number of 
inflammatory disorders; indeed two mouse P2X7R knockout models were created 
by GlaxoSmithKline and Pfizer. A number of second generation, more specific and 
selective P2X7R inhibitors were developed by structure activity relationship (SAR) 
based synthesis approaches; compounds from AstraZeneca and Abbott 
Laboratories are excellent examples of this approach (215). The antagonists 
A438079 and A740003 are highly selective inhibitors developed by Abbott from 
series of tetrazole and cyanoguanidine derivative compounds respectively. Both 
are competitive P2X7R inhibitors that show superior in vitro potency compared to 
the first generation P2X7R antagonists described above and have very little effect 
on other P2X and P2Y receptors at concentrations up to 100 μM (216–218). 
These compounds also show promise for the treatment of chronic pain as they are 
effective in in vivo rat models of nociception (217, 218). AstraZeneca also 
identified a series of cyclic imides and a series of adamantane amides as P2X7R 
antagonists, using a high throughput screening (HTS) and SAR approach (219, 
220); these studies led to the development of two lead compounds AZ116453743 




and AZ10606120. AZ116453743 is a potent in vitro inhibitor of human P2X7R 
expressed by HEK293 cells or endogenously expressed by THP-1 monocytic cells 
(221). Interestingly, this compound showed species specificity, being more potent 
at human than rat P2X7R. Pharmacological observations suggest that this 
compound is most likely a non-competitive inhibitor of P2X7R (221).  
A number of P2X7R antagonists have entered clinical trials, but have so far been 
unsuccessful in the treatment of inflammatory disorders. For example AZD9056, 
another AstraZeneca P2X7R antagonist, failed to show efficacy in a phase II trial 
for treatment of RA (222). Another trial showed that, in patients with Methotrexate 
















Figure 1.17: P2X antagonists. Structures for inhibitors of P2XR and P2X7R are 
given in this figure. The broad spectrum P2XR inhibitors PPADS and Suramin 
are presented alongside first generation P2X7R inhibitors oATP, KN62 and BBG. 
Specific P2X7R antagonists developed by Abbot Laboratories (A438079 and 
A740003) and AstraZeneca (AZ116453743 and AZ10606120) are also 
displayed. The antagonists used in this study are highlighted with a black box. 
IC50 values are presented in italics after compound names. These were 
calculated from pIC50 values for the inhibition of calcium influx in HEK293 cells 
expressing human P2X7R previously published (353). 




1.7.5. P2X7R structure 
cDNA for hP2X7R was first cloned in 1997 (the mouse receptor was cloned a year 
later (224)); it is present at 12q24.31 at the chromosomal level and the full length 
receptor subunit is encoded by 13 exons giving a receptor of 595 amino acids in 
length (189, 225). P2X7R was identified as the molecular identity for a receptor 
(P2Z) which responds to high, millimolar, concentrations of ATP by first opening a 
cationic selective channel, followed by delayed opening of a membrane 
associated pore (192). P2X receptor subunits form into hetero- or homo-trimeric 
complexes and biochemical and pharmacological approaches have been 
employed to determine association of P2X receptor subunits in these complexes. 
A number of hetero-trimeric receptor complexes have been identified including 
P2X1/P2X2, P2X1/P2X4, P2X1/P2X5, P2X2/P2X3, P2X2/P2X6, and P2X4/P2X6 
(226–233). P2X7R was previously thought to only form homo-trimeric 
associations; however, recent evidence suggest that it may partner with P2X4 
(234). 
Until recently the tertiary structure of P2X receptors was based on low resolution 
crystal structures, as well as a raft of studies investigating contributions of 
individual and groups of amino acids to P2XR trafficking, ATP biding and their 
subsequent activation (235). The publication of a high resolution crystal structure 
of Zebrafish P2X4R (198) in a closed or open state confirmed many key features 
identified by molecular studies (199, 236).  
P2X receptor subunits share common structure with intracellular N- and C-
terminus regions, two transmembrane domains (TMD1 and TMD2) joined by a 
large extracellular loop region (Figure 1.18). The number of amino acids that make 
up each P2X receptor varies largely with P2X7R being the largest due to a long C-
terminus. This C-terminus is key for a number of P2X7R functions including 
trafficking to the plasma membrane (237–240). 
 
 









Figure 1.18: P2X7R structure and function. A. Side on view of the plasma 
membrane. As described briefly in Figure 1.15 P2X receptors (such as P2X7R) are 
activated by ATP and couple to the influx of Ca2+ and Na+ into cells and the efflux of 
K+. B. Top-down view of the plasma membrane. This first permeation state can 
be followed by a second permeation state whereby prolonged P2X7R activation 
leads to the opening of a membrane associated pore. Biochemical evidence 
suggests this pore is the hemichannel Pannexin-1. Molecular and crystallography 
experiments suggest that ATP binds to a region between TM1 of one P2X subunit 
and TM2 of an adjacent P2X subunit. P2X7Rs have been shown to form both 
homotrimers and herterotrimers with P2X4Rs. 




1.7.6. P2X7R expression 
The use of molecular and biochemical techniques have revealed that P2X7R is 
expressed in almost every tissue of the rat body (241). A number of individual 
studies have confirmed expression in primary human cells i.e. those that have 
been isolated from tissues and cells of the human body without subsequent 
immortalisation as cell lines. The levels of P2X7R expression can differ greatly 
between cell types, but it is clear that cells of the immune system express high 
levels of P2X7R (242). However, it is unclear if neutrophils express functional cell 
surface P2X7R. P2X7R mRNA has been detected in human peripheral blood 
neutrophils and BzATP evokes a rapid transient increase in intracellular Ca2+ 
(243). However, expression of P2X7R in neutrophils could only be detected by 
flow cytometry after cells were permeabilised (242). One study demonstrated that 
in response to BzATP human neutrophils do not produce currents in patch clamp 
configuration, uptake ethidium bromide or generate ROS (244); neutrophils were 
also resistant to CD62L down-regulation induced by BzATP (245). Monocyte cell 
lines and primary human monocytes express high levels of P2X7R which has an 
important role in IL-1β processing in these cells and its subsequent release in 
microvesicles (246–249). Dendritic cells, Langerhans cells and Mast cells all 
express functional P2X7Rs (250–252). B lymphocytes also express P2X7R (242), 
although little is known about the physiological role of the receptor in these cells. 
Expression of P2X7R is increased in B lymphocytes from patients with B-CLL 
(253) and may provide a marker of evolutive (advanced) B-CLL (254).  
Even before the cloning of human P2X7R, a receptor for high millimolar 
concentrations of ATP was detected in murine T lymphocytes (191). Since then, 
the expression of P2X7R has been detected in mixed populations of T 
lymphocytes as well as T lymphocyte subsets (242). Thymocytes express P2X7R 
where it has an important role in cellular death (206, 255–258). Splenocytes also 
express P2X7R, with splenic T lymphocytes expressing higher levels than splenic 
B lymphocytes (206).  Naïve CD4+ and CD8+ T lymphocytes from mice express 
P2X7R (259, 260). Human peripheral CD4+ and CD8+ T lymphocytes express 
P2X7R mRNA (245, 261) and protein expression in CD4+ cells has been 
confirmed by fluorescence microscopy (261). Although CD8+ T lymphocytes 
express P2X7R, in mice the expression of P2X7R by CD8+ cells was restricted to 




intraepithelial cells (262). CD8+ T lymphocytes from the spleen expressed very low 
levels of P2X7R, but its expression could be up-regulated by retinoic acid (262). In 
mouse studies it was apparent that CD4+/CD25+ Tregs expressed high levels of 
P2X7R (263). This subpopulation of cells were more sensitive to the effects of 
ATP than CD4+/CD25- cells and a role for P2X7R in apoptosis of Tregs was 
revealed (259, 263–266). 
1.8. P2X7R function in cells of the immune system 
The actions of P2X7R and its endogenous ligand ATP have been investigated in 
the context of T and B lymphocyte mediated immunity. It has roles in different cell 
subsets, from thymocytes where it appears to have a role in cell death, naïve T 
lymphocytes where it may aid activation, through to differentiated subsets such as 
Tregs. 
1.8.1. Proliferation 
The observations that B lymphocytes from patients with B-CLL express high levels 
of P2X7R and that transfection of P2X7R deficient B cell lines with human P2X7R 
allowed serum independent growth, suggested a role for P2X7R in proliferation 
(254, 267). The broadly non-selective P2X7R antagonist oATP inhibits the 
proliferation of murine naïve CD4+ T lymphocytes stimulated with anti-CD3 and 
anti-CD28 antibodies (268). oATP and another broad spectrum P2X antagonist 
PPADS inhibited Erk phosphorylation 16 hours post activation of T lymphocytes. A 
proportion of calcium influx following T lymphocyte activation was inhibited by 
oATP, this suggests P2X7R may be involved in the global calcium response of T 
lymphocytes. Release of ATP following activation of CD4+ T lymphocytes was 
shown to act in an autocrine manner through P2X7R to mediate: calcium influx, IL-
2 production and NFAT activation (261). The same group also reported that P2X1 
and P2X4 receptors play a role in these processes following T lymphocyte 
activation and, unlike P2X7R, locate to the immunological synapse (188). This 
most recent study also suggests that ATP release following T lymphocyte 
activation is through the Pannexin-1 hemichannel.  
 
 




1.8.2. Pore formation and cell death 
Before cloning of the receptor, P2X7R (then P2Z) was distinguished from other 
P2X receptors by the ability of its activation to couple to the uptake of large 
molecular weight molecules (such as the dye ethidium bromide) into cells (269). 
Pore formation in response to ATP was exploited in the form of biochemical 
assays as a method of determining functional expression of P2X7R before it’s 
cloning in 1996; this method is still frequently used. Indeed, P2X7R was first 
identified in murine T lymphocytes through increased intracellular calcium levels 
coupled with ethidium bromide uptake following ATP treatment (191). Extraceullar 
calcium influx by P2X7R is rapid and dye uptake was shown to be slower, this 
suggested two permeation states for P2X7R (270) (Figure 1.18).  
The molecular identity of the pore that mediates this second permeation state has 
been the topic of much investigation. An initial theory that multiple P2X7Rs 
associate in the membrane to form a pore permeable to molecules larger than 
cations was discounted (173). Co-expression of the hemichannel Pannexin-1 with 
P2X7R was required to induce cell death through pore formation in zebrafish 
oocytes and this was inhibited by carbenoxolone (a channel blocker) (271). 
Transfection of siRNA against Pannexin-1 also reduced dye uptake induced by 
BzATP in cell lines (271, 272). Pannexin-1 may represent a route for the release 
of ATP from cells, which acts in an autocrine manner to activate P2X receptors on 
the cell surface (188, 268). 
Pore formation by activation of P2X7R and subsequent opening of Pannexin-1 
leads to biochemical changes in cells and has been linked to IL-1β release from 
macrophages (273, 274). Initially, work with mouse thymocytes revealed that 
prolonged ATP treatment resulted in the death of these cells through both 
apoptosis and necrosis (201, 255, 275). Apoptosis of cells in response to ATP was 
later shown to involve activation of caspases (276) and DNA fragmentation (275). 
Other global apoptotic events occur including exposure of phosphatidyl serine 
(PS), membrane blebbing, microvesicle shedding and cell shrinkage (277, 278). A 
number of mechanisms have been proposed for how P2X7R activation couples to 
cell death including: mitochondria, Erk1/2 MAPK activation and ROCK1 (255, 277, 
279) (Figure 1.19). The Pannexin-1 pore is involved in apoptosis, where it is 




allows the release of ATP from thymocytes, this acts as a chemoattractant for 
macrophages (280). 
A novel mechanism of P2X7R dependent cell death was discovered in mouse T 
lymphocytes which, unlike human T lymphocytes, express cell surface enzyme 
called mono-ADP-ribosyltransferase 2 (ART2) (281, 282). It is expressed by the 
majority of post thymic CD4+ and CD8+ T lymphocytes; however, it is down-
regulated upon treatment of T lymphocytes with PMA in an MMP dependent 
manner (281, 283). Nicotinamide adenine dinucleotide (NAD+) is a co-enzyme 
present in the cytosol of cells which may be released through lysis of cells such as 
erythrocytes (284). ART2 enzymes use NAD+ as a substrate to ADP-ribosylate 
P2X7R at Arg125 which leads to the irreversible activation of the receptor (285, 
286). This activation of P2X7R by NAD+ through ART2 leads to cell death, 
measured by annexin V binding to externalised PS and uptake of propridium 
Iodide (PI) (286). Genetic deletion of ART2 in these mice prevented NAD+ induced 
cell death (266, 286, 287), P2X7-/- mice were also protected (262, 265, 266, 288) 
and pharmacological inhibition of P2X7R was effective at blocking cell death (265, 
286). Higher concentrations of NAD+ than those required for cell death induced via 
ART2-P2X7R activation also cause activation of a delayed P2X7R independent 
cell death pathway (289). Cell death induced by NAD+ has been observed in 
murine CD4+/CD25+ Tregs (265, 266), Natural Killer T (NKT) cells (288), intestinal 
CD8+ T lymphocytes (262). Murine naïve CD4+ and CD8+ T lymphocytes isolated 
from lymph nodes may be more sensitive to NAD+ induced cell death than 
activated or memory T lymphocytes (260). In addition to inducing cell death, 
activation of P2X7R through this NAD-ART2 mechanism also causes shedding of 
CD62L from the surface of mouse T lymphocytes (284, 286). Antibodies against 
ART2 are able to prevent both cellular death and CD62L down-regulation in vitro 
(284) and their use in vivo inhibits the development of autoimmune type 1 
diabetes in mice (290).  
1.8.3. P2X7R, NADPH oxidase and activation of the inflammasome 
As mentioned previously in section 1.1.1, PAMPs from bacteria are recognised by 
pattern recognition receptors (PPRs) such as cell surface and intracellular TLRs 
as well as intracellular NOD like receptors (NLRs) (291, 292). The role of ATP as a 




DAMP extends far beyond causing cell death in lymphocytes. Through its 
receptor, P2X7R, ATP can act as a co-stimulatory signal for PAMP primed 
macrophages, causing the maturation and release of cytokines such as IL-1β and 
IL-18. This point of convergence between PAMPS, such as LPS and the DAMP 
ATP, is the activation of inflammasomes. Other inflammasome activating DAMPs 
include uric acid crystals, asbestos and UV light (291). There are three types of 
inflammasome, the NALP1, NALP3 and IPAF inflammasomes, which are involved 
in recruiting and activating caspases, through CARD domains in associated 
proteins. Caspases can have roles in the apoptosis of cells as well as the 
cleavage and maturation of cytokines. For example caspase 1 is activated by the 
NALP3 inflammasome and can both promote apoptosis and cleavage of pro- to 
mature-IL-1β (Figure 1.19). Production of pro-IL1β is increased by LPS, the 
subsequent maturation and release of this cytokine, as well as the associated IL-
18, requires activation of P2X7R by ATP (247, 293). The cellular mechanism 
involved in the activation of NALP3 by ATP requires the efflux of potassium ions 
(which can be recapitulated by the K+/H+ antiporter nigericin) and superoxide 
generation by NADPH oxidase (246, 248).  
NADPH oxidase has previously been mentioned in the context of the respiratory 
burst employed by neutrophils to kill opsonised cells (section 1.1.1), however, this 
enzyme complex has other important biological functions within cells such as 
inflammasome activation. NADPH oxidase comprises a family of enzyme 
complexes NOX1, 2, 3, 4, 5 and DUOX 1 and 2. NOX2 is comprised of membrane 
associated gp91phox and p22phox subunits and the intracellular p40phox, 
p47phox and p67phox. GTPases such as Rac1 or 2 also associate with the 
NADPH oxidase complex. The NOX2 enzyme complex is responsible for 
increased superoxide generation in response to ATP in macrophages; ATP has 
been shown to cause the translocation of the p67phox subunit to the plasma 
membrane of the monocytic leukemic THP-1 cell line (246). Loss of NOX2 in a 
NOX2-/- mouse causes increased number of pro-inflammatory CD11+ cells and 
profoundly affects the differentiation of Treg and Th17 cells and leads to the 
development of arthritis in these mice (294). However, whether P2X7R activation 
couples to NADPH oxidase in T lymphocytes is unclear. 




1.8.4. P2X7R, Mycobacterium tuberculosis and Autophagy 
Mycobacterium tuberculosis (M. tuberculosis) is a pathogen which causes 
infection predominantly of the lungs. The disease has previously been managed 
by vaccination and antibiotics; however, in some areas of the world heavy 
resistance to these antibiotics has developed. The immune response to M. 
tuberculosis has been extensively studied an may lead to novel treatments for 
infection by this pathogen (295). Macrophages are important for the defence 
against M. tuberculosis infection; one mechanism employed by these cells is the 
process of autophagy (296). In this process macrophages actively opsonise M. 
tuberculosis and portions of its cytoplasm and contain them within double 
membrane vesicles, termed autophagosomes (297). Autophagosomes vesicles 
are then trafficked to and destroyed by lysosomes. The mechanisms involved in 
autophagy have been investigated and involve a complex of the class III PI3K 
Vps34 with other proteins including Beclin-1 (297). A novel role for macrophage 
P2X7R in the killing of M. tuberculosis was suggested following the observation 
that ATP and BzATP enhanced apoptosis of bacille Calmette-Guerin (BCG) 
infected cells (298). Indeed, ATPases secreted by M. tuberculosis may form a 
mechanism to prevent ATP induced killing of pathogen infected cells (299). Other 
purinergic receptors may also integrate stimulation by ATP with pathogen 
clearance (300, 301). The mechanism of clearance was shown to involve 
autophagy which required phospholipase D (PLD) activity (300, 302) (303). Killing 
of M. tuberculosis by purines also involves nitric oxide (NO); however, this is 
independent of P2X7R (301, 302). This process of autophagy also enhances the 
processing and secretion of the inflammatory cytokine IL-1β (304). Microglial cells 
also undergo autophagosome formation in response to a model of Escherichia coli 
(E. coli) infection (305). The importance of P2X7R in clearance of M. tuberculosis 
is underscored by single nucleotide polymorphisms (SNPs) of P2X7R which 




















Figure 1.19: Apoptosis induced by P2X7R activation. 1. P2X7R is activated by 
ATP or BzATP which causes the induction of apoptosis. Reversible changes in 
the plasma membrane occur rapidly following activation of P2X7. 2. Firstly rapid 
blebbing of the membrane occurs which can eventually lead to the shedding of 
microvesicles (3); cells subsequently shrink in size.4. Phosphatidyl Serine (PS) is 
restricted to the inner leaflet of healthy cells however it can be translocated to the 
cell surface following activation of P2X7R. Externalised PS acts as an important 
“find me” signal for phagocytes to remove apoptotic cellular material. P2X7R 
activation also causes activation of a number of key apoptotic proteases termed 
caspases. 5. Caspase 1 forms part of the “inflammasome” which is responsible for 
IL-1β processing; but, independent of this it can promote apoptosis 6 and 7 
Caspase 8 is also activated down-stream of P2X7R which can in turn activate the 
effector caspases 3 and 7.Two mitochondrial mechanisms for effector caspase 
activation have been observed in macrophages and thymocytes 8. Prolonged 
activation of P2X7R can lead to the release of cytochrome C from the 
mitochondria, which activates caspase 3 and 7 through ROCK-1 activation. 9. De 
novo synthesis of ceramide in the mitochondria in response to ATP can also 
activate these effector caspases. 10. Caspase 3 and 7 are responsible for the 
cleavage of intracellular proteins during apoptosis. 11. ATP can also induce 
Fragmentation of DNA and condensation of the nucleus. 12. In mouse T 
lymphocytes apoptosis can be induced by irreversible activation of P2X7R through 
ADP-ribosylation by the enzyme ART2 using NAD+ as a substrate. 




1.8.5. Cell surface molecule regulation 
As mentioned previously, CD62L is an important molecule for naïve CD4+ T 
lymphocyte homing through its interaction with HEVs allowing transendothelial 
migration into SLOs. The mechanisms for its regulation have also been discussed 
in the context of lymphocyte activation, however activation of P2X7R by 
ATP/BzATP or NAD+ via ART2 has also been shown to cause CD62L down-
regulation. It was initially observed that mouse B lymphocytes isolated from spleen 
did not flux calcium in response to ATP (191). To investigate P2X7R on human B 
lymphocytes cells were isolated from patients with BCLL because B lymphocytes 
are the predominant peripheral immune cell type (190). BCLL B lymphocytes are 
more responsive to ATP than B lymphocytes isolated from healthy human donors 
(309). In patients with BCLL levels of cleaved soluble CD62L (sCD62L) correlate 
with cell number (310) and treatment of CLL B lymphocytes with ATP causes rapid 
loss of cell surface CD62L (207, 208). CD62L loss in response to ATP/BzATP was 
rapid, dependent on agonist concentration and blocked by KN-62, oATP and the 
ADAM17 inhibitor R 31-9790 (207, 208, 212). BzATP is more potent than ATP at 
inducing CD62L down-regulation; loss of CD62L was independent of extracellular 
calcium but the process was inhibited by Mg2+ (207). T lymphocytes are also 
sensitive to ATP induced CD62L down-regulation, in mice both CD4+ and CD8+ T 
lymphocytes are able to undergo ATP induced CD62L down-regulation however 
CD4+/CD25+ T lymphocytes appeared even more sensitive to this process (263). 
Indeed, lymphocytes isolated from mice deficient in P2X7R do not down-regulate 
CD62L in response to ATP or NAD+ (284, 311). A study of human PBMC revealed 
that both naïve CD4+ and naive CD8+ T lymphocytes down-regulate CD62L in 
response to BzATP and this was inhibited by oATP and KN-62 (245). Other cell 
surface molecules are also regulated by ATP through P2X7R activation including 
CD21 (245), CD23 (208, 312) and CD27 (313). The mechanism integrating 
P2X7R activation by ATP to CD27 processing involved activation of MMPs 
however this was not mediated by Erk1/2, p38 MAPK or PI3K signalling (313). 
Activation of P2X7R by ATP and BzATP has also been linked to the release of 
MMP9 in a calcium dependent manner from monocytes (314). Ultimately, the 
mechanisms that couple the activation of P2X7R by ATP or BzATP to a decrease 
in cell surface expression of CD62L are at present unclear. 





As mentioned previously, the role of migration in the co-ordination of lymphocytes 
within the body is critical to their function. Although little research has focussed on 
the role of P2X7R in lymphocyte migration, a number of other studies have 
explored the role of purines in the migration of immune cells.  
Purinergic regulation of migration has been most extensively investigated in the 
context of neuronal inflammation. The expression of both P2X7 and P2Y1 
receptors where identified in progenitors of oligodendrocytes. Here P2Y1 is 
involved in the migration of progenitors prior to their development into mature 
oligodendrites (315, 316). Microglia from P2Y12-/- mice show reduced ruffling of 
their membrane and impaired migration towards ADP and ATP (317). P2Y1 and 
P2Y12 also facilitate migration of microglial cells in response to ADP, a process 
which is enhanced by TGFβ and reduced by LPS (318). ATP also acts as a 
chemo-attractant for microglial cells through increased activation of MMP9 (319). 
This process was inhibited by P2Y antagonists and the pan-isoform PI3K inhibitor 
Wortmannin, suggesting the involvement of PI3K downstream of either P2Y1 or 
P2Y12. Indeed, another study demonstrated that Akt, phosphorylated in response 
to ADP, is involved in microglial migration through the P2Y12 receptor (320). 
Silencing of P2X4 expression in microglia, using Lentiviral mediated introduction of 
anti-P2X4 shRNA, significantly reduced migration towards ATP (321). This 
suggests that both ionotropic and metabotropic P2 receptors are involved in 
migration of microglia towards nucleotides. 
Following injury to epithelial cells there is an increase in calcium levels in these 
cells, apyrase inhibited this process indicating a role for purinergic receptor 
signalling (322). These changes were mimicked by purinergic agonists including 
ATP and ATPγS and facilitated paxcillin phosphorylation and migration of these 
cells. In human umbilical vein endothelial cells (HUVECs) P2X4 and P2X6 
receptors where shown to co-localise with VE-cadherin, an important junctional 
protein (323). Therefore, purines may play a role migration during in wound 
healing, following infection and inflammation (Figure 1.1). P2Y2, 11, 13 and P2X1, 
4 and 7 receptors are expressed by macrophages; evidence suggests that P2Y11 
receptors facilitate migration of these cells. However, migration was not directional 
and did not require the PI3K signalling effector Akt (324). The migration of other 




innate cells, such as neutrophils, is influenced by purines; indeed, chemotaxis 
towards IL-8 requires the function of P2Y2 receptors (325). Another study, which 
previously showed a role for P2Y2 in neutrophil migration, also suggests a 
mechanism whereby the hydrolysis of ATP to adenosine acts to promote 
neutrophil migration through A3Rs (326). This co-requirement for P1 and P2 
receptors for migration was also observed in microglial cells. As mentioned above, 
microglia migrate towards the nucleotides ATP, ADP and AMP and interestingly 
this migration requires expression of the ecto-ATPase CD39 (327). Neutrophil 
migration also requires the activity of CD39 (328, 329). 
Analysis of proteins which associated with rat P2X7R in vitro revealed interactions 
of this receptor with integrins and cytoskeletal components (330). Indeed, human 
eosinophils phosphorylate actin and up-regulate the integrin CD11 in response to 
ATP (331). PX7R can also be activated by αvβ3 integrin signalling in astrocytes, 
where it is required for calcium influx in response to the glycoprotein Thy-1 (332). 
P2X7R has also been shown to influence expression of the adhesion molecule 
CD62L described in the sections above. 
1.8.7. Signalling 
The P2X7R dependent functions described above require integration of P2X7R 
activation into biochemical changes within the cell, either through increased 
intracellular calcium levels and/or through activation of protein signalling 
cascades. While several studies have looked at P2X7R dependent signalling in T 
lymphocytes, a wider raft of studies in other cell types may also be relevant to 
lymphocytes and are also discussed here (Figure 1.20). Murine thymocytes 
isolated from mice show increased phosphorylation of the MAPKs Erk1/2 and p38, 
as well as JNK1/2 and the Src family kinases p56Lck and p59Fyn after ATP 
treatment (255). In these cells Erk1/2 phosphorylation was inhibited by oATP and 
ablated in thymocytes from P2X7R-/- mice. Mouse splenocytes also 
phosphorylated Erk1/2 in response to ATP through activation of MEK (206). 
Mouse Tregs from P2X7R deficient mice showed significantly reduced Erk1/2 
phosphorylation in response to anti-CD3 antibody +/- IL-6 (259). The enhanced 
anti-CD3 antibody + TGFβ dependent generation of mouse Treg cells from naïve 




CD4+ T lymphocytes in vitro using the mTOR inhibitor Everolimus requires P2X7R 
expression (333). 
Mouse thymocytes do not phosphorylate Akt after ATP treatment indicating that 
the PI3K signalling pathway may not be activated down-stream of P2X7R in these 
cells (255). In human 1321N1 astrocytoma cells transfected with rat P2X7R, 
stimulation with BzATP, ATP and UTP caused phosphorylation of Akt on Ser473 
indicating that both P2Y and P2X receptors can cause activation of the PI3K 
pathway (334). Phosphorylation of both Ser473 and Thr308 was dependent on 
BzATP concentration, was rapid and sustained for up to two hours. Extracellular 
and intracellular calcium were both required for Akt phosphorylation as was the 
activity of PI3K and Src kinase. 
In the microglial cell line MG6, the mTOR pathway was activated by millimolar 
concentrations of ATP. Moderate mTOR phosphorylation and robust S6K 
phosphorylation were observed (305); this study also revealed a slight increase in 
AMPKα phosphorylation following ATP treatment. In astrocyte and microglial cell 
lines Erk1/2, phosphorylation was observed in response to BzATP (305, 335, 336) 
and in primary rat astrocytes this effect was enhanced by co-application of 
arachidonic acid (335, 337). The mechanism for BzATP induced Erk1/2 
phosphorylation required upstream activation of MEK and PKC as well as both 
extracellular and intracellular calcium. Pyk2, a protein tyrosine kinase which is 
activated by both increases in intracellular calcium concentration and PKC was 
also required (336, 338).  
The novel PKC isoform PKCδ can be phosphorylated following ATP/BzATP 
treatment of cells (205, 336). Osteoblasts and osteoclasts express P2X7R and its 
role in bone function may be of importance in osteoporosis (339). Mouse 
osteoclasts translocate PKCα from the cytosol to the cell membrane in response 
to BzATP in a P2X7R dependent manner, this was shown in the RAW 264.7 
macrophage cell line to require extracellular calcium (340). PKCβ1 was also 
recruited to the membrane following BzATP treatment; however, this translocation 
was significantly more transient than for PKCα. In contrast, PKCδ did not show 
BzATP induced translocation. Primary rabbit osteoclasts demonstrate BzATP 
induced NF-κB nuclear translocation through activation of P2X7R (341). Mouse 




embryonic stem (mES) cells express functional P2X7Rs (342) where it is involved 
in survival, but may also cause cell death following prolonged activation. ATP 
induced proliferation of mES cells required PKC activity and ATP induced the 
relocation of PKCα, δ and ζ from the cytosol to the membrane (343). It is unclear 
however if P2X7R was responsible for these effects, as its involvement was not 









Figure 1.20: Signalling via P2X7R. Studies have revealed that ATP or BzATP 
can induce activation of signalling cascades and phosphorylation of a number of 
different proteins. Left: In mouse thymocytes members of the MAPK family 
(green) are activated by BzATP. PX7R activation also phosphorylates the TCR 
signalling components p56Lck and Fyn. In Treg cells Erk1/2 phosphorylation in 
response to anti-CD3 and IL-6 partially requires P2X7R. Centre: Microglial cells 
activate the mTOR signalling cascade in response to ATP. BzATP caused 
activation of the Erk1/2 pathway in both astrocyte and microglia cell lines through 
the cascade described. p38 MAPK is also activated via P2X7R. Right: In 
osteoclasts BzATP causes translocation of PKCα/β and phosphorylation but not 
translocation of PKCδ. NFAT was translocated to the nucleus following P2X7R 
activation. 




1.9. P2X7R knockout mice and P2X7R in human disease 
In an effort to confirm the role of P2X7R in immune processes before the 
development of suitably selective antagonists, the pharmaceutical companies 
Pfizer and GlaxoSmithKline developed mice lacking P2X7R (344, 345). Both 
mouse strains were generated on a B57BL/6 background with the P2X7R gene 
targeted at either exon 1 (GlaxoSmithKline) or exon 13 (Pfizer), resulting in viable 
and fertile mice lacking P2X7R expression (Figure 1.21). These P2X7R deficient 
mouse strains were initially used to confirm processes previously attributed to 
P2Z/P2X7R such as: IL-1β processing, pore formation and cell death (345, 346). 
A more detailed analysis of these P2X7R-/- mice using established models of 
specific diseases, as well as pharmacological inhibition of P2X7R in wild type 
mice, revealed a role for P2X7R in the pathology of a number of inflammatory and 
autoimmune diseases. P2X7R is involved in multiple sclerosis [MS] (347–350), 
amyotrophic lateral sclerosis [ALS] (351), pain (217, 218, 352–357), hepatitis (262, 
288), osteoporosis (339, 358) and RA (311). 
However, there have been significant discrepancies between results obtained from 
each of the two P2X7R-/- mouse strains. For example in one study P2X7R 
deficiency was associated with decreased disease incidence and clinical score in 
mice lacking P2X7R in a MOG35-55 peptide model of MS (349). In another study 
P2X7R-/- mice actually showed increased clinical scoring for EAE disease, through 
increased proliferative ability and decreased apoptosis of lymphocytes from these 
mice (348). Sharp et al. used mice provided by GlaxoSmithKline (349) whereas 
Chen et al. used P2X7R-/- mice provided by Pfizer (348). A possible explanation 
for this has only recently been elucidated and involved the discovery of alternative 
splicing of the P2X7R. 
P2X7R exhibits a large number of SNPs, which can cause loss or gain of receptor 
function and as such have been implicated in a number of diseases including 
depression (359) and M. Tuberculosis infection (307, 360). 
1.10. Splice variants: A potential caveat to studying P2X7R 
A recent study revealed that the human P2X7R, like other P2X receptors (173, 
361, 362), can undergo alternative splicing to produce splice variants of the full 
length receptor (363). So far, little has been studied in the context of human 




P2X7R (364) however mouse P2X7R is also alternatively spliced and has led to a 
re-evaluation of data gleaned from the two P2X7R knockout mice models. An 
initial study by Taylor et al. revealed that T lymphocytes from GlaxoSmithKline 
P2X7R-/- mice exhibited enhanced PS exposure, cell death and CD62L down-
regulation in response to ATP treatment (365). Cells from these mice did not 
express exon 1 of P2X7R (this is the site where the gene is targeted for deletion), 
however exon 3 was detectable in these cells. The group postulated that a splice 
variant of P2X7R escaped deletion in these mice, this was confirmed by the 
discovery of the K splice variant of P2X7R in mice (365, 366). The tissue 
expression of the K splice variant has been investigated as well as cell specific 
expression (342, 366). This splice variant has an alternative exon 1 compared to 
the wild type P2X7R and therefore is not removed by the GlaxoSmithKline 
targeting strategy, but it is removed in the Pfizer mouse. The electrophysiology of 
P2X7K differs from the full length P2X7A when expressed in HEK293 cells. 
P2X7K has a much longer channel inactivation time following withdrawal of 
agonist; it also has an increased sensitivity to ATP which may explain the 
enhanced responses observed in the GlaxoSmithKline P2X7R-/- mice. Rat P2X7K 
showed enhanced pore formation and membrane blebbing compared to P2X7A. 
Recently, a further two splice variants have been identified in the mouse which 
have shortened exon 13s (P2X713b and P2X713c) resulting in expression of 
truncated P2X7Rs (367). These isoforms are present in the wild type mouse, 
deleted from the GlaxoSmithKline P2X7R-/- mouse but P2X713b (and to a lesser 
extent P2X713c) was observed in Pfizer P2X7R
-/- mice; an additional “hybrid” 
P2X7R isoform was identified in the Pfizer P2X7R-/- mouse. The electrophysiology 
of the cloned receptors showed that P2X713b and the hybrid have significantly 
reduced currents compared to P2X7A and co-expression of P2X7A and P2X713b 
attenuated currents. 
In the study which first identified the human P2X7R splice variants two of these 
isoforms where cloned and studied: P2X7B which has a truncated C-terminal 
domain and P2X7H which lacks TMD1. P2X7H is non-functional and, although 
P2X7B couples to calcium influx, its activation does not cause pore formation or 
apoptosis when it is expressed alone. However, when P2X7B was co-expressed 
with P2XA it in fact caused an enhancement of pore formation and apoptosis. 




These isoforms were both expressed in a wide variety of tissues; however, P2X7B 
was expressed at a higher level than P2X7H. The relative levels of P2X7A and B 
vary between the studies and require further investigation. A more recent study 
also identified another truncated P2X7R splice variant (P2X7J) which lacks not 
only the C-terminus but also TMD2 and part of the extracellular loop (368). P2X7J 
was cloned from the CaSki cervical cancer cell line and was sub-cloned into 
HEK293 and MDCK cell lines for evaluation. When expressed alone P2X7J did 
not couple to pore formation or apoptosis of cells and only partially increased 
intracellular calcium levels; however, when co-expressed with wild type P2X7A it 
acted as dominant-negative isoform partially inhibiting these processes. Epithelial 
cells from the cornea from both healthy and diabetic humans express both 
isoforms but at varying levels (364). 
If these isoforms of P2X7R can form heterotrimers in primary cells, then the 
pharmacology of the P2X7R and its down-stream functions will depend on the 
association of these full length (P2X7A), function enhancing (P2X7B) and non-
functional (P2X7H and J) isoforms. Cloning and characterisation of the remaining 
P2X7R splice variants and the detailed analysis of these isoforms in primary 
tissues and cells will be important for understanding of P2X7R function in the 
future. The discovery of splice variants of the human P2X7R, coupled with the 
large number of SNPs for this receptor may explain, in part, why studies involving 






















Figure 1.21: P2X7R Splice variants in humans and mice. P2X7R has 
been reported to undergo alternative splicing in human and murine cells 
(240, 363, 366–368). The exons present in the full length (A) and other 
isoforms B-K and 13b and 13c are given in boxes. Where exons are 
present in the isoform they are given in black and where they are absent, 
due to alternative start and stop codons, they are given in red. The 
alternative n3 and 1’ exons as well as the shorter 13b and 13c exons are 
also given. The intro between exon 10 and 11 which inserts a new stop 
codon is shown as a red line. The strategies for developing P2X7 
knockout mice adopted by GlaxoSmithKline and Pfizer use a LacZ and 
Neomycin Cassette inserted into exons 1 and 13 respectively. P2X7K 
escapes the GlaxoSmithKline strategy and P2X13b and c escape the 
Pfizer strategy. 




1.11. Summary  
In summary, the function of T lymphocytes, particularly their circulation and 
homing to SLOs and peripheral sites of inflammation are tightly regulated 
processes. P2X7R expressed by T lymphocytes has a number of functions which 
include regulation of proliferation and adhesion molecules. Evidence from a wide 
variety of cell lines has shown P2X7R to activate multiple signalling pathways; 
however, the role of these signalling mechanisms coupling P2X7R activation to 
biochemical function in T lymphocytes is poorly understood. P2X7R is associated 
with a number of inflammatory and autoimmune disorders and while the receptor 
represents a novel therapeutic route of intervention, little progress has been made 
in translation to medicine. While chemical synthesis has provided P2X7R 
antagonists with vastly improved selectivity and potency, a better understanding of 
how P2X7R transduces its signals in T lymphocytes may improve its potential 
targeting in these diseases. In addition much pre-clinical work involving P2X7R 
has taken place in mice; however, the recent discovery of alternative splicing of 
the P2X7R in both mouse and human genomes has added further complexity. In 
addition, species differences are observed also observed for P2X7R activity (e.g. 
activation of P2X7R by ART2/NAD in mice). It was therefore the intention of this 
study to investigate the potential signalling mechanisms coupling P2X7R 














1.12. Aims and Objectives 
The aims of this project were three fold and designed to investigate the role of 
PI3K in ATP-gated P2X7 receptor signalling in lymphocytes. 
1) Confirm expression of P2X7R in Leukemic T cell lines and primary human 
T lymphocytes 
2) To confirm functional expression of P2X7R by use of biochemical assays 
and determine which processes to investigate the role of PI3K signalling in 
3) To investigate if PI3K signalling couples to P2X7R dependent processes 


























2.1. Materials and compounds list 
Unless otherwise stated all materials were purchased from Sigma Aldrich, Poole, 
Dorset, UK. 
2.2. Cell culture 
2.2.1. Cell lines 
THP-1 human acute monocytic leukaemia cell line (European collection of cell 
cultures, ECACC, Salisbury, UK) and leukemic T cell line J6 Jurkats (Cancer 
Research UK) were cultured in RMPI-1640 media supplemented with 10% FCS, 
10 μg/ml penicillin and 10 μg/ml streptomycin (All: Gibco, Invitrogen, Paisley, UK). 
The acute monocytic leukaemia cell line THP-1 was differentiated into 
macrophage-like cells by overnight incubation with 10 ng/ml IFN-γ and 25 ng/ml 
Lipopolysaccharide (LPS). Cells were cultured in cell culture flasks with a surface 
area of 75 cm2 at 37oC with a constant supply of air mixed with 5% CO2. Cultures 
were maintained by changing media every 2-3 days and kept at a confluency of 
approximately 0.5x106 cells per ml. Cultured cells were discarded after 12 weeks 
and replaced with frozen cell stocks stored in cryo-tubes in liquid nitrogen tanks. 
2.2.2. Isolation of Peripheral Blood Mononuclear Cells (PBMCs) from 
whole blood 
Syringes were prepared with heparin as an anti-coagulant (2 Units/ml whole 
blood) and blood was removed from an arm vein of a healthy human volunteer. 
Blood was mixed with RMPI-1640 without supplements at a ratio of 1:1 and 25-35 
ml was layered onto 15 ml lymphoprep (Axis Shield, Oslo, Norway). Preparations 
were then centrifuged at 1,500 rpm (250 g) for 30 minutes, ending with an 
unassisted stop. A sterile Pasteur pipette was used to remove the PBMC layer 
and transfer these cells to a fresh centrifuge tube. Cells were then washed 3 times 
by the addition of RMPI-1640 without supplements and centrifugation at 250g for 
10 minutes. 
2.2.3. Clonal expansion of αβTCR T cells 
After washing, freshly isolated PBMC was re-suspended in fully supplemented 
RMPI-1640 at a volume equal to that of the initial volume of whole blood drawn 
from the donor. SEB was added at a final concentration of 1 μg/ml for 72 hours. 




Cells were then washed 3 times to remove SEB before addition of twice the 
original volume of fully supplemented RMPI-1640 and 36 U/ml IL-2. To maintain 
cells, the volume of culture medium was doubled every 2 days and fresh IL-2 
added. Cells were used between 9-11 days post isolation and rested in fully 
supplemented RMPI-1640 without IL-2 overnight before use. 
2.2.4. Isolation of Naive CD4+ T lymphocytes from PBMC 
High purity naive CD4+ T lymphocytes were isolated from PBMC using a negative 
selection cell isolation kit [#130-094-131] from Miltenyi Biotec, Bisley Ltd., Surrey. 
After washing, freshly isolated PBMC were counted. PBMCs were re-suspended 
in 40 μl MACS buffer (PBS + 2 mM EDTA + 0.5% BSA, pH 7.4 – sterile filtered) 
per 107 cells. A cocktail of biotin conjugated antibodies labelling non-naïve CD4+ 
cells was then added, 10 μl per 107 cells, and cells placed at 4oC for 10 minutes. 
Labelling was stopped by the addition of 10 ml of ice cold MACS buffer and 
centrifugation at 250 g for 10 minutes. Supernatant was discarded; cells re-
suspended in fresh MACS buffer 80 μl per 107 cells and anti-biotin micro-beads 
added: 20 μl per 107. Cells were incubated for 15 minutes at 4oC followed by 
addition of 10 ml of ice cold MACS buffer and centrifugation at 250 g for 10 
minutes. Supernatant was discarded and cells re-suspended in 500 μl fresh 
MACS buffer. Cells were passed through a pre-washed LS column [#130-042-401] 
and collected in a fresh centrifuge tube. The column was washed 3 times with 3 ml 
MACS buffer. Cells were centrifuged and washed into fully supplemented RMPI-
1640 for immediate use in assays or activation and subsequent long-term culture. 
2.2.5. Isolation of splenocytes from mice 
Spleens from Cd1 mice were removed and disaggregated through a 40 μm filter. 
Red blood cells were removed by centrifugation through a layer of Lymphoprep 
and the remaining splenocytes were washed three times in serum free RPMI 1640 
by centrifugation at 250 g for 5 minutes. Cells were finally re-suspended at a 
concentration of 5x106/ml in complete RPMI 1640 and used immediately in 
experiments. 
2.3. Coupling of anti-CD3/CD28 antibodies to micro-beads 




Antibodies raised against human CD3 (clone: UCHT-1) and human CD28 (clone: 
9.3) were added, 75 μg each, to a 0.1 M borate buffer (pH 9.5). This antibody 
solution was added to 4 x 108 magnetic Dynabeads® (Invitrogen, Paisly, UK) and 
rotated overnight at 37oC. The next day the beads were held with a magnet and 
borate buffer was removed. Using the bead wash solution (Table 2.1), beads were 
washed three times for 10 minutes, once for 30 minutes and then overnight by 
rotation at 4oC. The following day beads were re-suspended in 10 ml bead wash 
solution for storage at 4oC; 40 x 106  anti-CD3/CD28 antibody coated beads/ml. 
Before use, beads were washed 3 times in phosphate buffered saline, re-
suspended in supplement free RPMI-1640 and added to cells at the indicated 
ratios. 
2.4. Stimulation and protein isolation 
For stimulations, cells were re-suspended in supplement free RMPI-1640 at a 
concentration of 2x106 and rested for 30 minutes in a 37oC water bath. Inhibitors 
or appropriate vehicle was applied to cells for indicated times before the addition 
of stimulants. After stimulation, cells were centrifuged for 30 seconds, supernatant 
removed and cells re-suspended in 50 μl NP40 lysis buffer per 1x106 cells 
(containing protease and phosphatase inhibitors as described in Table 2.2).  
For analysis of protein expression cells were removed from culture, washed and 
cells re-suspended in 50 μl NP-40 lysis buffer per 1x106 cells. After re-suspension 
in lysis buffer cells were rotated at 4oC for 15-30 minutes to assist lysis, after 
which debris was removed by centrifugation at 13,000 rpm 4oC for 10 minutes and 
the supernatant containing protein was stored at briefly at -20oC before 
immunoblotting. 
For measurement of CD62L released into the supernatant, cells were stimulated 
as described above except cells were at a concentration of 5x106 cells/ml. After 
stimulation, centrifugation for 30 seconds was used to pellet cells. The 
supernatant was removed and placed into a new micro-centrifuge tube and 350 μl 
ice cold 100% acetone was added per 500 μl supernatant. Cells were placed on 
ice for 10 minutes followed by centrifugation at 13,000 rpm 4oC for 10 minutes. 
The supernatant was discarded and precipitated protein was re-suspended in 50 
μl NP40 lysis buffer. 





Acrylamide gels were cast to the desired percentage for optimum resolution of 
different protein sizes. A resolving phase containing Tris-HCl pH 6.8 was first cast 
followed by a stacking phase containing Tris-HCl pH 8.8, with a comb to leave 
impressions for loading protein. 5 μl 5 x sample buffer (SDS and 2-Mercapto-
Ethanol) was added to 20 μl protein in NP-40 lysis buffer and samples were boiled 
at 100oC for 5 minutes. Samples were briefly centrifuged and then 20 μl of each 
sample was loaded onto the acrylamide gel. The gel tank was filled with running 
buffer and electrodes connected to the tank. Proteins were separated by 
electrophoresis first by passing through the stacking phase at 75 V for 15 minutes, 
followed by 150 V through the resolving phase until the desired molecular weight 
markers were adequately separated. 
Markers and proteins were transferred from the gel onto nitrocellulose membrane 
at 40 mA per membrane for 1 hour using semi-dry buffer and apparatus. The 
membrane was blocked with 5% milk in TBST (Tris buffered saline + 0.05% 
Tween 20) for 1 hour at room temperature. The membrane was then washed once 
briefly in TBST to remove excess milk, before being sealed in a plastic bag with 
the primary antibody. Primary antibodies were diluted as described (Table 2.3) in 
TBST + 1% BSA + 0.01% sodium azide and membranes were incubated overnight 
in 5 ml diluted primary antibody per membrane. 
The next day the membrane was removed from the bag and placed in a tray. The 
membrane was washed 3 x 5 minutes in TBST before incubation in HRP-
conjugated secondary antibody (raised against the same species as the primary 
antibody) diluted 1:10000 in TBST for 1-2 hours at room temperature. The 
membrane was then washed 3 x 5 minutes in TBST and once in TBS. 
Amersham™ ECL detection reagents (GE Healthcare, Little Chalfont, 
Buckinghamshire, UK) were mixed 1:1, placed over the membrane and allowed to 
cover the membrane for 1 minute. The membrane was then sealed in cling film 
and covered by X-ray film [Fuji Medical X-Ray Film 100 NIF 18 x 24] (Fisher 
Scientific) inside a film cassette. After the desired time, the film was removed and 
developed using a developer (Photon Imaging Systems, Swindon, Wilts, UK). 




To assess the relative phosphorylation levels of the signalling proteins Akt, Erk1/2 
and S6 ribosomal subunit, the intensity of phosphorylated protein detected by 
immunoblotting with specific antibodies was normalised to total levels of Akt or 
Erk1/2 protein. This was achieved using Image J software: developed film was 
scanned and intensity of background image was subtracted from protein bands, 
these bands were then normalised as described above. 
2.6. Gelatin Zymography 
Naïve CD4+ T lymphocytes were freshly isolated or leukemic T cell line Jurkat 
removed from culture, cells were washed before treatment with PMA or ATP. Cells 
were briefly centrifuged at 300 g for 30 seconds, the supernatant was collected 
and the cell pellet lysed as for immunoblotting except EDTA, protease and 
phosphatase inhibitors were removed from the lysis buffer (Table 2.2). Gelatin 
gels containing 0.1% w/v Gelatin were prepared, samples were added to the gel 
without boiling and proteins were separated using SDS-PAGE. Gels were 
developed the same protocol as Ghosh et al: gels were washed in developing 
solution (Table 2.4) with 2.5 % Triton X 100 for 1 hour (369). After a second 5 
minute wash, gels were developed overnight in developing solution with 1 % 
Triton X 100. This allows proteases separated by SDS-PAGE to break down the 
gelatin within the gel. Finally gels were stained with Coomassie blue for 30 
minutes and washed with destain solution containing methanol and acetic acid. 
2.7. Electrophysiology 
Naïve CD4+ T lymphocytes were freshly isolated from peripheral human blood and 
pipette in to a custom made cell bath filled with external buffer solution (Table 2.5). 
The bath was carefully fixed onto an Olympus IX71 inverted microscope 
(Olympus, Southend-on-Sea, Essex, UK). Cells were allowed to settle on to the 
bottom of the bath for 15-20 minutes. 
Borosilicate glass capillaries with filaments [GC150TF-10 Part #30-0066] (Harvard 
Apparatus, Kent, UK) were pulled into points using a Narishige PC-10 micropipette 
puller (Digitimer, Welwyn Garden City, Hertfordshire, UK). Pipettes were polished 
using a Narishige MF-830 microforge to give a filled resistance of 3-6 MΩ, when 
placed into the cell bath. Pipettes were back-filled with internal solution (Table 2.6) 




using a 1 ml syringe attached to a MF28-G5 syringe filter (World Precision 
Instruments, Sarasota, FL, USA). Filled pipettes were tapped to remove bubbles 
and fixed over the silver chloride electrode, this was fitted to a HEKA head-stage. 
The head-stage was attached to a Marzhauser Micromanipulator MM-33 (Intracel, 
Roysten, Hertfordshire, UK) which was used for coarse manipulation to position 
the pipette in the cell bath. 
The pipette was positioned carefully over a cell and fine manipulation was used to 
bring the pipette into contact with the cell (Figure 2.1). Using a syringe attached to 
the electrode and pipette, a small amount of negative pressure was applied to 
attach the pipette to the cell before further pressure was applied to form a seal of 
at least 1 GΩ resistance. Using a HEKA patch clamp EPC10 amplifier (Digitimer) 
and HEKA patch master 2.11 software the cell was voltage clamped at -60 mV 
and changes in the current required to maintain this voltage were recorded. 
Experiments were performed at ambient room temperature. 
Once a seal was formed and the cell voltage clamped, external buffer solution was 
passed over the cell through polyethylene tubing (Portex LTD, Smiths Medical, 
Hythe, Kent, UK). Excess external solution was removed from the bath using a 
pump [Dymax 5] (Charles Austen Pumps LTD, Byfleet, Surrey, UK) allowing the 
constant washing of cells with external buffer solution. 
Agonist and antagonist solutions were applied to the cells using a rapid solution 
changer (RSC) [RSC-200] (Biologic Science Instruments, Claix, France). Solutions 
were suspended above the RSC in syringes and allowed to pass by gravity 
through tubing; a remotely controlled valve determined when solutions were 
passed through tubing into borosilicate glass capillaries with filaments [GC100TF-
10 Part #30-0035] attached to the RSC. RSC positioning over the cell and valve 
opening and closing were controlled by RSC software. Solutions were applied 
using the RSC as described above and changes in current were recorded using 
HEKA patch master 2.11 software. Information from the HEKA amplifier was also 
passed through a Power lab 2/20 data acquisition system (ADInstruments, Oxford, 
UK) and recorded on chart recorder Chart V4.0.1 software. 
All equipment was mounted on an anti-vibration table [Isolate System 2000] 
(Intracel, Roysten, Hertfordshire, UK). All equipment was earthed to reduce 




electrical interference and during recordings a small earthed sheet of foil was 








2.8. Ethidium bromide Uptake 
Freshly isolated naïve CD4+ T lymphocytes were re-suspended external buffer 
solution (Table 2.5) containing 25 μM ethidium bromide at a concentration of 
1x106 cells per ml. 90 μl of cell suspension was placed into each well of a 96 well 
black bottom plate. The plate was then placed into a FluoStar Optima plate reader 
(BMG Labtech) at 37oC and allowed to rest for 5 minutes. Cells were excited at 
544 nm and emission collected at 590 nm every 30-90 seconds. Baseline 
fluorescence was recorded before the application of vehicle or ATP. At the end of 
the experiment cells were lysed by addition of 0.2% Triton X-100 to give a value 
for maximum ethidium bromide fluorescence, all data points were then normalised 
to the maximum fluorescence. Finally, linear regression was used to determine the 
Figure 2.1 Electrophysiology apparatus. A cell is rested at the bottom of the bath 
surrounded by external buffer with divalent cations (Table 2.4). This solution is 
slowly perfused over the cell through a drip feed pipe and removed using an 
aspirating pump. An electrode is introduced into the bath, suction is applied through 
the electrode to form a seal with the cell of >1 GΩ resistance. The cell voltage is 
“clamped” at -60 mV and changes in the current across the membrane are 
recorded. Solutions containing agonists/antagonists are applied by the RSC using 
the protocols described in Figure 3.3. Changes in membrane current are recorded 
and represented in graphical form on a personal computer using HEKA software. 




rate of fluorescence increase (change in percent maximum fluorescence per 
minute) in the first 15 minutes prior to ATP addition using the below equations. 
 
2.9. Cellular Death Assays 
2.9.1. Apoptosis 
Freshly isolated naïve CD4+ T lymphocytes were treated with ATP at the indicated 
concentrations. 250,000 cells per point were washed twice in ice cold PBS and 
then re-suspended to a concentration of 1x106 cells/ml in annexin V binding buffer 
(10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl2, 0.1% BSA). APC 
conjugated annexin V (Southern Biotec, Birmingham, Alabama, USA) was then 
added to each tube 10 µl/1x106 cells and cells incubated on ice protected from 
light for 15 minutes. Further binding buffer was added followed by propridium 
Iodide (PI) 2 µg/1x106 cells. Cells were immediately analysed by flow cytometry. 
2.9.2. LDH measurement 
Freshly isolated naïve CD4+ T lymphocytes were re-suspended in phenol red free 
RMPI-1640 without supplements at a concentration of 1x106 cells/ml. 90 μl of cell 
suspension was added to each well of a sterile 96 well plate and each condition 
was performed in triplicate. Vehicle or antagonists were added before agonists 
were added for the indicated times and the plate was incubated at 37oC with a 
constant supply of air mixed with 5% CO2. 0.2% Triton X-100 was added to three 
wells for 5 minutes to rupture cell membranes and cause the maximum release of 
LDH from cells. The plate was centrifuged at 250 g for 10 minutes with a brake 
assisted stop and 50 μl of supernatant for each well was transferred to a new clear 
bottomed 96 well plate using a multi-channel pipette. Three wells were left blank to 
measure absorbance of the plate alone, three wells were filled with 50 μl phenol 
red free RMPI-1640 without supplements to measure absorbance of the medium 
and LDH positive control (Bovine heart LDH 1:5000 dilution in PBS) was also 




added to three wells. LDH assay reagent [G1780] was mixed according to the 
manufacturer’s instructions (Promega, Southampton, UK) and 50 μl added to each 
well. The plate was covered in foil to protect from light and incubated at room 
temperature for 30 minutes. The LDH reaction and colorimetric reaction to 
produce a red product are described below. 
 
 To stop the LDH reaction 50 μl 1 M acetic acid was added to each well, bubbles 
were carefully removed and absorbance recorded at 490 nm. 
2.10. Proliferation 
The Cell Trace CFSE Cell Proliferation Kit (C34554) (Invitrogen, Paisly, UK) was 
used to measure proliferation of cells according to the manufacturer’s instructions. 
Carboxyfluorescein diacetate succinimidyl ester (CFSE) is cell permeable, binds 
DNA and emits fluorescence at 517 nM when excited at 492 nm. After each mitotic 
cell division the two daughter cells receive half the CFSE labelled DNA from the 
parent cell each; therefore, the fluorescence intensity effectively halves. This can 
be used to determine the proliferative capabilities of cells under specific treatment 
conditions. Briefly, freshly isolated naive CD4+ T lymphocytes were re-suspended 
at a concentration of 1x106/ml in PBS + 0.1% BSA. CFSE was added for a final 
concentration of 5 μM and cells incubated in the dark at 37oC for 15 minutes. Cells 
were washed once into fresh complete RMPI-1640 and incubated in the dark at 
37oC for a further 30 minutes. Cells were then washed again into fresh complete 
RMPI-1640 and a small number of freshly labelled cells were analysed by flow 
cytometry for incorporation of CFSE at day 0 alongside unlabelled naive CD4+ T 
lymphocytes (unlabelled control). Remaining cells were pre-treated with vehicle or 
inhibitors as indicated. Cells were then activated by the addition of anti-CD3/CD28 
antibody coated beads to cells at a ratio of 3:1 plus the addition of 36 Units/ml 
recombinant IL-2. After 7 days cells were analysed for CFSE fluorescence using 
flow cytometry; population gates were set around peaks and the percentage of 
cells in each division counted. 




2.11. In vitro migration assays 
2.11.1. Neuroprobe chamber assay 
A chamber based in vitro migration assay was used as described (95). Freshly 
isolated naive CD4+ t lymphocytes were re-suspended at a concentration of 
3.2x106 cells/ml in phenol red free RMPI-1640 with 0.01% BSA (chemotaxis 
media) added. Cells were pre-treated with vehicle or inhibitors at the indicated 
concentrations. To equilibrate a fresh Neuroprobe chemotaxis plate (Chemo® 
Tx101-5 Receptor Technologies) PBS was added to each well and the plate 
placed in a 37oC 5% CO2 incubator for 1 hour. PBS was then aspirated from the 
plate and replaced with 29 μl of either plain chemotaxis media or chemokine 
diluted in chemotaxis media at the given concentrations. The supplied 5 μM pore 
membrane was placed over the plate and 25 μl of cell suspension carefully 
applied to each well as a bubble using a pipette (Figure 2.2 A-C). The plate was 
then incubated in a 37oC 5% CO2 incubator for 3 hours. A single piece of 
Wattmann paper was quickly passed evenly across the membrane to remove cells 
which have not moved from the top bubble. Centrifugation at 300 g for 10 minutes 
without a brake assisted stop allowed collection of cells which had passed through 
the membrane into the bottom well. The membrane was removed and cells from 
each well were placed in 300 μl PBS for analysis by flow cytometry. A gate was 
set for “live” cell size, based upon CD4+ labelling of freshly isolated naive CD4+ T 
lymphocytes, and the number of cells counted within this gate in 30 seconds was 
recorded for each sample (well). 
2.11.2. IBIDI live cell microscopy 
For multi-parameter analysis of cell migration across a fibronectin coated surface 
an μ-Slide assay #80301 (IBIDI, Martinsried, Germany) system was employed as 
described here (370). Each μ-Slide chamber was coated with pre-warmed (37oC) 
45 μg/ml fibronectin for 1 hour at room temperature before washing twice with 
ultra-pure MilliQ water. One μ-Slide chamber was then filled with chemotaxis 
media followed by addition of 18 μl of chemokine into the top part of the chamber 
(Figure 2.2 D). Chemokine was used at 100 nM to give an approximate 
concentration of 33 nM at the bridge area by diffusion, according to the 
manufacture’s product information (Figure 2.2 E). Freshly isolated naive CD4+ T 
lymphocytes were re-suspended in chemotaxis media to a concentration of 1x107 




cells/ml and 6 μl cell suspension pipetted into the bridge area using the hole 
provided (Figure 2.2 D). The μ-Slide was placed into an environmental chamber 
heated to 37oC attached to a Zeiss LSM 510 Meta and a chemokine gradient 
allowed to form over 15 minutes. An area of cells at the top of the bridge was 
selected by the criterion that it must contain at least 25 cells. A time series of 60 
images were recorded every 15 seconds for 15 minutes. Cells were tracked using 
Image J software, the Manual Tracking plug-in (Fabrice Cordelières) and using the 
Chemotaxis and Migration Tool (Gerhard Trapp and Elias Horn). A total of 20 cells 









Figure 2.2 Apparatus for measuring In vitro cell migration. A. Top down 
view of a 96 well Neuroprobe plate. B. Side on view of a 96 well Neuroprobe 
plate showing cell suspension bubbles on the surface. C. Cartoon showing a 
bubble of cell suspension on the surface of the membrane, with chemokine in 
the bottom chamber. Cells migrate towards chemokine through the membrane 
and are retained in the bottom chamber. Cells are then counted as described. 
D. Top down view of IBIDI µslide. Chemokine and cells are added where 
indicated. E. Side on view of IBIDI µslide showing chemokine gradient (C0-100) 
and the bridge where cell migration is recorded using confocal microscopy. 




2.12. CD62L and CCR7 expression by Flow Cytometry 
Freshly isolated naive CD4+ T lymphocytes, SEB activated T lymphocytes or the 
leukemic T cell line Jurkat were re-suspended in fully supplemented RMPI-1640 at 
a concentration of 1x106 cells per ml in a 24 well plate. Vehicle or antagonist was 
added to cells before addition of agonist for the indicated time period. Cells were 
transferred to micro-centrifuge tubes and centrifuged for 30 seconds, ice cold 
FACS buffer (PBS + 2% FCS) was added to wash cells and the process repeated 
a second time. After washing, cells were re-suspended in 100 μl FACS buffer + 1 
μl FITC-conjugated anti-CD62L antibody clone DREG-56 (eBioscience, Hatfield, 
UK) or isotype control IgGκ1 (R and D Systems, Abingdon, UK). Alternatively cells 
were also labelled with APC-conjugated anti-CCR7 antibody clone 3D12 or 
isotype control IgG2aκ (Both: eBioscience, Hatfield, UK). Cells were labelled with 
antibody on ice for 1 hour and washed twice more in FACS buffer. Finally cells 
were re-suspended in PBS and placed into 5 ml round bottomed tubes (VWR, 
Lutterworth, Leicestershire, UK) for analysis by flow cytometry. Fluorescent 
labelling of cells was recorded using a BD FACS Canto II flow cytometer (BD 
Biosciences, Oxford, UK) and analysed using BD FACS Diva software.  
Mean fluorescence index (MFI) was used to describe the level of CD62L 
expression. For measuring the effect of inhibitors on anti-CD3, anti-CD3/CD28 
antibody coated beads or ATP treatment, the change in MFI following treatment 
was first analysed by a t-test to check for significance. Following this, the vehicle 
control MFI was set as 100% CD62L expression and all other treatment groups 
were normalised as percent of control MFI (%). Initial (control) CD62L MFI was 
variable between donors; therefore normalising to control allows easy comparison 
of responses between experiments. One Way ANOVA followed by Tukey’s post-
test was used to compare the loss of cell surface CD62L observed for DMSO 
versus inhibitor treated groups. 
2.13. Reactive Oxygen Species Generation 
Cells were re-suspended in supplement free RMPI-1640 and labelled with 10 mM 
2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA, Invitrogen, Paisley, UK) at 
room temperature protected from light for 45 minutes. Cells were then washed into 
external buffer solution (Table 2.5) and re-suspended at a concentration of 1x106 




cells per ml. 90 μl of cell suspension was placed into each well of a 96 well black 
bottom plate. The plate was then placed into a FluoStar Optima plate reader (BMG 
Labtech) at 37oC and allowed to rest for 5 minutes. Cells were excited at 485 nm 
and emission collected at 520 nm every 30-90 seconds. Baseline fluorescence 
was recorded before the application of vehicle or ATP. Samples were stimulated in 
three triplicate wells per treatment group. Linear regression was performed on to 
determine the rate of ROS generation per minute using the below equation: 
 
To measure mitochondrial O2
- levels cells were loaded with 2.5 μM MitoSOX Red 
(Invitrogen, Paisley, UK) for 30 minutes at 37oC protected from light. Cells were 
then washed, treated with agonist for the indicated time, washed into PBS and 
analysed using flow cytometry. Cells were excited at 488 nm and emission 
recorded at 585/42 nm. 
2.14. Statistical analysis 
Data were normalised as described above and in figure legends, statistical 
analysis was performed using GraphPad Prism software. Graphical 
representations of data include mean values ± standard error of the mean (SEM) 
or ± standard deviation (STDEV) for n≥3 and n=2 respectively. For normalised 
data a One Way ANOVA followed by Tukey’s post-test was performed to analyse 
significance between treatment groups. For all experiments the following marks 
are used to indicate the levels of significance: 
*/#/^  p<0.05 
**/##/^^ p<0.01 
***/###/^^^ p<0.001 
For CD62L experiments mean fluorescent index (MFI) for vehicle and agonist 
treatment was first compared using a paired one-way Student’s t-test, then data 
was normalised and analysed as described above to compare inhibitor treated 
groups. 




2.15. Appendix of Tables 
Component Concentration 
Phosphate buffered saline (without 
Ca2+ and Mg2+) 
- 
Human AB serum 3% v/v 
Sodium Azide 1% v/v 
EDTA pH 8.0 2 mM 
Table 2.1: Antibody bead wash solution 
 
Component Concentration Protease/phosphatase inhibitor 
target 
H2O -  







Nonident P-40 (NP-40) 1% v/v  
EDTA 5 mM  
Sodium Vanadate 1 mM Tyrosine Phosphatases, ATPases, 
Phosphate Transferring Enzymes 
Sodium Molybdate 1 mM Acid and Phosphoprotein 
Phosphatases 
Sodium Fluoride 10 mM Serine/Threonine Phosphatases 
PMSF 40 μg/ml Serine Proteases 
Pepstatin A 0.7 μg/ml Acidic Proteases 
Aprotinin 10 μg/ml Lipoprotein Lipases 
Leupeptin 10 μg/ml Serine and Thiol Proteases 
Soybean Trypsin 
Inhibitor 
10 μg/ml Trypsin 
Table 2.2: Composition of NP40 lysis buffer and targets of protease and 
phosphatase inhibitors 








P2X7R Rabbit 0.2 Santa Cruz 
CD62L Mouse 0.5 E-bioscience 
P-Erk1/2 Rabbit (1:1000 dilution) Cell Signalling 
Technologies 
P-Akt Rabbit 0.4 Santa Cruz 
P-S6 Ribosomal 
Subunit 
Rabbit (1:1000 dilution) Cell Signalling 
Technologies 
Erk1 Rabbit 0.2 Santa Cruz 
Akt1 Goat 0.2 Santa Cruz 
Table 2.3: Antibodies used for Immunoblotting 
Where dilutions are given in brackets information about the initial antibody 
concentration was unavailable. 
Component Concentration 
H2O - 
Tris-HCl pH 7.0 50 mM 
Calcium Chloride 6.5 mM 
Zinc Chloride 5 μM 
Sodium Azide 0.5 g/L 
Triton X 100 0-2.5 % as required 




Sodium Chloride 147 mM 
Potassium Chloride 2 mM 
Calcium Chloride 2 mM 
Magnesium Chloride 1 mM 
Hepes 10 mM 
D-Glucose 12 mM 
 pH 7.4 with Sodium Hydroxide 
Table 2.5: Composition of external buffer solution used for methods 2.5, 2.6 and 
2.7. 







Potassium Chloride 147 mM 
Hepes 10 mM 
EGTA 1 mM 
 pH 7.4 with Potassium Hydroxide 
Table 2.6: Composition of internal solution for electrophysiology experiments. 





3. Chapter 3: Expression and 





















3.1. Expression of P2X7R in T lymphocytes 
3.1.1. Rationale 
P2X7R was first cloned in 1997 (189) and its expression was identified in the 
majority of tissues (241). High levels of P2X7R expression is observed in cells of 
the immune system including: monocytes, Natural Killer (NK) cells, B and T 
lymphocytes (242). Before investigating the role of P2X7R in human T lymphocyte 
function, it was necessary to confirm functional expression of P2X7R in these 
cells. PCR and immuno-blotting are commonly used to confirm expression of 
P2X7R at the mRNA and protein levels respectively. Functional expression can 
also be confirmed by a number of well-established assays. Activation of P2X7R 
induces influx of Ca2+ and Na+ and efflux of K+ ions which can all be measured 
using fluorescent dyes. This movement of ions causes a change in the current 
across the cell membrane which can be measured using electrophysiological 
techniques. The ability to measure current across cell membranes by fixing 
(clamping) the cell voltage was initially developed by Cole et al. in the late 1940s 
and involved a circuit combining an external and internal electrode. This technique 
was further developed in the 1950s by Hodgkin and Huxley (371). A breakthrough 
came in the 1970s and 80s, when Neher and Sakmann developed the patch 
clamp technique, this allowed the measurement of currents through single 
channels on cells (372). The voltage patch clamp technique (described in 
materials and methods and here (342)) has been used here to investigate the 
changes in membrane current in response to agonists and antagonists. Prolonged 
P2X7R activation can also result in the influx of large molecules through the 
opening of a membrane associated pore, Pannexin-1 (191, 270, 271, 274). A 
biochemical assay employing large molecular weight fluorescent dyes such as 
ethidium bromide can be used to indirectly measure activation of P2X7R (246, 
342). 
3.1.2. Aim 
The aim of these initial experiments is to confirm expression of P2X7R at the 
protein level and demonstrate using electrophysiology and an ethidium bromide 
uptake assay that this protein functions as an ion channel and induces 




biochemical changes in T lymphocytes. The role of P2X7R in cell proliferation and 
death will also be investigated briefly. 
3.1.3. P2X7R protein is expressed in Leukemic cell lines and human 
naïve CD4+ T lymphocytes 
The leukemic T cell line Jurkat was established from a 14 year old boy with acute 
T cell leukaemia. This cell line was identified for its ability to produce high levels of 
the cytokine IL-2; T cell signalling mechanisms were also explored using the 
leukemic T cell line Jurkat (373–376). It was subsequently discovered that this cell 
line has aberrant signalling pathways; lack of SHIP and PTEN expression leads to 
high basal levels of PI(3,4,5)P3 and constitutive PI3K signalling pathway activation 
(377). Other leukemic T cell lines include CEM, a cell line derived from an acute 
lymphoblastic leukaemia in a 4 year old girl. Cell lines have also been developed 
for studying other cell types such as monocytes; for example, the THP-1 acute 
monocytic leukaemia cell line (378). THP-1 monocytic leukaemia cells can be 
differentiated into a macrophage-like cell type by stimulation with PMA or IFN-γ 
and LPS (379). P2X7R is expressed by the THP-1 monocytic leukaemia cell line 
and its expression levels are up-regulated following differentiation into 
macrophage-like cells (380, 381). Treatment of induced macrophage-like cells with 
ATP causes them to process and release the pro-inflammatory cytokine IL-1β, a 
process which requires P2X7R activity (246–248). Therefore, the THP-1 acute 
monocytic leukaemia cell line was used as a positive control for P2X7R 
expression and function in biochemical assays in this study. 
While P2X7R expression has previously been shown in leukemic cell lines, and 
primary murine and human T lymphocytes it is necessary to confirm this in the 
cells used for this study. Protein lysates were isolated as described in materials 
and methods, separated using SDS-PAGE and immunoblotted for P2X7R. Full 
length P2X7R is 595 amino acids in length (189) and its molecular weight based 
on this sequence is  68.57 KDa (calculated using P2X7R sequence  Accession 
number: ACS72266 and protein molecular weight tool from 
www.sciencegateway.org/tools/proteinmw.htm). P2X receptors are subject to a 
number of post translational modifications including glycosylation (382) and 
palmitoylation (383). P2X7R is also known to undergo alternative splicing to 




produce a number of splice variants of varying size described in more detail in the 
introduction to this study (240, 363, 366, 384) (Figure 1.21). A rabbit polyclonal 
antibody raised against human P2X7R that recognises amino acid residues 331-
595 of the C-terminus (Santa Cruz P2X7R (H-265)) was used for immunoblotting. 
This antibody reveals 6 bands indicated by arrows in the top panel of Figure 3.1. 
In the cell lines and samples from primary cells a band, sometimes appearing as a 
doublet, between 55 and 72 KDa and is the strongest band in these samples. The 
largest band is between 95 and 130 KDa which only appears in leukemic cell 
lines; a band at approximately 72 KDa is faintly visible in all samples except THP-
1 acute monocytic leukaemia cell line and naïve CD4+ donor 2. THP1 and Jurkat 
cell lines also display 1 and 2 band(s) respectively between 43 and 55 KDa, but 
these are not observed elsewhere. The membrane was stripped and re-probed, 
using antibody against Erk1 (that also recognises Erk2), to determine the level of 
protein loaded and transferred to the immunoblot. Protein levels varied across the 
samples and this may account for the difference in the intensity of bands observed 


























Figure 3.1: Expression of P2X7R protein in leukemic cell lines and human 
naïve CD4+ and SEB activated T lymphocytes. Naive CD4+ T lymphocytes were 
freshly isolated from four healthy donors (D1-4); SEB cells were expanded from 
PBMC as described in materials and methods and removed from ex vivo culture 
after 9 days. THP1, Jurkat and CEM leukemic cell lines were cultured as described 
and cells removed from culture. All cells were lysed as described, loaded onto poly-
acrylamide gels and proteins separated under reducing conditions using SDS-
PAGE. Proteins were transferred to nitro-cellulose membrane, blocked and 
immunoblotted for P2X7R using anti-P2X7R antibody (Santa Cruz clone: H-265). 
Membranes were stripped of antibody, blocked and re-probed for Erk1/2 using anti-
Erk1 (Santa Cruz). For naïve CD4+ T lymphocytes the blot is representative of 6 
donors investigated. For leukemic cell lines and SEB activated T lymphocytes the 
blot is representative of multiple experiments. 




3.1.4. Electrophysiology of P2X7R channel in T lymphocytes 
Whole cell patch clamp technique was used to investigate the electrophysiological 
properties of P2X7R in the leukemic T cell line Jurkat and primary human naïve 
CD4+ T lymphocytes. Human T lymphocytes expanded ex vivo by SEB or PHA 
were also very briefly investigated. The whole cell patch clamp technique allows 
the measurement of membrane capacitance, which is defined as “the quantity of 
charge that must be moved across unit area of the membrane to produce a unit 
change in membrane potential” (385). Membrane capacitance is measured in 
Farads (F) and gives an indication of the size of a cell. The membrane 
capacitance for the leukemic T cell line Jurkat and naïve CD4+ T lymphocytes, as 
well as ex vivo SEB or PHA activated T lymphocytes, is given in Figure 3.2. The 
membrane capacitance of the leukemic T cell line Jurkat ranged from 1.19 pF to 
16.39 pF and the mean membrane capacitance was 7.92 pF ± 0.99 (n=81 cells ± 
SEM). For naïve CD4+ T lymphocytes it ranged from 1.19 pF to 11.54 with a mean 
capacitance of 2.53 ± 0.45 pF (n=24 cells ± SEM). Naïve CD4+ T lymphocytes had 
significantly lower membrane capacitance than the leukemic T cell line Jurkat and 
T cells expanded ex vivo using SEB. For post-analysis of recorded currents, the 
change in current was normalised to the membrane capacitance recorded for that 



















Figure 3.2: Membrane capacitance of different T lymphocytes. Cells were 
isolated or removed from culture (9 days post activation for SEB and PHA 
expanded cells). Whole cell seal with resistance >1GΩ was achieved as described 
and the membrane capacitance was recorded from HEKA patch master 2.11 
software. Data is displayed as box and whisker diagrams and analysed by One 
Way ANOVA followed by Tukey’s post hoc test #p<0.05, **p<0.01 and ***p<0.001. 
Lower (l) and upper (u) 95% confidence intervals and number of cells (n) for each 
cell type: CD4+ l=1.58, u=3.49 and n=23; SEB l=3.22, u=12.23 and n=8; PHA 
l=3.23, u=5.84 and n=12; and Jurkat l=7.08, u=8.75 and n=81. 
Figure 3.3: Protocols for ATP application. Agonists and/or antagonists were 
applied in the solution described in Table 2.5, with or without (Free) divalent cations 
at the indicated points, for the required time periods. After 21 seconds all tubes 
from the rapid solution changer were switched off and the slow perfusion of divalent 
cation containing buffer was the only feed into the cell bath. A rest period of 60 
seconds was taken between applications of the protocols, to allow full cleansing of 
the cell bath by the slow perfusion system. 




Agonists and antagonists were applied using the protocols in Figure 3.3 using the 
rapid solution changer (RSC). Protocol A was used to apply ATP in buffer 
containing divalent cations (MgCl2 and CaCl2); Protocol B to apply ATP in buffer 
free from divalent cations and Protocol C was used to apply ATP in divalent cation 
free buffer in the presence of the P2X7R antagonist A438079. 
3.1.4.1. Leukemic T cell Line Jurkat 
The leukemic T cell line Jurkat was initially used to set up the whole cell patch 
clamp technique for human T lymphocytes, as Western Blotting indicated that 
these cells expressed high levels of protein recognised by the anti-P2X7R 
antibody (Figure 3.1). P2X7R is activated by high millimolar concentrations of ATP 
and small inward currents were observed in response to 5 mM ATP applied for 10 
seconds in buffer containing 2 mM CaCl2 and 1 mM MgCl2 (Figure 3.4 A). When 
CaCl2 and MgCl2 were removed from the application buffer the current density of 
response induced by 10 second 5 mM ATP application was increased (Figure 3.4 
B). The inhibitory effect of these divalent cations was significant (Figure 3.4 C). 
The ability of ATP to induce currents in the leukemic T cell line Jurkat was 
dependent on the concentration of ATP applied for 10 seconds (Figure 3.4 D). 
Interestingly, application of 0.1 mM ATP caused a small outward current (Figure 
3.4 D). Small inward currents were observed with 1 and 3 mM ATP treatment 
however 5 mM ATP produced a noticeably larger current. The P2X7R competitive 
antagonist A438079 was applied prior to, and during, 10 second 5 mM ATP (in 
divalent free buffer). Use of 3 µM A438079 almost completely blocked the 
response to 5 mM ATP, suggesting that a major component of the inward current 
in response to ATP is due to activation of the P2X7R channel (Figure 3.4 E and 
F). 
 










Figure 3.4: Electrophysiology of P2X7R in the leukemic T cell line Jurkat. 
Whole cell patch clamp electrophysiology was used to voltage clamp cells at -
60mV; change in current was measured in response to ATP. A. 5 mM ATP was 
applied for 10 seconds in buffer containing CaCl2 and MgCl2. B. 5 mM ATP was 
applied for 10 seconds in buffer free from CaCl2 and MgCl2. C. Current density in 
presence and absence of divalent cations is compared. D. Increasing 
concentrations of ATP were applied for 10 seconds followed by 60 second pause. 
E. 5 mM ATP was applied for 10 seconds in the presence or absence of 3 μM 
A438079. F. Current density when ATP was applied in the presence or absence of 
3 μM A438079 is compared. Currents are from single representative cells and data 
are the mean of at least 3 independent experiments ± SEM, except E and F n=2 ± 
range. Student paired t-test was performed to compare treatments *p<0.05 




3.1.4.2. Activated primary T lymphocytes 
Having established the voltage clamp technique using the leukemic T cell line 
Jurkat, it was desirable to apply this to the investigation of P2X7R expression in 
primary human T lymphocytes. Naïve CD4+ T lymphocytes were to be the focus of 
subsequent functional experiments, however the electrophysiology of primary 
human T lymphocytes activated ex vivo by SEB or PHA was briefly investigated. 
Whole cell patch clamp recordings revealed a small inward current upon 10 
second application of 5 mM ATP in both SEB and PHA expanded T lymphocytes 
(n=1). 
3.1.4.3. Naïve CD4+ T lymphocytes 
Similar to the leukemic T cell line Jurkat, naïve CD4+ T lymphocyte freshly isolated 
from peripheral human blood demonstrated inward currents in response to 10 
second application of 5 mM ATP. These currents were sensitive to inclusion of 
divalent cations in the application buffer. Application of 5 mM ATP in CaCl2 and 
MgCl2 buffer caused an inward current, this was increased when ATP was applied 
in CaCl2 and MgCl2 free buffer (Figure 3.5 A and B). Although this difference was 
marked, it was not significant (Figure 3.5 C). Consecutive application of ATP at 
increasing concentrations, with 60 seconds between applications, reveals 
concentration dependence for ATP in evoking inward currents. Low 
concentrations (0.01 and 0.1 mM) of ATP caused very small outward currents but 
higher concentrations (1, 3 and 5 mM) of ATP caused inward currents (Figure 3.5 
D). The requirement for high millimolar concentrations of ATP is characteristic of 
the pharmacology of the P2X7R, and use of A438079 confirmed P2X7R 
involvement. Pre-treatment of cells with 10 μM A438079 caused a significant 
inhibition of current evoked by 10 second 5 mM ATP application (Figure 3.5 E and 
F). 
 










Figure 3.5: Electrophysiology of P2X7R in Naive CD4+ T lymphocytes. Whole 
cell patch clamp electrophysiology was used to voltage clamp cells at -60mV; 
change in current was measured in response to ATP. A. 5 mM ATP was applied for 
10 seconds in buffer containing CaCl2 and MgCl2. B. 5 mM ATP was applied for 10 
seconds in buffer free from CaCl2 and MgCl2. C. Current density in presence and 
absence of divalent cations is compared. D. Increasing concentrations of ATP were 
applied for 10 seconds followed by 60 second pause. E. 5 mM ATP was applied for 
10 seconds in the presence or absence of 10 μM A438079. F. Current density when 
ATP was applied in the presence or absence of 10 μM A438079 is compared. 
Currents are from single cells and representative of experiments conducted in cells 
from at least 3 independent donors. Data are the mean of at least 3 independent 
experiments using cells from different donors ± SEM. Student paired t test was 
performed to compare treatments *p<0.05 




3.1.5. ATP causes the uptake of large molecular weight molecules 
into primary human T lymphocytes and leukemic cell lines  
As described in the previous section, short (10 second) application of ATP causes 
the movement of ions across the cell membrane by the activation of P2X7R. 
Prolonged application of ATP has been shown to lead to a second permeation 
state through the opening of associated Pannexin-1 hemichannels (271, 274), this 
leads to the uptake of large molecular weight molecules. Before cloning of the 
P2X7R, the proposed receptor P2Z was identified by the ability of ATP to cause 
activation of this second permeation state and subsequent cell death. Therefore, 
this thesis sought to use an assay for measurement of pore formation, by uptake 
of the large molecular weight dye ethidium bromide, to provide further evidence for 
P2X7R expression on human naïve CD4+ T lymphocytes. Previous work in our 
group has demonstrated that ATP couples to ethidium bromide uptake in HEK293 
cells transfected with mouse or rat P2X7R, RAW 264.7 and J774.2 murine 
macrophage cell lines, primary mouse BMDMs and LPS/IFNγ differentiated 
human acute monocytic leukaemia cell line THP-1 (204, 246). THP-1 cells 
differentiated with LPS and IFNγ were used as a positive control to optimise an 
ethidium bromide assay for measuring pore formation. 
[ATP] (mM) 0 1 3 5 EC50 
THP-1 0.09 ± 0.02 0.302 ± 0.04 
 




















Table 3.1: Effect of ATP on ethidium bromide uptake in primary cells and cell lines 
Values are given for the rate of ethidium bromide uptake over 15 minutes 
(normalised to Triton X-100 control) after vehicle or 1, 3, 5 mM ATP treatment 
(%ΔMax.min-1 ± SEM). The final column also gives the EC50 values where they 
have been calculated for that cell type. One Way ANOVA followed by Tukey’s 
post-test used to determine significance *p<0.05, **p<0.01 and ***p<0.001. 




3.1.5.1. Ethidium bromide uptake in THPs 
THP1 cells differentiated overnight with LPS and IFNγ and treated with ATP 
showed an increased rate of ethidium bromide uptake, compared to vehicle 
treatment (Figure 3.6 A and Table 3.1). This was concentration dependent and the 
EC50 for ATP induced ethidium bromide uptake is 1.65 mM (Figure 3.6 B and 
Table 3.1). This value is similar to that previously published by our group under 
the same experimental conditions (246). 
3.1.5.2. Ethidium bromide uptake in naïve CD4+ T lymphocytes 
Naive CD4+ T lymphocytes freshly isolated from peripheral human blood also 
show an increase in the rate of ethidium bromide uptake following ATP treatment 
(Figure 3.7 A and Table 3.1). Rate of ethidium bromide uptake in response to 15 
minute vehicle treatment increased significantly following treatment with 5 mM 
ATP. This effect of ATP was concentration dependent with an EC50 of 1.47 mM 
(Figure 3.7 B and Table 3.1). Un-expectedly, the P2X7R inhibitor A438079 at 10 
μM failed to inhibit 5 mM ATP induced ethidium bromide uptake (Figure 3.7 C). 
3.1.5.3. Ethidium bromide uptake in SEB activated T lymphocytes 
Similarly to human naïve CD4+ T lymphocytes, human T lymphocytes clonally 
expanded from PBMC using SEB showed increased ethidium bromide uptake in 
response to ATP (Figure 3.8 A). This response was greater and significant at 
lower concentrations than for naive cells, with significant increases for 1, 3 and 5 
mM ATP treatment (Table 3.1). In SEB activated T lymphocytes 3 mM ATP 
induced ethidium bromide uptake was significantly inhibited by the exclusion of 
CaCl2 and MgCl2 in the external buffer solution (Figure 3.8 B).However, there 
were no significant differences with 1 or 5 mM treatment. 
3.1.5.4. Ethidium bromide uptake in the leukemic T cell line 
Jurkat  
The final cell type assessed for their ability to incorporate ethidium bromide 
following ATP treatment were cells from the leukemic T cell line Jurkat. As with 
SEB activated T lymphocytes, Jurkat cells also showed increased ethidium 
bromide uptake in response to ATP with significant increases at 3 and 5 mM 
(Figure 3.8 C and Table 3.1). ATP induced ethidium bromide uptake was also 
sensitive to divalent cations (Figure 3.8 D). 





Figure 3.6: ATP induced uptake of ethidium bromide in 
differentiated THP1 acute monocytic leukaemia cells. THP1 acute 
monocytic leukaemia cells were differentiated overnight with IFNγ and 
LPS in a 96 well plate as described (246). Cells were washed and media 
replaced with physiological buffer containing ethidium bromide. Changes 
in fluorescence were recorded using a FluoStar Optima plate reader as 
described and normalised to a percentage of maximum uptake using 
Triton X-100. A. Example kinetic showing the addition of agonist followed 
by readings for 15 minutes. Rate of ethidium bromide uptake was 
calculated over the 15 minute period post agonist application and the 
effect of vehicle compared to increasing concentrations of ATP. B. The 
mean response to 5 mM ATP was set at 100% and other concentrations 
normalised to this for a concentration response curve (n=3). Prism Graph 
Pad was used to fit a sigmoidal concentration response curve.  







Figure 3.7: ATP induced uptake of ethidium bromide in human naïve CD4+ T 
lymphocytes. Freshly isolated naïve CD4+ T lymphocytes were washed and media 
replaced with physiological buffer containing ethidium bromide. Changes in 
fluorescence were recorded using a FluoStar Optima plate reader as described and 
normalised to a percentage of maximum uptake using Triton X-100. A. Example 
kinetic showing the addition of agonist followed by readings for 15 minutes. Rate of 
ethidium bromide uptake was calculated over the 15 minute period post agonist 
application and the effect of vehicle compared to increasing concentrations of ATP. 
B. The mean response to 5 mM ATP was set at 100% and other concentrations 
normalised to this for a concentration response curve (n=4). Prism Graph Pad was 
used to fit a sigmoidal concentration response curve. C. Cells were pre-treated with 
10 μM A438079 for 30 minutes before ATP application and measurement of 
ethidium bromide uptake (n=4). One Way ANOVA followed by Tukey’s post-test 
used to determine significance **p<0.01 













Figure 3.8: ATP induced uptake of ethidium bromide in SEB activated T 
lymphocytes and the leukemic T cell line Jurkat. Jurkat T cells were removed 
from culture and washed on day of use. T lymphocytes were activated and clonally 
expanded from PBMC as described. 8 Days post activation cells were washed and 
rested overnight in complete RMPI-1640 without IL-2. The following day, cells were 
removed from culture, washed and media replaced with physiological buffer 
containing ethidium bromide. Changes in fluorescence were recorded using a 
FluoStar Optima plate reader, as described and normalised to a percentage of 
maximum uptake using Triton X-100. For A. SEBs and C. Jurkats the rate of 
ethidium bromide uptake was calculated over a 15 minute period post agonist 
application and the effect of vehicle compared to increasing concentrations of ATP 
(n=3). For B. SEBs and D. Jurkats before ATP application cells were re-suspended 
in ethidium bromide containing physiological buffer or physiological buffer without 
MgCl2 and CaCl2 (n=3). A. and C. One Way ANOVA followed by Tukey’s post-test 
used to determine significance *p<0.05, **p<0.01 and ***p<0.001 B. and D. Two 
Way ANOVA followed by post-test used to determine significance between groups 
*p<0.05 and **p<0.01 




3.2. Effect of ATP on naïve CD4+ cell death 
Pore formation by activation of P2X7R has been proposed as a component of an 
ATP induced cell death (201, 255, 275). Cell death is an important process and is 
required for negative selection of T lymphocytes (386–388). The thymic selection 
and clearance of thymic T lymphocytes are tightly controlled processes, and 
apoptosis of cells occurs in response to specific stimuli (389). The death of T 
lymphocytes in the periphery is also required for resolution of inflammation (390). 
Mature T lymphocytes undergo apoptosis, and the less regulated process of 
necrotic cell death, during inflammation in response to DAMPS such as ATP. The 
P2X7R has been extensively investigated for its ability to cause cellular death in a 
wide variety of cell lines and mouse and human primary cells (391). In the context 
of murine T cells a raft of studies have focussed on the ability of the enzyme ART2 
to irreversibly activate P2X7R by ADP ribosylation leading to a number of P2X7R 
dependent processes including cell death (206, 260, 262, 263, 265, 266, 284–286, 
288, 289, 392). However, human T lymphocytes do not express ART2 or a 
homologous enzyme, therefore P2X7R induced cell death in human T 
lymphocytes must be investigated in the context of activation by ATP or BzATP. 
This current work sought to briefly establish whether human naïve CD4+ T 
lymphocytes stimulated by ATP would undergo apoptosis and/or necrosis. 
3.2.1. Apoptosis 
As described previously, apoptosis is a tightly controlled process of cell death by 
which cells are destroyed without the leaking of their cellular contents into the 
extracellular space (393). This is coordinated by a complex signalling cascade of 
caspase activation, cleavage of intracellular proteins, exocytosis of cellular 
contents in “blebs” and eventual shrinkage of cells and phagocytosis of apoptotic 
material. A key early step in apoptosis is the loss of lipid membrane structure with 
PS being “flopped” to the outer leaflet of the cell membrane; this aids 
phagocytosis (394). PS externalisation can be measured using the protein 
annexin V; a fluorescent form of annexin V can bind cell surface PS and allow 
measurement by flow cytometry. ATP has previously been shown to cause cell 
shrinkage and externalisation of PS in murine thymocytes and CD4+ T 
lymphocytes (395, 396). Human primary naive CD4+ T lymphocytes were treated 
with 3 mM ATP for increasing periods of time; although ATP caused a noticeable 




increase in annexin V fluorescence this was not significant (Figure 3.9 A). Cells 
were treated for 1 hour with increasing concentrations of ATP from 1-5 mM and 
again visible but insignificant increases in annexin V binding were observed 
(Figure 3.9 B). 
Another marker of apoptosis is uptake of the large molecular weight dye PI, which 
enters the cell and binds to DNA; this causes its fluorescence to increase. Cells 
were treated with ATP for 5 or 60 minutes before labelling with annexin V and 
staining with PI; example dual staining plots can be seen in Figure 3.9 C. The 
percentage of cells which were positive for binding of annexin V and uptake of PI 
increased after 5 to 60 minutes treatment with 3 mM ATP (Figure 3.9 D).   
ATP induced apoptosis is accompanied by a reduction in cell size (shrinkage), for 
mouse CD4+ T lymphocytes this was required for PS exposure (206, 278). 
However, human naïve CD4+ T lymphocytes did not significantly shrink in 

















Figure 3.9: Measurement of PI uptake and PS exposure in naïve CD4+ T 
lymphocytes treated with ATP. Naïve CD4+ T lymphocytes were freshly isolated 
from peripheral human blood and re-suspended in complete RMPI-1640. A. Cells 
were treated with 3 mM ATP for increasing periods of time or B. with increasing 
concentrations of ATP for 1 hour. Cell surface PS was quantified by measurement 
of Annexin V binding, as described in materials and methods (n=4). C. Cells were 
treated with vehicle or 3 mM ATP for 5 or 60 minutes before staining with Annexin V 
and PI. Representative dual staining plots are given including an unstained control 
(USC), which was used to set the quadratic gate with 1% of cells in Annexin V and 
PI single positive gates. D. The percentage of cells which were dual Annexin V+/PI+ 
following vehicle or ATP treatment are given (n=2 ± range). E. Cells were treated 
with increasing concentrations of ATP for 1 hour and cell size measured as forward 
scattered light using flow cytometry. The size of vehicle treated cells was set as 
100% and treatments normalised as a percentage of this. One Way ANOVA 
followed by Tukey’s post-test was used to determine significance. 





Necrosis is a form of cellular death that occurs in pathological conditions and can 
be caused by a wide variety of stimulants. It is often un-restrained and can lead to 
the “bursting” of cells and the release of intracellular contents into the extracellular 
space. T lymphocytes have been shown to undergo necrotic cell death in 
response to ATP (206, 255). An early marker of necrosis is the incorporation of 
dyes such as PI into cells; however, results presented here have already shown 
ATP not to couple to significant PI uptake. Additionally, as necrotic cells leak 
cellular contents the level of this release can be used to quantify necrotic cell 
death. Specifically, the release of the enzyme lactate dehydrogenase (LDH) is a 
common method for identifying cells undergoing necrosis (342, 397). Supernatant 
of cells treated with vehicle or ATP were collected and assayed for LDH content, 
as described in materials and methods. After subtraction of LDH detection in 
medium alone, naïve CD4+ T lymphocytes show a basal release of 8.94 ± 1.38 % 
(n=3 ± SEM) of maximum cellular LDH. No significant increase in LDH release 
was observed after treatment with 0.01-5 mM ATP (Figure 3.10 A). Cells pre-
treated for 30 minutes with increasing concentrations of A438079 (0.01-10 μM) 
followed by 1 hour 3 mM ATP treatment showed markedly lower levels of LDH 
release compared to both 3 mM ATP plus vehicle pre-treatment (Figure 3.10 B). 
As 3 mM ATP alone does not increase LDH release, it is possible that the effect of 
A438079 is an effect on basal LDH release, although this was not investigated 
further. Finally inhibition of caspases with the broad spectrum inhibitor Z-VAD-
FMK had no effect on LDH release in response to 1 hour treatment with 3 mM 
ATP (Figure 3.10 C). 
 














Figure 3.10: Measurement of LDH release in naïve CD4+ T lymphocytes 
treated with ATP. Naïve CD4+ T lymphocytes were freshly isolated from peripheral 
human blood and re-suspended in complete RMPI-1640 without phenol red. A. 
Cells were treated with increasing concentrations of ATP for 1 hour, or cells were 
pre-treated with increasing concentrations of A438079 (B) or Z-VAD-FMK (C) for 30 
minutes before treatment with 3 mM ATP for 1 hour. Supernatant was collected 
from cells and LDH levels measured as described (n=3). One Way ANOVA was 
performed followed by Tukey’s post test to determine significance. 




3.3. Effect of P2X7R inhibition on T lymphocyte 
proliferation 
P2X1, P2X4 and P2X7 receptors have been implicated in human T lymphocyte 
activation and proliferation. Silencing of P2X7R expression by siRNA or use of the 
Suramin and oATP demonstrate a role for this receptor in anti-CD3 antibody 
induced calcium mobilisation, NFAT activation and IL-2 mRNA production  (188, 
261, 268).  In this present study, the role of P2X7R in activation of human naïve 
CD4+ T lymphocytes was investigated using the selective P2X7R antagonist 
A438079. The ability of this compound to inhibit T cell proliferation following anti-
CD3/CD28 antibody coated bead and IL-2 treatment was investigated. Cells 
labelled with CFSE were pre-treated with 10 μM A438079 for 30 minutes followed 
by anti-CD3/CD28 + IL-2 activation, as described in materials and methods. No 
significant differences in the number of cells in each division of CFSE intensity 
were observed between vehicle and A438079 treated cells (Figure 3.11 A and B). 
No significant differences between DMSO and 10 μM A438079 treated cells were 


























Figure 3.11: Effect of P2X7R inhibition on proliferation of human T 
lymphocytes. Freshly isolated naïve CD4+ T lymphocytes were labelled with CFSE 
as described. Cells were analysed on the same day (Day 0) or pre-treated with 
vehicle (DMSO) or 10 μM A438079 for 30 minutes followed by addition of anti-
CD3/CD28 antibody coated beads to cells at a ratio of 3:1. IL2 was added at a final 
concentration of 36 Units/ml and cells cultured for 7 days before analysis for CFSE 
fluorescence. A. Representative flow cytometry histograms displaying population 
divisions 0-6. B. The effect of A438079 on percentage of cells in each division 
(n=3). C. Statistical analysis of percentage of cells in final division 6 (minimum 
CFSE fluorescence) (n=3). Two Way ANOVA followed by post-test used to 
determine significance 




3.4. Results Section 3 Summary 
 P2X7R protein is expressed by leukemic THP-1 monocyte, Jurkat and CEM 
T cell lines, as well as primary SEB activated human T cells and naive 
CD4+ T lymphocytes 
 Using voltage clamp electrophysiology, cation sensitive inward currents in 
response to ATP are observed 
 These currents are dependent on ATP concentration and inhibited by the 
P2X7R antagonist A438079 
 Following ATP treatment, significant increases in the rate of ethidium 
bromide uptake were observed in the acute monocytic leukaemia cell line 
THP-1, leukemic T cell line Jurkat, human SEB activated and naive CD4+ T 
lymphocytes 
 ATP does not cause significant PS externalisation or PI uptake 
 LDH release is not affected by ATP 






Figure 3.12: Expression of P2X7R by T lymphocytes summary. 1. Anti-
CD3/CD28 antibody coated beads activate human naïve CD4+ T lymphocytes; this 
induces proliferation of these cells, independent of P2X7R (2). 3. ATP causes 
inward currents in the leukemic T cell line Jurkat and human naïve CD4+ T 
lymphocytes. 4. These currents are sensitive to inclusion of divalent cations in the 
ATP application buffer; currents were also inhibited by the competitive P2X7R 
antagonist A438079. 5. The rate of ethidium bromide uptake is increased by ATP, 
however this process is insensitive to A438079 suggesting involvement of other 
P2XRs such as P2X4R. 6. In the leukemic T cell line Jurkat and SEB activated T 
lymphocytes ethidium bromide uptake was partially dependent on external CaCl2 
and MgCL2. 




3.5. Results Chapter 3 Discussion 
3.5.1. P2X7R Expression 
Immunoblotting confirmed that P2X7R is expressed in a number leukemic cell 
lines and importantly in primary human naïve CD4+ T lymphocytes. The antibody 
used in this study recognised several bands of varying sizes and there may be 
biochemical explanations for this. As mentioned previously, P2X7R can be 
alternatively spliced to produce nine different mRNA transcripts (363). The 
antibody used in this study recognises a region of the C-terminus of P2X7R and 
therefore would not be expected to detect the four splice variants which have a 
truncated c-terminus. This leaves five isoforms including the full length P2X7A 
receptor, one of which lacks the exon 4 (P2X7C) and three which have alternative 
start codons (P2X7D, F and H). As P2X7C only lacks a small portion of the 
receptor it could represent the lower part of the doublet observed in Figure 3.1. 
The D, F and H transcripts could potentially lead to the expression of shorter 
P2X7R protein which could correspond to the two bands observed between 54 
and 43 kDa in the Jurkat and THP-1 samples. P2X7R is highly glycosylated and 
the band above the 72 kDa marker may be a highly glycosylated P2X7A receptor, 
whereas the band below 72 kDa may represent P2X7A in a less glycosylated state 
as observed by A. Nicke (398). P2X7R can form homotrimeric subunit 
arrangements or heterotrimeric complexes with P2X4R, either of these 
conformations could explain the band just below 130 kDa. The fact that these 
experiments were performed under reducing conditions makes this unlikely, but 
not an impossibility. While the antibody used here would not be expected to detect 
P2X7B, E, G or J splice variants; these could still be expressed in T lymphocytes.  
The full length P2X7A and truncated P2X7B isoforms are expressed widely 
throughout cells of the immune system, including naïve and activated CD4+ T 
lymphocytes, and the P2X7H isoform is expressed at lower levels (363). Although 
these are the only splice variants studied so far, it is apparent that loss of TM1 or 
truncation of the C-terminus causes partial or complete loss of P2X7R induced 
pore formation and cell death (363). Co-expression of the cloned P2XB isoform 
with P2XA in fact enhances pore formation (240). The relative expression of these 
P2X7R isoforms and the pattern of their association in primary cells will therefore 
likely influence the function of these P2X7R complexes. This may help explain 




differences between P2X7R responses in healthy human donors and isoform 
expression may even correlate with disease promotion or progression. Although 
this is yet to be determined, single nucleotide polymorphism of the P2X7R do 
correlate with a number of diseases and conditions including: depression (359), M. 
Tuberculosis infection (307, 360) and pain (399). 
3.5.2. Analysis of electrophysiological properties of P2X7  
Much of what is known about P2X7R electrophysiology has been determined 
using P2X7R receptors cloned from mouse, rat or human cells. There are notable 
differences between receptors cloned from these species, therefore the results 
presented here will be compared with the electrophysiology of human P2X7R 
(400). Activation of human P2X7R cloned from B lymphocytes and expressed in 
Xenopus oocytes caused an inward current which increased first exponentially 
then in a second slower more linear phase (401). In this thesis a similar activation 
kinetic was observed for both the leukemic T cell line Jurkat and human naïve 
CD4+ T lymphocytes (Figure 3.3 and 3.4). Little research has been conducted on 
the electrophysiology of P2X7R in primary cells; however, ATP activates a rapid 
inward current in murine thymocytes (402). This thesis is therefore novel in its use 
of voltage clamping to investigate P2X7R expression in primary human T 
lymphocytes. The P2X7R antagonist A438079 has previously been shown to 
block 100 μM BzATP evoked currents in 1321N1 cells expressing human P2X7R 
with a pIC50 value of 6.6 (216). The experimental conditions are not directly 
comparable to those used in this study; however for the leukemic T cell line Jurkat 
3 μM A438079 did not completely abolish currents whereas 1 μM A438079 was 
sufficient in the study by Nelson et al (216).  
Divalent cations have previously been shown to inhibit P2X7R activation and the 
activity of P2X7R in a number of assays, including: ethidium bromide uptake, cell 
shrinkage and adhesion molecule shedding (CD62L and CD23) (202–208). ATP 
can be applied in a solution with low concentrations of divalents (252) or nominally 
free of divalent cations (cations are not added but EDTA or EGTA are also not 
added to remove contaminating ions) (342) to enhance detection of P2X7R 
activity.  




By using voltage clamp electrophysiology and a dye uptake assay, a large range 
of divalent cations were compared for their action on the rat P2X7R expressed in 
HEK293 cells (203). When cells were treated with 30 µM BzATP, Ca2+ inhibited 
50% of currents and dye uptake at 3.2 and 2.2 mM respectively, whereas Mg2+ 
IC50 values were lower at 2.2 and 0.82 mM for these two assays. In this thesis, 
currents recorded from the leukemic T cell line Jurkat and human naïve CD4+ T 
lymphocytes in response to 5 mM ATP were diminished when 2 mM CaCl2 and 1 
mM MgCl2 were present. Studies have reported species differences for cloned 
P2X7R; indeed, BzATP is more potent at rat P2X7R than the mouse or human 
receptor for both currents and dye uptake (400). These species differences can 
also apply to the effect of divalent cations at the receptor. For example, Zn2+ is 
inhibitory at rat P2X7R but may inhibit or potentiate mouse P2X7R, depending on 
whether BzATP or ATP is used as the agonist (204). This was measured using 
ethidium bromide uptake as a read out of P2X7R activation. For human P2X7R 
transfected into HEK293 cells, 1 mM CaCl2 blocked 38% and 1 mM MgCl2 blocked 
50% of YO-PRO-1 uptake into cells stimulated with BzATP (202). This study is in 
contrast to data presented in this thesis for ATP induced ethidium bromide uptake 
in the leukemic T cell line Jurkat and SEB activated T lymphocytes. Here, for 
these two cell types removal of extracellular CaCl2 and MgCl2 in fact inhibited 
ethidium bromide uptake in response to ATP, this was clearest in the leukemic T 
cell line Jurkat. It is unclear whether this is due to differences in the agonist, dye or 
native cell versus recombinant system used in these studies. Additionally, the 
study by Michel et al. used an external buffer solution containing 280 mM sucrose, 
whereas this thesis used 147 mM NaCl. Whether it is CaCl2 or MgCl2 that is 
required for pore formation is also unclear, however one study has shown that 
external Ca2+ is partially required for 1 mM ATP induced PS translocation in 
mouse thymocytes (256). 
Under physiological conditions the extracellular environment would be expected to 
contain Mg2+ and Ca2+ ions. With this in mind, although electrophysiology was 
conducted under divalent free conditions, all other experiments were performed 
using buffer or culture media containing these ions unless otherwise stated.  
 




3.5.3. Pore formation by leukemic cell lines and human T lymphocytes  
Voltage patch clamp experiments focussed on brief 10 second applications of 
ATP; however prolonged ATP treatment has been associated with opening of a 
membrane associated pore, Pannexin-1. The THP-1 acute monocytic leukaemia 
cell line was used to establish an ethidium bromide assay. This assay revealed 
significant ethidium bromide uptake by the leukemic T cell line Jurkat, SEB 
activated T lymphocytes and human naïve CD4+ T lymphocytes. Although the 
P2X7 antagonist A438079 has been shown to potently inhibit Yo-Pro uptake in 
THP-1 cells with a pIC50 value of 6.7 (216). This is in contrast to the observation 
here, that 10 μM A438079 was insufficient to inhibit ATP induced ethidium 
bromide uptake in naïve CD4+ T lymphocytes (Figure 3.7). P2X2R and P2X4R can 
both couple to pore formation and could therefore be responsible for the A438079 
insensitive ethidium bromide uptake observed in this study (403, 404). As 
expression of only P2X1R, P2X4R and P2X7R has been reported in T 
lymphocytes, it is most likely that P2X4 is responsible for this pore formation. 
P2X4R expression was not explored in this study and no selective P2X4R 
antagonists have been reported in the literature. A molecule, Ivermectin, can 
potentiate activation of P2X4R and has been used to investigate the role of this 
receptor in a number of processes (186). However, recently it has been observed 
that Ivermectin can actually interact with human P2X7R (405). Recent studies 
have reported a close association between the function of P2X4R and P2X7R; for 
example shRNA mediated silencing of P2X4 reduces ATP induced LDH release in 
macrophages (406, 407). ATP induced IL-1β release from macrophages isolated 
from P2X7-/- mice is promoted by Ivermectin (408). Interestingly, this study by Seil 
et al. also showed Ivermectin to potentiate 30µM ATP induced Yo-Pro-1 uptake in 
macrophages from P2X7-/- mice.  
3.5.4. Involvement of P2X7R in T lymphocyte death and activation 
The opening of Pannexin-1 hemichannels following P2X7R activation is important 
in the process of ATP induced apoptosis (Figure 1.19). The observation that ATP 
did not cause significant translocation of PS, nor did it cause a significant increase 
in PI uptake is in contrast to previous studies (277, 284). The observation that 
significant ethidium bromide, but not PI, uptake was not seen in naïve CD4+ T 




lymphocytes treated with ATP is in agreement with a study of murine T 
lymphocytes (191). Ethidium bromide is 314 Da and PI is 415 Da suggesting that 
the pore activated in T lymphocytes following ATP treatment has a cut off 
somewhere between the size of these two molecules. Indeed, for B lymphocytes 
this has been suggested to be approximately 320 Da, much smaller than the 
proposed cut off of 900 Da for other cell types (409). In this thesis, PI and ethidium 
bromide uptake were not directly compared under the same conditions so it is 
unclear why one dye was omitted whilst the other was allowed entry. One caveat 
to measuring ATP induced apoptosis using PS translocation as a marker, is that 
PS exposure has been suggested as a non-apoptotic signalling mechanism 
involving activation of P2X7R in murine CD4+ T lymphocytes (395). P2X7R 
activation may also lead to necrotic cell death; however this was ruled out using 
an LDH release assay. The observation that antagonism of P2X7R partially 
reduces basal release of LDH suggests the receptor may play a role in naïve 
CD4+ T lymphocyte survival. 
Several studies have explored the role of P2X7R in T lymphocyte activation (188, 
261, 268), however in this thesis pre-treatment of naive CD4+ T lymphocytes with 
A438079 before anti-CD3/CD28 antibody and IL-2 treatment did not affect their 
ability to proliferate. The fact that long term culture of these cells was performed in 
the presence of IL-2 may have masked a possible role for P2X7R in NFAT 
activation and IL-2 transcription by these cells as seen by Woehrle et al. However, 
oATP was still able to inhibit T lymphocyte proliferation when cells were cultured 
with anti-CD3 and anti-CD28 antibodies in combination with IL-2 (at a higher 
concentration than used in this thesis) (188). oATP has P2X7R independent 
immuno-suppressant activity (210), therefore it may have non-specific effects that 
the specific P2X7R antagonist A438079, used here, does not. In published 
studies, small interfering RNA (siRNA) was also used to investigate inhibit P2X7R 
and demonstrate a role for it in T cell activation (188, 261). Gene silencing may 
provide a more robust system to investigate the role of P2X7R in T cell activation 
and proliferation than pharmacological inhibition. 
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4.1. Mechanisms of loss of surface CD62L expression from 
human T lymphocytes 
4.1.1. Rationale 
CD62L is highly expressed on the surface of neutrophils, B cells and naïve and 
central memory T lymphocytes (18, 107, 410) (Figure 11.1). Recognition and 
binding to its substrates aids the homing of lymphocytes to secondary lymphoid 
organs (SLOs), as well as the initial tethering and rolling phases of extravasation 
into peripheral tissues (Figure 1.10). Activation of lymphocytes by a number of 
stimuli can lead to the down-regulation of CD62L surface expression (112, 113). In 
murine naïve CD4+ and CD8+ T lymphocytes the mechanisms for down-regulation 
in response to soluble anti-CD3 antibody have been elucidated (Section 1.5.4 and 
Figure 1.13) (114). There is evidence that these pathways may also be involved in 
the same process in human lymphocytes (133). The molecule PMA activates PKC 
to cause CD62L processing through ADAM17 and subsequent loss of cell surface 
expression. These well characterised PKC and CD3 dependent mechanisms were 
initially used to establish a protocol for measuring cell surface expression of 
CD62L, as well as the mechanisms involved in its processing from the cell 
surface. 
CD62L is not only down-regulated in response to T lymphocyte activation or PMA 
stimulation; a number of other extracellular signalling molecules can lead to 
CD62L loss. One of these is ATP which activates purinergic receptors, such as 
P2X7R which was characterised in naïve CD4+ T lymphocytes in Chapter 3. ATP 
induced CD62L down-regulation has been previously reported from B and T 
lymphocytes (245). The down-regulation of CD62L from the surface of cells from 
human patients with B cell chronic lymphocytic leukaemia has been shown to 
involve ATP and P2X7R (208). However, studies involving ATP induced CD62L 
loss from the surface of T lymphocytes has mainly focused on mouse cells. As 
stated previously in the context of cellular death mouse T lymphocytes express 
ART2 which facilitates irreversible activation of P2X7R by NAD (Section 1.8.2 and 
Figure 1.19). This activation also causes CD62L loss and the role of NAD and 
P2X7R in this process has been investigated (262, 266, 284–286, 288, 289, 392). 
The effect of the P2X7R ligands ATP and BzATP on CD62L expression in mouse 
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T lymphocytes has also been studied. Few studies have used primary human T 
lymphocytes and only one uses naïve CD4+ T lymphocytes; however, these are 
stimulated within a population of PMBCs and not isolated themselves (208, 245, 
411). This can provide confounding factors from bystander cells. There are also 
species differences between a number of processes in human and mouse T 
lymphocytes, these differences will become apparent in the context of anti-
CD3/CD28 antibody induced CD62L down-regulation in this section.  
4.1.2. Aim 
To isolate high purity naïve CD4+ T lymphocytes from healthy donors and explore 
the pharmacology of the P2X7R agonist ATP and P2X7R antagonists, before 
trying to elucidate a mechanism of CD62L down-regulation. It was first desirable to 
establish a positive control for assessing signalling mechanisms involved in 
CD62L processing. An established method of T cell activation was employed, this 
involved ex vivo culture of isolated human naïve CD4+ T lymphocytes with micro 
beads (Dynabeads®, Invitrogen, Paisley, UK) coated with anti-CD3/CD28 
antibodies. Signalling mechanisms responsible for CD62L down-regulation will 
then be explored and compared to previously published studies (24, 412). This will 
allow P2X7R dependent down-regulation of cell surface CD62L to be explored in 
detail and the mechanisms coupling ATP to CD62L loss to be elucidated. 
4.1.3. Anti-CD3/CD28 antibody coated bead mediated CD62L down-
regulation 
Studies using murine T lymphocytes demonstrated that treatment with soluble 
anti-CD3 antibodies could lead to significant CD62L down-regulation within 4 
hours (114). In this study, these treatment conditions were sufficient to show that 
inhibition of PI3K by LY294002 and MEK by PD98059 prevented CD3 mediated 
CD62L down-regulation. Here it is shown that treatment of freshly isolated naïve 
CD4+ T lymphocytes with 5 µg/ml soluble anti-CD3 antibodies (UCHT-1 clone) 
was also sufficient to cause significant loss of cell surface CD62L expression 
(Figure 4.1 A and B).  
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A stronger activation signal for naïve T lymphocytes is the co-stimulation of CD3 
and CD28 co-receptors (24). Cross-linking of anti-CD3 (UCHT1 clone is used in 
this thesis) antibody by coating of micro beads was able to cause a greater down-
regulation of cell surface CD62L expression (Figure 4.1 A and C). Additional 
coating of beads with anti-CD28 antibody further enhanced CD62L down-
regulation (Figure 4.1 A and C). Using anti-CD3/CD28 antibody coated 
microbeads a time-course of T cell activation was initially performed, this was to 
determine the earliest time point where CD62L down-regulation became 
significant. Significant down-regulation was shown to occur after an 18 hour 
treatment of cells with anti-CD3/CD28 microbeads (Figure 4.1 C and D). 
4.1.4. Involvement of MMPs 
ADAM 17 is the proposed MMP responsible for down-regulation of cell surface 
CD62L expression in response to a number of stimuli. This has been determined 
using inhibitors of MMPs such as Ro31-9790 (117) or silencing of MMP mRNA 
using siRNA (121). Here, a broad spectrum inhibitor of MMPs GM6001 was used 
to see if anti-CD3/CD28 antibody treatment down-regulated CD62L through the 
activity of MMPs. GM6001 is a dipeptide based inhibitor of MMP activity, which 
binds at the zinc active site of the enzyme. It has activity against a broad range of 
MMPs with Ki values in the nM to low µM range, it also inhibits the function of 
ADAM17 ectodomain (413). However, pre-treatment with GM6001 had no effect 
on anti-CD3/CD28 antibody induced down-regulation of cell surface CD62L 
(Figure 4.1 E).  









Figure 4.1: Activation of naive CD4+ T lymphocytes induces CD62L down-
regulation. A. Representative histograms of CD62L expression measured as 
described by flow cytometry. Freshly isolated naïve CD4+ T lymphocytes were 
treated with vehicle, B. 5 µg/ml UCHT1 for 4 hours or C. anti-CD3 or anti-
CD3/CD28 antibody coated beads for 18 hours (n=3). Surface CD62L expression 
was measured by flow cytometry, as described. Student’s t-test was used to 
compare treatments *p<0.05. For future experiments the effect of bead treatment 
on MFI was analysed by Student‘s t-test, CD62L MFI was then normalised as a 
percent of control (100%) expression. Treatment groups were then analysed by 
One Way ANOVA followed by Tukey’s post-test. D. Cells were treated with anti-
CD3/CD28 antibody coated beads for indicated time points and CD62L expression 
measured (n=3). E. Cells were pre-treated for 30 minutes with vehicle (DMSO) or 
indicated concentrations of GM6001 before anti-CD3/CD28 antibody coated bead 
treatment (n=4).  
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4.1.5. PI3K/mTOR and Erk1/2 MAPK signalling is not required for anti-
CD3/CD28 induced loss of cell surface CD62L expression 
A panel of commercially available small molecule inhibitors of intracellular 
signalling proteins (Table 4.1) were used to determine the signalling mechanism of 
anti-CD3/CD28 mediated down-regulation of cell surface CD62L expression. 
 
Compound Target Source IC50 Values Ref 
LY294002 Pan-isoform 
PI3K 





Gift (See table 1.1) 




Gift (See table 1.1) 
p110δ = 0.13 µM  
(71) 
PD98059 MEK1/2 Calbiochem MEK1 = 2-7 µM 
MEK2 = 50 µM  
(415) 
Gö6976 PKC Calbiochem PKCα = 2.3 nM 
PKCβ1 = 6.2 nM  
(416) 
Rottlerin PKC Calbiochem PKCδ = 3-6 µM 
PKCα,β,γ = 30-42 
µM 
Mitochondrial 
uncoupling = 10 µM 
(417, 
418) 
PP2 Src kinases Sigma Aldrich Lck = 4 nM 
Fyn = 5 nM  
(419) 
Rapamycin mTOR Sigma Aldrich ~1 nM (420) 
 
Table 4.1: Small molecule, cell permeable inhibitors of signalling proteins. 
Inhibitors acquired from the sources mentioned here, are displayed with their 
primary target. The IC50 values for inhibition of these signalling proteins, as 
described in the references, are also displayed. 
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LY294002, a pan-isoform PI3K inhibitor, was unable to inhibit CD62L down-
regulation in response to 18 hour anti-CD3 antibody coated bead treatment 
(Figure 4.2 A). Reduced CD62L surface expression following 18 hour anti-
CD3/CD28 antibody coated bead treatment was not inhibited by LY24002 or 
ZSTK474, another pan-isoform PI3K inhibitor (Figure 4.2 B and C). This suggests 
that the PI3K pathway is not involved in CD62L down-regulation in response to 
anti-CD3/CD28 treatment, however the role of PI3K δ was still explored, as this is 
the isoform involved in murine CD62L processing (114). Use of the selective PI3K 
δ inhibitor IC87114 had no effect on anti-CD3/CD28 induced CD62L cell surface 
loss (Figure 4.2 D).  
It is of note that, whilst LY294002 had no inhibitory effect on anti-CD3/CD28 
induced CD62L down-regulation, a marked but statistically insignificant 
enhancement of CD62L down-regulation was observed. Anti-CD3/CD28 antibody 
coated beads plus DMSO control caused a mean down-regulation of 59.17 % ± 
21.5 (n=3 ± SEM) when cells were pre-treated with 10 μM LY294002 down-
regulation was increased to 74.63 ± 9.88 (n=3 ± SEM). Further down-regulation 
was seen when using 20 μM LY294002 (n=2 data not shown) and when using 
anti-CD3 coated antibody beads as a stimulus. 
Erk1/2 kinase can phosphorylate ADAM17 on Thr735 which mediates its 
trafficking to the cell surface and subsequent maturation of the pro form of 
ADAM17 (132). Indeed, in mice inhibition of MEK upstream of Erk1/2 with 
PD98059 prevented anti-CD3 induced CD62L down-regulation (114). However, 
with 18 hour anti-CD3/ CD28 induced CD62L loss in human T lymphocytes 
PD98059 had no significant effect (Figure 4.2 E). 
Nutrient uptake during T lymphocyte activation is very important and expression of 
the amino acid transport CD69 is increased upon activation (145). mTOR is an 
important component of the nutrient sensing pathway, it is required for T 
lymphocyte activation and proliferation (53). mTOR has also been shown to be 
involved in CD62L down-regulation in mouse naïve CD8+ cells following 
stimulation of cells with IL-2 (114). In this thesis, Rapamycin was used to inhibit 
mTOR prior to activation with anti-CD3/ CD28; however no significant inhibition of 
CD62L loss was observed (Figure 4.2 F). 
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Figure 4.2: PI3K/mTOR and Erk1/2 MAPK signalling is not required for anti-
CD3/CD28 induced loss of cell surface CD62L expression. Freshly isolated 
naive CD4 T lymphocytes were pre-treated with vehicle (DMSO) or small molecule 
inhibitors at the given concentrations: A. and B. LY294002 for 1 hour (n=3) C. 
ZSTK474 (n=6) D. IC87114 (n=5) E. PD98059 (n=6) F. Rapamycin (n=3) for 30 
minutes. Cells were then treated with A. anti-CD3 or B-F. anti-CD3/CD28 antibody 
coated beads for 18 hours. CD62L expression was analysed by flow cytometry as 
described, the effect of bead treatment on MFI was analysed by Student‘s t-test 
*p<0.05 **p<0.01 ***p<0.001. CD62L MFI was then normalised as a percent of 
control (100%) expression, DMSO treated groups were compared to inhibitors by 
One Way ANOVA followed by Tukey’s post-test *p<0.05 **p<0.01 ***p<0.001. 
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4.1.6. Activation of mouse splenocytes by anti-CD3 antibody and 
signalling mechanisms involved in loss of cell surface CD62L 
expression 
As mentioned, the initial experiments to explore the mechanisms of TCR induced 
CD62L down-regulation involved mouse CD4+ and CD8+ T lymphocytes (114). 
Therefore, these experiments were briefly repeated using mouse splenocytes to 
confirm the involvement of PI3K and MEK/Erk1/2 in this process. Treatment of 
mouse splenocytes with soluble anti-CD3 antibody (Clone 2C11) had noticeably 
more effect on CD62L expression than anti-CD3 antibody on human CD4+ T 
lymphocytes. Species differences may therefore explain why little cell surface 
CD62L was lost with soluble anti-CD3 antibody alone and that immobilisation 
and/or combination with anti-CD28 antibody was required for more robust CD62L 
loss from human naïve CD4+ T lymphocytes. Pre-treatment with LY294002 or 
PD98059 appears to partially inhibit CD62L loss induced by anti-CD3 antibody 






Figure 4.3: Effect of PI3K and MEK inhibition on anti-CD3 antibody induced 
CD62L loss in mouse splenocytes. Mouse splenocytes were isolated from mouse 
spleens as described and re-suspended at a concentration of 5 x 106 cells/ml. Cells 
were pre-treated with vehicle (DMSO) or indicated concentrations of LY294002 or 
PD98059 for 1 hour and 30 minutes respectively. Cells were then treated for 4 
hours with 5 μg/ml anti-CD3 antibody (clone: 2C11).CD62L expression was 
measured by flow cytometry as described (n=2 ± STDEV). 
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4.1.7. Validation of small molecule inhibitor of signalling proteins 
As a further positive control, SEB activated T lymphocytes were pre-treated with 
LY294002, PD98059, IC87114 or Rapamycin for indicated time periods before 
treatment with 10 μg/ml soluble anti-CD3 antibody for 5 minutes. SEB activated T 
lymphocytes were used for these experiments because they are easier to obtain in 
large numbers and contain higher protein levels than naïve CD4+ T lymphocytes. 
These compounds inhibited the phosphorylation of MAPK and PI3K signalling 
pathway components as expected following T lymphocyte activation (Figure 4.4). 
Cells pre-treated with vehicle (DMSO) followed by 5 minute 10 μg/ml anti-CD3 
antibody treatment showed markedly enhanced phosphorylation of Akt on Ser473, 
Erk1 on Thr202 and Erk2 on Tyr204, and S6 ribosomal subunit protein (S6) on 
Ser235 and Ser236 (Figure 4.4). Activation of the PI3K signalling cascade can 
lead to the phosphorylation of all three of these proteins. Pre-treatment with 10 μM 
LY294002, 10 μM ZSTK474 or 1 μM IC87114 completely abolished Akt 
phosphorylation (Figure 4.4 A). Both LY294002 (Figure 4.4 A and B) and IC87114 
had a small inhibitory effect on Erk1/2 and S6 phosphorylation, however ZSTK474 
ablated anti-CD3 antibody induced phosphorylation of all three proteins (Figure 
4.4 A). Activation of MEK leads to phosphorylation of Erk1/2 and MEK can be 
inhibited by PD98059. As expected, pre-treatment with 10 μM PD98059 
completely inhibited Erk1/2 phosphorylation and also partially inhibited Akt 
phosphorylation (Figure 4.4 A and C). The protein mTOR is part of the PI3K 
signalling cascade and controls protein synthesis through activation of S6 
ribosomal subunit, via S6 kinase (S6K). Pre-treatment with 1 μM Rapamycin 
partially inhibited S6 phosphorylation in response to anti-CD3 antibody stimulation 
(Figure 4.4 D). 
 
 









Figure 4.4: Validation of small molecule kinase inhibitors in activated T 
lymphocytes. SEB activated T lymphocytes were expanded from PBMC as 
described in materials and methods, IL-2 removed on day 8 and cells removed from 
ex vivo culture after 9 days. Cells were pre-treated for 30 minutes with vehicle 
(DMSO), 10 µM ZSTK474, 1 µM IC87114, 10 µM PD98059, 1 µM Rapamycin or for 
1 hour with 10 µM LY294002. Cells were then treated with vehicle (media) or 10 
μg/ml anti-CD3 antibody (UCHT1) for 10 minutes. All cells were lysed as described, 
loaded onto poly-acrylamide gels and proteins separated under reducing conditions 
using SDS-PAGE. Proteins were transferred to nitro-cellulose membrane, blocked 
and immuno-blotted for: pAkt (Ser473), pErk1/2 (Thr202 and Tyr204/Thr185 and 
Tyr187) and pS6 (Ser235 and Ser236). Membranes were stripped of antibody, 
blocked and re-probed for Erk1/2 using anti-Erk1 antibody (Santa Cruz). A n=2 and 
B-D n=1 
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4.1.8. Cell surface loss of CD62L following long term ex vivo culture.  
Initial experiments focussed on 18 hour treatment of naïve CD4+ T lymphocytes 
with anti-CD3/CD28, as this was the earliest time point where significant down-
regulation of CD62L from the surface of these cells was observed. However, it 
was possible that the effects of PI3K and/or Erk1/2 inhibition would not be 
apparent until CD4+ T lymphocytes were fully activated over a longer time period. 
PI3K and mTOR can control CD62L expression at the transcriptional level, 
through Akt mediated suppression of FOXO1 and repression of the SELL gene for 
CD62L (114, 115). Therefore, the effect of the pan-isoform PI3K inhibitor 
LY294002 and the MEK inhibitor PD98059 on surface levels of CD62L expression 
on human CD4+ T lymphocytes over a 7 day period of ex vivo culture was 
explored. It is important to note that for long term culture the protocol required to 
maintain T lymphocytes is different, it requires an anti-CD3/CD28 antibody bead to 
cell ratio of 3:1 and the addition of 36 Units/ml IL-2. IL-2 has a role in CD62L 
down-regulation; therefore this system is not directly comparable to 18 hour anti-
CD3/CD28 treatment alone (109, 110). After one day, cells treated with DMSO 
alone expressed 17.11 % ± 4.84 (n=3 ± SEM) of their initial cell surface CD62L 
levels (Figure 4.5). Over time CD62L levels increased: 29.67 % ± 8.71 after 2 days 
and 226.4 % ± 110.01 at 7 days. Pre-treatment with 10 μM LY294002 or 10 μM 





















Figure 4.5: PI3K and Erk1/2 are not required for modulating 
CD62L expression levels over 7 days. Freshly isolated naive 
CD4 T lymphocytes were pre-treated with vehicle (DMSO) or 10 
μM PD98059 for 30 minutes, or 10 μM LY294002 for 1 hour. Cells 
were then treated with anti-CD3/CD28 antibody coated beads at a 
ratio of 3:1 (beads:cells). 36 Units/ml IL-2 was added on day 0 and 
added again every 48 hours, along with a doubling of media 
volume. Cells were removed from culture at 0, 1, 2 and 7 days 
post activation and CD62L expression measured by flow 
cytometry as described (n=3 ± SEM). To compare treatment 
groups a Two Way ANOVA was performed followed by post hoc 
test. 
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4.1.9. CCR7 also undergoes down-regulation following T lymphocyte 
activation 
In addition to CD62L, naïve CD4+ T lymphocytes express high levels of the 
chemokine receptor CCR7; this was confirmed by dual staining of freshly isolated 
cells for both CD62L and CCR7. Initially 83.05 ± 7.37 % (n=4 ± SEM) of cells were 
CD62L+/CCR7+ (Figure 4.6 A). As for CD62L, the change in CCR7 expression was 
measured using the mean fluorescent index (MFI). After 18 hour treatment with 
anti-CD3/CD28 antibody coated beads a significant loss of cell surface CCR7 was 
observed (Figure 4.6 B and C). The same signalling pathways investigated for 
CD62L down-regulation were assessed for their involvement in CCR7 processing 
(Figure 4.6 D). Inhibition of PI3K by the pan-isoform inhibitor LY294002 and 
ZSTK474, as well as the PI3Kδ inhibitor IC87114, caused partial restoration of 
CCR7 surface expression lost after anti-CD3/CD28 treatment. This was also seen 
when cells were pre-treated with the Src kinase inhibitor PP2. Like CD62L, CCR7 
is down-regulated initially at 1-2 days post activation, but after 7 days levels return 
















Figure 4.6: Cell surface expression of CCR7 is down-regulated following T 
lymphocyte activation and may require PI3K and Erk1/2 signalling. A. Freshly 
isolated naïve CD4+ T lymphocytes were treated with anti-CD3/CD28 antibody 
coated beads, stained for CD62L and CCR7 and dual staining measured using flow 
cytometry. B. Cells were treated for up to 18 hours and CCR7 surface expression 
measured (n=4). C. Analysis of significant CCR7 MFI decrease at 18 hours by 
Student’s t-test **p<0.01 (n=3). D. Cells were pre-treated with vehicle, 1 μM 
IC87114, 10 μM LY294002, 10 μM ZSTK474, 10 μM PP2 or 10 μM PD98059. Cells 
were then treated with anti-CD3/CD28 antibody coated beads for 18 hours. CCR7 
surface expression was then measured (n=4). E. The effect of 7 day anti-
CD3/CD28 antibody coated beads on cell surface CCR7 expression (n=3). 
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4.1.10. Effect of PMA and ATP on cell surface CD62L expression 
on human naïve CD4+ T lymphocytes and the leukemic T cell line 
Jurkat 
Having established an assay for measuring changes in cell surface expression of 
CD62L and confirmed P2X7R expression on the leukemic T cell line Jurkat and 
human naïve CD4+ T lymphocytes (Results Chapter 3), the ability of PMA and 
ATP to induce cell surface CD62L loss was investigated. Vehicle treated naïve 
CD4+ T lymphocytes show uniformly high levels of CD62L expression (Figure 4.7 
A), however the leukemic T cell line Jurkat expresses very low levels of CD62L 
(Figure 4.7 B). In naïve CD4+ T lymphocytes both PMA and ATP significantly 
induced loss of cell surface CD62L (Figure 4.7 A), whereas the leukemic T cell line 
Jurkat responded only to PMA (Figure 4.7 B).  
PMA has been used to investigate CD62L processing in a number of cell types 
(121, 421). Here the loss of cell surface CD62L expression from the leukemic T 
cell line Jurkat and naïve CD4+ T lymphocytes with PMA was dependent on PMA 
concentration (Figure 4.8 A and B). Using concentration response curves, EC50 
values for PMA on CD62L down-regulation were determined for both cells types: 
Jurkat EC50 = 12.24 nM and naïve CD4
+ EC50 = 12.68 nM.  














Figure 4.7: The effect of PMA and ATP on CD62L surface expression 
on the leukemic T cell line Jurkat and human naïve CD4+ T 
lymphocytes A. Freshly isolated human naive CD4+ T lymphocytes were 
treated with vehicle, 100 nM PMA for 30 minutes or 3 mM ATP for 1 hour. 
Surface CD62L expression was measured by flow cytometry as described. 
Representative histograms of CD62L expression are given, with the mean 
fluorescence index (MFI) displayed. A gate (P2) has been set to include 
1% of cells from the isotype control; CD62L positive (+ve) cells from control 
and treatment groups are those which fall within this gate. B. The leukemic 
T cell line Jurkat was also treated under the same conditions and analysed 
for surface CD62L expression. 
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4.1.11. Loss of cell surface CD62L from human naïve CD4+ T 
lymphocytes is dependent on ATP concentration 
To explore the concentrations of ATP required to elicit a significant down-
regulation of CD62L in the leukemic T cell line Jurkat and human naïve CD4+ T 
lymphocytes, non-cumulative dose response experiments were performed (Figure 
4.8 C and D). After 5 minute or 1 hour treatment with ATP, naïve CD4+ T 
lymphocytes showed significantly decreased cell surface CD62L expression 
(Figure 4.8 C). This effect was dependent on ATP concentration with EC50 values 
of 877 µM and 888.6 µM for 5 minutes and 1 hour treatments respectively. The 
EC50 values for both time points are close to 1 mM which is typical for the 
pharmacology of P2X7R and less indicative of P2X1R or P2X4R. However, no 
down-regulation was observed in the leukemic T cell line Jurkat after 1 hour 
treatment with ATP at concentrations from 0.01 – 5 mM. As described above, 
PMA can induce significant CD62L loss in this cell line, therefore PMA acted as a 
positive control for CD62L down-regulation in these experiments. 
4.1.12. Loss of cell surface CD62L from human naïve CD4+ T 
lymphocytes is rapid and sustained 
Next, the kinetics of ATP induced CD62L down-regulation were investigated; 3 
mM ATP was chosen because it is a suboptimal concentration above the EC50 for 
both 5 minute and 1 hour ATP treatment described above. Here, significant 
CD62L down-regulation was observed from naïve CD4+ T lymphocytes after 5 
minutes and after 15 minutes of treatment only 59.67 ± 6.45 % (n=3 ± SEM) of cell 
surface CD62L remained (Figure 4.8 E). Significant loss of CD62L expression was 
maintained for up to 6 hours, although cell surface expression began to increase; 
at 6 hours cells expressed 70.53 ± 6.45 % (n=3 ± SEM). The leukemic T cell line 
Jurkat did not display CD62L down-regulation in response to 3 mM ATP treatment 
at any time point from 1 – 60 minutes (Figure 4.8 F). As expected, cell surface loss 
of CD62L expression by the leukemic T cell line Jurkat was observed in response 
to PMA treatment. 








Figure 4.8: PMA and ATP induce CD62L down-regulation from naïve CD4+ T 
lymphocytes and the leukemic T cell line Jurkat. Freshly isolated naïve CD4+ T 
lymphocytes (A, C and E) or leukemic T cell line Jurkat (B, D and F) were treated 
with either PMA or ATP. A 30 minute treatment with 100 nM PMA was used as a 
positive control for leukemic T cell line Jurkat. A and B: cells were treated with 
increasing concentrations of PMA for 30 minutes (n=3). C and D: Cells were 
treated for 5 minutes or 1 hour with increasing concentrations of ATP (0.01 – 5 mM) 
(n=3). A-C For concentration response curves the maximum observed down-
regulation of cell surface CD62L following agonist treatment is set as 100% and 
other concentrations are normalise to this.  E. and F. Cells were treated with 3 mM 
ATP for the times indicated (n=3). Surface CD62L expression was measured by 
flow cytometry as described. One Way ANOVA was used to compare treatment 
groups *** p<0.001 
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4.1.13. P2X7R inhibitors block ATP induced, but not anti-
CD3/CD28 induced down-regulation of cell surface CD62L 
In chapter 3 the expression of P2X7R was confirmed in naïve CD4+ T lymphocytes 
this, coupled with almost millimolar EC50 values, suggest an involvement of 
P2X7R in ATP induced loss of CD62L surface expression. This needed to be 
confirmed pharmacologically as T lymphocytes express ATP sensitive P2Y2 
receptors which can also cause ADAM activation and substrate cleavage (422). 
Two P2X7R antagonists were used in this study: the competitive A438079 and 
non-competitive antagonist AZ11645373 (Figure 1.17). A438079 was previously 
used to confirm P2X7R was responsible for currents evoked by ATP in naïve 
CD4+ T lymphocytes (Figure 3.5 E and F). A438079 caused a concentration 
dependent inhibition of CD62L loss induced by 1 hour 3 mM ATP treatment with 
an IC50 value of 2.25 µM (n=3) (Figure 4.9 A). AZ11645373 also caused a 
concentration dependent inhibition of CD62L loss with an IC50 value of 1.35 µM 
(n=3) (Figure 4.9 A). However, A438079 had no effect on loss of cell surface 
CD62L expression induced by anti-CD3/CD28 treatment of naïve CD4+ T 






Figure 4.9: Loss of cell surface CD62L expression in response to ATP, but 
not anti-CD3/C28 antibody coated beads requires the P2X7R. Freshly 
isolated naive CD4 T lymphocytes were pre-treated with vehicle (DMSO) or the 
P2X7R antagonists A438079 or AZ11645373 at the indicated concentrations for 
30 minutes. A. 3 mM ATP was then applied for 1 hour and CD62L surface 
expression was measure using flow cytometry as described. The initial loss of 
surface CD62L expression with vehicle pre-treatment was normalised to a 100% 
response. Inhibition was then defined as the percentage of this initial response 
remaining following inhibitor treatment. B. Alternatively cells were treated with 
anti-CD3/CD28 antibody coated beads for 18 hours and CD62L expression 
measured as described (n=3). Student’s t-test was used to compare MFI of CO 
to bead treated cells **p<0.01. Effect of A438079 was measured by One Way 
ANOVA followed by Tukey’s post-test. 
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4.1.14. Variation between loss of cell surface CD62L responses 
in human donors 
Human P2X7R can be alternatively spliced and exhibits SNPs; this can lead to 
lead to differences in the ability of P2X7R to respond to ATP. Two donors were 
compared, one which significantly down regulated cell surface expression of 
CD62L in response to 1 hour 3 mM ATP treatment (Figure 4.10 Donor A), and a 
second which showed no significant loss (Figure 4.10 Donor B). The difference 
between these donors was significant in respect to ATP induced loss of surface 











Figure 4.10: Variation of ATP and anti-CD3/CD28 antibody coated bead 
responses in two donors. Freshly isolated naïve CD4+ T lymphocytes were 
treated with vehicle (DMSO), 3 mM ATP for 1 hour or anti-CD3/CD28 antibody 
coated beads for 18 hours (n=3). Surface CD62L expression was measured by flow 
cytometry as described. One Way ANOVA was used to compare treatment groups 
in individual donors followed by Tukey’s post-test * p<0.05, **/##p<0.01. Two Way 
ANOVA was used to compare donors ^^ p<0.01. 
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4.1.15. Involvement of MMPs in ATP induced loss of cell surface 
CD62L from naïve CD4+ T lymphocytes 
The loss of CD62L from the surface of a number of different cell types in response 
to mitogenic and apoptotic signals is dependent on ADAM17 activity. ATP causes 
rapid release of MMP9 from PBMCs (312) and BzATP induced CD62L loss from 
mouse CD4+ T lymphocytes is MMP dependent (423). Therefore, it was 
investigated whether CD62L loss in response to ATP from human naïve CD4+ T 
lymphocytes is dependent on the actions of MMPs. Gelatin Zymography was first 
used to observe if MMPs were induced following ATP treatment of cells.  
Bands of digested gel were observed at approximately 72 and 90 kDa in the 
supernatant of both resting and PMA treated leukemic Jurkat T lymphocytes (n=3) 
(Figure 4.11 A). These bands potentially correspond to active MMP2 and 9 
respectively. PMA treatment did not increase the levels of either MMP above 
control. Whilst low levels of MMP9 was detected in supernatant samples of 
untreated naïve CD4+ T lymphocytes, no increase in MMP9 activity was observed 
when these cells were treated with 1 mM ATP for up to 1 hour (n=2) or 5 mM ATP 
for 30 minutes (n=1) (Figure 4.11 B). Treatment of mouse splenocytes with 50 µM 
GM6001 has been shown to inhibit ATP induced CD27 down-regulation (424); 
GM6001 is a broad spectrum MMP inhibitor. Human naïve CD4+ T lymphocytes 
were pre-treated with either DMSO, as a vehicle, or increasing concentrations of 
GM6001 for 30 minutes. Pre-treatment with 100 µM GM6001 significantly inhibited 
CD62L loss in response to 1 hour 3mM ATP treatment (Figure 4.11 C). 
4.1.16. Measurement of soluble CD62L in the supernatant of 
cells 
The cleavage of CD62L by ADAM proteases causes the release of a soluble 
fragment of CD62L (sCD62L), which is released into the extracellular environment 
where it is biologically active. The method chosen here for measuring CD62L 
down-regulation was to measure the loss of cell surface CD62L expression. 
However, it should be possible to also measure the release of sCD62L into the 
supernatant of treated cells. This has previously been shown for human PBMCs 
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treated with BzATP and was fully inhibited by oATP and partially by KN62, two 
P2X7R antagonists (245). Here, whole cell lysates and supernatants collected 
from vehicle, PMA and ATP treated naïve CD4+ T lymphocytes were measured for 
CD62L expression by immunoblotting. Lymphocyte CD62L has an expected 
molecular weight of 74 kDa (108). However, the anti-CD62L antibody used here 
recognises a number of bands in the whole cell lysate (WCL) (Figure 4.11 D). Two 
of the predominant bands are just below the 72 kDa marker and could therefore 
represent CD62L from either the membrane or the cytosol. PMA causes significant 
loss of cell surface CD62L expression from human naïve CD4+ T lymphocytes, it 
has previously been reported that in response to PMA treatment human 
lymphocytes shed a 62 kDa fragment of CD62L into the supernatant (108). PMA 
was therefore used as a positive control for measuring sCD62L in supernatant. 
Immunoblotting of supernatants for sCD62L revealed a smear of protein between 
72 and 55 kDa which may contain sCD62L or other protein(s) recognised by the 
anti-CD62L antibody (Figure 4.11 D). Two other bands are visible in the 
supernatant, one of approximately 50 kDa just below the smear in all samples and 

















Figure 4.11: Supernatant from leukemic T cell line Jurkat and human naïve 
CD4+ T lymphocytes contain MMPs; MMPs are responsible for ATP induced 
loss of cell surface CD62L expression. A. Jurkat T cells were removed from 
culture, washed and treated with vehicle or 80 ng/ml PMA for 1 hour. Supernatants 
(S) and whole cell lysates (WCL) were collected as described and separated by 
SDS-PAGE using Gelatin gels. Gels were developed as described and stained with 
Coomassie blue to reveal protein (n=3). B. Freshly isolated naïve CD4+ T 
lymphocytes were treated with vehicle, 1 mM ATP for 15-60 minutes or 5 mM ATP 
for 30 minutes (n=2). Gelatin zymography was performed as for A. C. Cells were 
pre-treated for 30 minutes with vehicle (DMSO) or indicated concentrations of 
GM6001 before 1 hour 3 mM ATP treatment (n=3). Initial response analysed by 
Student’s t-test **p<0.01 and GM6001 treated groups were compared to DMSO 
control by One Way ANOVA. D. Naïve CD4+ T lymphocytes were treated with 
vehicle (DMSO), 100 nM PMA for 30 minutes or 3 mM ATP for 1 hour. Cells were 
lysed and CD62L expression in WCL and S were measured by immunoblotting with 
anti-CD62L antibody (n=1). 
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4.1.17. Hydrolysis of ATP is not responsible for down-regulation 
of cell surface CD62L expression. 
ATP can be rapidly hydrolysed to AMP by cell surface CD39 (168, 169), this can 
be further hydrolysed to adenosine by CD73 (170) (Figure 1.16). CD39 is 
expressed on cells of the immune system, and in combination with CD73 is 
important for the function of Treg cells (171, 172), expression of CD39 along with 
P2X7R is up-regulated in chronic pancreatitis and pancreatic cancer (171). Flow 
cytometry was employed to measure the expression of CD39 on freshly isolated 
human naïve CD4+ T lymphocytes. Only 3.83 ± 1.64 % (n=3 ± SEM) of naïve 
CD4+ T lymphocytes were positive for CD39 whereas analysis of the whole PBMC 
revealed 25.03 ± 10.65 % (n=3 ± SEM) CD39+ cells (Figure 4.12 A and B).  
Adenosine can cause pro-inflammatory or anti-inflammatory responses from 
immune cells, this depends on the P1 adenosine receptor family members 
expressed and on the concentration of adenosine (179, 181). Adenosine 
generated by CD73 expressed on HEV negatively regulates L-selectin dependent 
migration of lymphocytes into draining lymph nodes (DLNs) (425). Increasing 
concentrations of adenosine from 2.5 µM to 2.5 mM for 1 hour did not have a 
significant effect on cell surface CD62L expression (Figure 4.12 C). In the same 
experiments 3 mM ATP was applied for 1 hour, as expected this treatment did 
cause a significant loss of cell surface CD62L (Figure 4.12 C). Addition of 
exogenous apyrase grade VI (which preferentially hydrolyses ATP to ADP) at 4 
Units/ml had no effect on basal CD62L levels, but caused a significant inhibition of 
3 mM ATP induced loss of cell surface CD62L expression (Figure 4.12 D). 











Figure 4.12: Naive CD4 T lymphocytes express low levels of CD39, adenosine 
does not cause loss of cell surface CD62L and apyrase prevents ATP induced 
loss A. PBMC and naïve CD4+ T lymphocytes were freshly isolated, washed and 
labelled with antibody against CD39 and CD4. B. Percentages of cells expressing 
CD39 (n=3). C. Naive CD4 T lymphocytes were treated with increasing 
concentrations of adenosine or 3 mM ATP for 1 hour before CD62L expression 
measurement as described (n=3). D. Naive CD4 T lymphocytes were pre-treated 
with vehicle or 4 Units/ml Apyrase (Grade VI) for 30 minutes before treatment with 3 
mM ATP for 1 hour (n=3). One Way ANOVA followed by Tukey’s post-test used to 
determine significance */#p<0.05, ***p<0.001.  
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4.2. Investigation of the mechanisms of ATP induced 
CD62L down-regulation 
4.2.1. Rationale and Aim 
P2X7R has been shown to lead to the phosphorylation of a number of signalling 
proteins in a variety of cell types, including the MAPKs Erk1/2 and p38, PKC, 
PKD, JNK, Src and Akt (205, 238, 255, 330, 334–336, 426–428) (Figure 1.20). 
Several of these pathways are also implicated in ADAM17 mediated processing of 
substrates including CD62L, it was therefore desirable to explore the potential 
involvement of these pathways in ATP induced CD62L down-regulation.  
4.2.2. ATP induced CD62L down-regulation is calcium independent 
Increase in intracellular calcium levels through ionophore mediated influx or 
depletion of intracellular stores can lead to processing of CD62L (122). However, 
previous studies looking at P2X7R mediated CD62L down-regulation 
demonstrated that extracellular calcium was not required (207). This calcium 
independent mechanism was also observed in this thesis using human naïve 
CD4+ T lymphocytes. No significant difference was observed in the ability of ATP 
to cause loss of CD62L surface expression when the agonist was applied in buffer 
with, or without CaCl2 (Figure 4.13 A).  
To confirm that calcium mobilisation by other mechanisms could lead to CD62L 
cell surface loss in human naïve CD4+ T lymphocytes, cells were treated with 
either Ionomycin (a calcium ionophore) or Thapsigargin (a SERCA pump blocker) 
for 1 hour before measuring CD62L surface expression. Ionomycin was unable to 
induce a significant down-regulation of cell surface CD62L expression, this 
observation is in contrast to a study by Le Gall et al (122), but consistent with 
Jamieson et al (207) (Figure 4.13 B). Thapsigargin caused a significant 
concentration dependent loss of cell surface CD62L (Figure 4.13 C).  
ATP treatment may not only lead to an increase in intracellular calcium through 
cation influx, but it could also couple to intracellular store release. To test this, a 
PLC inhibitor U73112 and its inactive analogue U73433 were intended for use. 
However, whilst U73433 had no effect on basal surface expression of CD62L the 
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active PLC inhibitor U73112 alone caused a visible decrease in CD62L expression 
(Figure 4.13 D). This prevented the use of this compound to investigate the 
coupling of P2X7R to PLC activation in CD62L down-regulation as a possible 



















Figure 4.13: ATP induced CD62L down-regulation is not dependent on 
extracellular calcium, but modulation of intracellular calcium can affect 
surface expression of CD62L. A. Freshly isolated naïve CD4+ T lymphocytes 
were treated with vehicle, or 3 mM ATP for 1 hour in buffer containing or free of 
CaCl2. CD62L expression was measured by flow cytometry as described. B. Cells 
were treated with Ionomycin for 1 hour (n=3). C. Cells were treated with increasing 
concentrations of Thapsigargin (n=3). D. Cells were treated with vehicle (DMSO) or 
the PLC inhibitor U73122 or its inactive analogue U73433 for 90 minutes (n=2). E. 
Cells were pre-treated with vehicle or U73122 for 30 minutes before 1 hour 3 mM 
ATP treatment (n=3). One Way ANOVA followed by Tukey’s post-test used to 
determine significance ***p<0.001 
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4.2.3. Phosphorylation of signalling proteins in response to ATP 
treatment 
4.2.3.1. PI3K/Akt Pathway 
Akt is an important down-stream protein in the PI3K/mTOR pathway and can also 
be activated independently by IKBKE (429). Full activation occurs following 
phosphorylation of two residues: Ser473 and Thr308 (Figure 1.6). Measurement of 
phosphorylation of these residues on Akt by immunoblotting is commonly used to 
show activation of the PI3K pathway. The class IB p110γ can be activated by 
ligands for the chemokine GPCRs CXCR3 and CXCR4 as well as others. Indeed 
both chemokines CXCL11 (CXCR3) and CXCL12 (CXCR4) caused an increase in 
Akt Ser473 phosphorylation (n=2 ± STDEV) (Figure 4.14 A and B). In astrocytes 
Akt is phosphorylated on Ser473 and Thr308 within 2 minutes of 100 μM BzATP 
treatment (334). Akt phosphorylation was significantly inhibited by the pan-isoform 
PI3K inhibitors LY294002, Wortmannin, the Src inhibitor PP2 and by extracellular 
calcium chelation. Akt is also phosphorylated in response to ATP treatment in 
mouse embryonic stem cells (255); however in mouse thymocytes 2 hour 1 mM 
treatment did not increase Akt phosphorylation (255). In mouse CD4+ and CD8+ T 
lymphocytes Akt down-regulates CD62L expression by phosphorylating FOXO1 
and turning off CD62L gene transcription (114). Therefore, the hypothesis formed 
was that ATP may activate the PI3K pathway and cause CD62L down-regulation 
by Akt activation. 
After 15 minutes treatment with 1 mM ATP a non-significant 1.77 ± 0.55 (n=3 ± 
SEM p>0.05) fold increase in Akt phosphorylation was observed (4.15 A and C). 
To investigate whether P2X7R was involved the antagonist A438079 was applied 
to cells at a concentration of 1 μM 30 minutes before ATP treatment. Pre-
treatment with A438079 alone appears to increase Akt phosphorylation 1.68 ± 
0.47 fold. However, after 15 minutes ATP treatment Akt phosphorylation is only 
1.09 ± 0.43 fold above control when A438079 is pre-applied compared to 1.77 ± 
0.55 for vehicle pre-treatment; this inhibition is however not significant (n=3 ± SEM 
p>0.05). 
Activation of the PI3K/mTOR pathway can also lead to activation of S6K and 
subsequent phosphorylation of S6 ribosomal subunit; a step required for 
increased protein synthesis (53, 417). Therefore, phosphorylation of S6 can be 
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used as a further read out of activation of the PI3K/mTOR pathway. S6 was 
phosphorylated following CXCL11 and CXCL12 treatment (Figure 4.15 A and B). 
S6 was more robustly phosphorylated upon 1 mM ATP treatment than Akt with a 
peak of 13.01 ± 8.08 fold (n=3 ± SEM p>0.05) increase in S6 phosphorylation after 
5 minutes (Figure 4.15 A and C). Pre-treatment with A438079 appears to have a 
small, but insignificant effect on S6phosphorylation in response to ATP (Figure 
4.15 C).  
4.2.3.2. MAPK Pathways 
Erk1/2 MAPK is one of the most extensively studied signalling proteins down-
stream of P2X7R activation by ATP or BzATP. ATP induced Erk1/2 
phosphorylation has been shown to have a role in thymocyte death which was 
interestingly independent of extracellular calcium (255). A 5 minute 1 mM ATP 
treatment was sufficient to induce Erk1/2 phosphorylation in mouse splenocytes 
(255). Erk1/2 are also phosphorylated via P2X7R in astrocytes (335–337). In the 
study by Sinclair et al which highlighted a role for PI3K in TCR induced CD62L 
loss, Erk1/2 involvement was also described by using the MEK1 inhibitor PD98059 
(114). Another MAPK, p38 was phosphorylated in response to ATP in murine 
thymocytes (255).  Threonine phosphorylation of ADAM17 by Erk1/2 and p38 
MAPK aids its trafficking to the cell surface, where it acts to down-regulate its 
substrates including CD62L (129–132). 
Erk1/2 phosphorylation following chemokine stimulation has been described 
elsewhere (430) and CXCL11 and CXCL12 treatment was used as a positive 
control for Erk1/2 phosphorylation (Figure 4.16 A and B). Indeed, 5 minute 10 nM 
CXCL11 or CXCL12 treatment caused 7.90 ± 3.57 and 8.32 ± 3.58 fold increases 
in Erk1/2 respectively (n=3 ± SEM p>0.05). After 15 minute treatment with 1 mM 
ATP a noticeable but insignificant 4.40 ± 2.21 fold increase in Erk1/2 
phosphorylation was observed; this was reduced to a 2.38 ± 1.35 fold increase 
when cells were pre-treated with 1 μM A438079 for 30 minutes (n=3 ± SEM 
p>0.05) (Figure 4.16 A and C). 
 
 











Figure 4.14: Measurement of Akt Phosphorylation down-stream of P2X7R. 
SEB cells were expanded from PBMC as described in materials and methods, IL2 
was removed and cells re-suspended in fresh complete RMPI-1640 on day 8 post 
isolation and used for experiment on day 9. Cells were washed three times, re-
suspended in serum free RMPI-1640 at a concentration of 2 x 106 per ml, pre-
treated with vehicle (media) or 1 μM A438079 for 30 minutes. Cells were then 
treated with vehicle, 1 mM ATP or 10 nM CXCL11/12 for the indicated time periods. 
All cells were lysed as described, loaded onto poly-acrylamide gels and proteins 
separated under reducing conditions using SDS-PAGE. Proteins were transferred 
to nitro-cellulose membrane, blocked and immuno-blotted for Ser473 
phosphorylation of Akt using antibody from Santa Cruz. Membranes were stripped 
of antibody, blocked and re-probed for Akt1 using anti-Akt1 antibody (Santa Cruz). 
Blots were analysed using Image J as described, first pAkt was normalised to Akt1 
for equal protein loading and then all treatments were normalised as a fold change 
of pAkt above vehicle alone treated cells. ). A. Representative western blot showing 
pAkt (upper panel) and Akt (lower panel). MWM = molecular weight markers B. 
Effect of 5 minutes 10 nM chemokines CXCL11 and CXCL12 on Akt 
phosphorylation (n=2). C. Effect of 1 mM ATP on pAkt levels in vehicle or 1 μM 
A438079 pre-treated cells (n=3) Two Way ANOVA followed by Tukey’s post-test 
was performed to measure significance. 







Figure 4.15: Measurement of S6 ribosomal subunit Phosphorylation down-
stream of P2X7R. SEB cells were expanded from PBMC as described in materials 
and methods, IL2 was removed and cells re-suspended in fresh complete RMPI-
1640 on day 8 post isolation and used for experiment on day 9. Cells were washed 
three times, re-suspended in serum free RMPI-1640 at a concentration of 2 x 106 
per ml, pre-treated with vehicle (media) or 1 μM A438079 for 30 minutes. Cells 
were then treated with vehicle, 1 mM ATP or 10 nM CXCL11/12 for the indicated 
time periods. All cells were lysed as described, loaded onto poly-acrylamide gels 
and proteins separated under reducing conditions using SDS-PAGE. Proteins were 
transferred to nitro-cellulose membrane, blocked and immuno-blotted for 
phosphorylation of S6 using antibody from Cell Signalling Technologies. 
Membranes were stripped of antibody, blocked and re-probed for S6 using anti-
Erk1 antibody (Santa Cruz). Blots were analysed using Image J as described, first 
pS6 was normalised to Erk1 for equal protein loading and then all treatments were 
normalised as a fold change of pS6 above vehicle alone treated cells. A. 
Representative western blot showing pS6 (upper panel) and Erk (lower panel). 
MWM = molecular weight markers. B. Effect of 5 minutes 10 nM chemokines 
CXCL11 and CXCL12 on S6 phosphorylation (n=2). C. Effect of 1 mM ATP on pS6 
levels in vehicle or 1 μM A438079 pre-treated cells (n=3). Two Way ANOVA 
followed by Tukey’s post-test was performed to measure significance. 













Figure 4.16: Measurement of Erk Phosphorylation down-stream of P2X7R. 
SEB cells were expanded from PBMC as described in materials and methods, IL2 
was removed and cells re-suspended in fresh complete RMPI-1640 on day 8 post 
isolation and used for experiment on day 9. Cells were washed three times, re-
suspended in serum free RMPI-1640 at a concentration of 2 x 106 per ml, pre-
treated with vehicle (media) or 1 μM A438079 for 30 minutes. Cells were then 
treated with vehicle, 1 mM ATP or 10 nM CXCL11/12 for the indicated time periods. 
All cells were lysed as described, loaded onto poly-acrylamide gels and proteins 
separated under reducing conditions using SDS-PAGE. Proteins were transferred 
to nitro-cellulose membrane, blocked and immuno-blotted for phosphorylation of 
Erk1/2 using antibody from Cell Signalling Technologies. Membranes were stripped 
of antibody, blocked and re-probed for Erk1/2 using anti-Erk1 antibody (Santa 
Cruz). Blots were analysed using Image J as described, first pErk1/2 was 
normalised to Erk1 for equal protein loading and then all treatments were 
normalised as a fold change of pErk1/2 above vehicle alone treated cells. A. 
Representative western blot showing pErk1/2 (upper panel) and Erk (lower panel). 
MWM = molecular weight markers. B. Effect of 5 minutes 10 nM chemokines 
CXCL11 and CXCL12 on Erk1/2 phosphorylation (n=2). C. Effect of 1 mM ATP on 
pErk1/2 levels in vehicle or 1 μM A438079 pre-treated cells (n=3). Two Way 
ANOVA followed by Tukey’s post-test was performed to measure significance. 
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4.2.4. The PI3K/mTOR, Erk1/2 and p38 MAPK signalling pathways are 
not required for ATP induced down-regulation of cell surface 
CD62L 
Having observed that the PI3K/mTOR and Erk1/2 may be activated by ATP 
treatment, inhibitors of PI3K, Erk1/2 and p38 (another MAPK) were used to see if 
these pathways were involved in ATP induced loss of cell surface CD62L 
expression. To prevent Akt activation via PI3K cells were pre-treated for 30 
minutes with the pan-isoform specific inhibitor ZSTK474 (or DMSO as a vehicle 
control). Cells were then treated for 1 hour with 3 mM ATP and cell surface CD62L 
expression measured. ZSTK474 (0.01 – 10 μM) failed to significantly inhibit ATP 
induced down-regulation of cell surface CD62L (Figure 4.17 A). Pre-treatment with 
the MEK1 inhibitor PD98059 at 0.01 – 10 μM, also had no effect on ATP induced 
loss of cell surface CD62L expression (Figure 4.18 B). Although the coupling of 
P2X7R activation to the p38 MAPK pathway was not investigated here, the p38 
inhibitor SB203580 had no effect on 3 mM ATP induced down-regulation of cell 







Figure 4.17: A number of kinases are not required for ATP induced CD62L 
down-regulation. Freshly isolated naive CD4 T lymphocytes were pre-treated with 
vehicle (DMSO) or small molecule inhibitors at the given concentrations: A. 
ZSTK474 (n=3) B. PD98059 (n=3) or C. SB203580 (n=2) for 30 minutes, Cells were 
then treated with 3 mM ATP for 1 hour. CD62L expression was analysed by flow 
cytometry as described. Student’s t-test was used to compare MFI of CO to ATP 
treated cells *p<0.05. Effect of inhibitors was measured by One Way ANOVA 
followed by Tukey’s post-test. 
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4.2.5. PKC is required for loss of cell surface CD62L expression in 
response to PMA, but not anti-CD3/CD28 antibody coated beads 
or ATP 
Previously, PMA was shown to cause significant loss of CD62L expression from 
the surface of human naïve CD4+ T lymphocytes and the leukemic T cell line 
Jurkat (Figure 4.7 and Figure 4.8 A and B). PMA is known to activate PKC and 
this signalling protein has been implicated in PMA induced CD62L processing; 
indeed PKC can directly phosphorylate ADAM17. Treatment of naïve CD4+ T 
lymphocytes with 100 nM PMA for 30 minutes caused a significant down-
regulation of CD62L from the cell surface. The PKC antagonist Gö6976 inhibits 
the classical PKC isoforms and 1 μM and 10 μM Gö6976 significantly inhibited 
PMA induced down-regulation of cell surface CD62L expression (Figure 4.18 A). 
However, anti-CD3/CD28 induced CD62L down-regulation was independent of 
classical PKC signalling (Figure 4.18 B). 
Treatment of osteoclasts with ATP leads to the translocation of the classical PKC 
isoforms PKCα and PKCβI to the cell surface (340). It was therefore desirable to 
investigate whether PKC is responsible for loss of cell surface CD62L expression 
in response to ATP. Using naïve CD4+ T lymphocytes isolated at the same time 
from donors showing PMA/PKC mediated CD62L loss, the involvement of PKC in 
ATP induced loss of cell surface CD62L expression was investigated. Pre-
treatment with Gö6976 had no effect on ATP induced CD62L down-regulation, 
suggesting classical PKC isoforms are not involved (Figure 4.18 C). BzATP can 
also cause the activation of PKCδ;  Rottlerin is a non-specific PKC antagonist 
which inhibits the novel PKC isoform, PKCδ (336). Pre-treatment of cells with 
Rottlerin did not significantly inhibit ATP induced loss of cell surface CD62L 
expression, but unexpectedly pre-treatment with 10 µM Rottlerin enhanced ATP 
induced CD62L loss (Figure 4.18 D). 
 
 













Figure 4.18: PKC is responsible for PMA, but not anti-CD3/CD28 
antibody coated bead or ATP induced loss of cell surface CD62L. 
Freshly isolated naïve CD4+ T lymphocytes were pre-treated with vehicle 
(DMSO), Gö6976 (A-C) or Rottlerin (D) for 30 minutes (n=3). Cells were then 
treated with: A 100 nM PMA for 30 minutes, B anti-CD3/CD28 antibody 
coated beads for 18 hours, C 3 mM ATP for 30 minutes or D 1 hour. CD62L 
expression was analysed by flow cytometry as described, the effect of PMA/ 
anti-CD3/CD28 antibody coated bead/ATP treatment on MFI was analysed 
by Student‘s t-test *p<0.05 and ***p<0.001. CD62L MFI was then normalised 
as a percent of control (100%) expression, DMSO treated groups were 
compared to inhibitors by One Way ANOVA followed by Tukey’s post-test 
#p<0.05 and ###p<0.001. 
Results Chapter 4 
150 
 
4.2.6. Results Section 4.1 Summary 
 Activation of naïve CD4+ T lymphocytes causes CD62L down-regulation 
 This down-regulation is significant after 18 hours of anti-CD3/CD28 
antibody coated micro-bead treatment 
 PI3K/mTOR and Erk1/2 MAPK signalling are not required for anti-
CD3/CD28 bead mediated CD62L down-regulation 
 ATP induced down-regulation of cell surface CD62L from naïve CD4+ T 
lymphocytes but not the leukemic T cell line Jurkat. 
 ATP induced CD62L down-regulation was rapid, peaking at 15 minutes 
 ATP induced CD62L down-regulation occurs with an EC50 value of 888.6 
μM for 1 hour treatment 
 The P2X7R antagonists A438079 and AZ11645373 inhibited 1 hour 3 mM 
ATP induced CD62L down-regulation with IC50 values of 2.25 and 1.35 µM 
respectively. 
 CD62L surface down-regulation induced by ATP was dependent on the 
actions of MMPs 
 Naive CD4+ T lymphocytes express low levels of CD39. The hydrolysis of 
ATP prevented CD62L down-regulation, whilst adenosine had no effect. 
4.2.7. Results Section 4.2 Summary 
 CD62L loss from naive CD4+ T lymphocytes was independent of 
extracellular calcium. However, modulation of intracellular calcium stores 
causes CD62L loss 
 Treatment with ATP causes a noticeable but insignificant increase in the 
phosphorylation of Erk1/2 and S6 ribosomal subunit.  
 A less marked effect was observed for Akt phosphorylation. 
 It is unclear whether this phosphorylation is dependent on P2X7R 
 Inhibitors of PI3K and MEK have no effect on ATP induced CD62L down-
regulation 
 PKC is required for PMA, but not anti-CD3/CD28 antibody coated bead or 
ATP induced down-regulation of cell surface CD62L 
 















Figure 4.19: Anti-CD3/CD28 antibody coated bead induced down-
regulation of surface CD62L and CCR7 1. Anti-CD3 antibody coated 
beads cause down-regulation of CD62L; this is enhanced by also 
stimulating CD28 with anti-CD3/CD28 antibody coated beads (2). 3. 
This process did not appear to involve the action of MMPs. 4. Pre-
incubation with the Pan-PI3K inhibitor LY294002 enhanced anti-CD3 
and anti-CD3/CD28 antibody coated bead induced loss of CD62L 
expression. 5. Anti-CD3/CD28 antibody coated beads also cause loss 
of cell surface CCR7 expression. 
 














Figure 4.20: PMA, Ca2+ store depletion and ATP, through P2X7R, cause 
down-regulation of cell surface CD62L expression. 1. PMA causes 
significant down-regulation of surface CD62L expression through PKC 
activation. 2. The broad spectrum MMP inhibitor GM6001 reveals that MMPs 
are responsible for ATP induced loss of cell surface CD62L expression. 3. ATP 
acts through P2X7R, as the competitive and non-competitive P2X7R 
antagonists A438079 and AZ11645373 respectively inhibit loss of CD62L 
surface expression. ATP induced loss is also inhibited by grade VI apyrase. 4. 
The signalling proteins Akt, S6 ribosomal subunit and Erk1/2 are 
phosphorylated in response to ATP, however this effect is minimal and these 
signalling pathways are not responsible for ATP induced CD62L loss. 5. 
External calcium is not required for ATP induced loss of CD62L surface 
expression; however Ca2+ store depletion does induce significant CD62L loss. 
6. The non-specific PKC inhibitor Rottlerin enhances ATP induced loss of 
CD62L surface expression. 
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4.3. Results Chapter 4 Discussion 
4.3.1. CD3/CD28 mediated down-regulation of cell surface CD62L 
This study revealed that anti-CD3/CD28 antibody coated bead induced down-
regulation of CD62L from the surface of naïve CD4+ T lymphocytes was 
independent of PI3K/mTOR, Erk1/2 and PKC signalling. This is in direct contrast 
to a study by Sinclair et al which explored the mechanisms for loss of cell surface 
CD62L in murine T lymphocytes (114).  
There are several possible reasons for differences between published data and 
data presented in this thesis. Firstly, this thesis employed anti-CD3/CD28 antibody 
coated beads; this was because in human CD4+ T lymphocytes soluble anti-CD3 
antibody alone caused very little CD62L down-regulation compared to mouse 
CD4+ T lymphocytes. CD28 is an established co-stimulatory receptor for T 
lymphocytes during activation and may contribute to CD62L down-regulation. In 
one study, the leukemic T cell line Jurkat was treated with soluble anti-CD3 or 
anti-CD28 antibodies and CD62L expression compared. Ligation of CD3 was 
sufficient to cause 73% down-regulation of cell surface CD62L, whereas ligation of 
CD28 caused 35% loss of CD62L surface expression (431). The treatment of 
isolated lymph node cells with anti-CD28 antibody for 10 hours also caused a 
marked reduction in the cell surface expression of CD62L, alongside an up-
regulation of LFA-1 (432). In vivo, inhibition of CD28 by CTLA4Ig caused a 
decrease in the number of CD62Llow effector memory T lymphocytes found in the 
spleen and mesenteric lymph nodes of mice treated with influenza hemagglutinin 
(HA) or ovalbumin (OVA) peptides (433). However, it is unclear from this study if 
this is due to reduced shedding of cell surface CD62L and the authors suggest it is 
likely due to ineffective conversion of central to effector memory T lymphocytes. 
Therefore, it may be that co-stimulation allows coupling to novel mechanisms of 
CD62L down-regulation. However, in this thesis the relative contribution of anti-
CD3 and anti-CD28 antibodies to down-regulation was not explored.  
Secondly, although mouse models provide a useful tool for investigating immunity 
and inflammation, there are several important differences between the mouse and 
human immune system (434). For instance, the level of CD28 expression by CD4+ 
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and CD8+ T lymphocytes varies between humans and mice. The mouse anti-CD3 
antibody (2C11) and human anti-CD3 antibody (UCHT-1) both bind to epitopes in 
the CD3ε receptor (435, 436). However, data presented in this thesis suggests the 
signal transduction following CD3 ligation that leads to CD62L down-regulation 
may differ between species. Finally, it is possible that the micro-beads used may 
also provide a mechanistic signal imitating cell-cell contact induced CD62L down-
regulation (437).  
It was surprising that long term inhibition of PI3K or MEK/Erk1/2 did not affect 
CD62L expression in ex vivo expanded CD4+ T lymphocytes. However, 
confounding factors are present in this long term culture model: the bead to cell 
ratio is increased from 1:1 (in 18 hour study) to 3:1; IL-2 is also added to maintain 
cell growth which has been shown, in CD8+ T lymphocytes, to contribute to CD62L 
loss (110). After 7 days ex vivo culture, CD62L expression may actually be 
increased above initial naïve CD4+ expression levels. This increase could be due, 
in part, to enrichment of central memory T lymphocytes which re-express high 
levels of CD62L to home back to SLOs for memory based antigen surveillance 
(89). Indeed, when T lymphocytes were expanded ex vivo from PBMC using SEB 
they display a biphasic CD62L expression profile, with a population of cells 
showing very high levels of expression. A study also using anti-CD3/CD28 
antibody coated beads and IL-2 to activate human umbilical cord blood, observed 
92% CD3+/CD62L+ cells after 14 days (438). 
4.3.2. ATP induced loss of CD62L surface expression 
Although the leukemic T cell line Jurkat and human naïve CD4+ T lymphocytes 
express functional P2X7Rs, there are differences in their ability to down-regulate 
cell surface CD62L in response to ATP. Several signalling pathways are perturbed 
in the leukemic T cell line Jurkat including PI3K signalling, however this cell type is 
complex and it would be difficult to elucidate the reason for the lack of ATP 
induced CD62L surface loss (377). The basal levels of CD62L expression were 
lower for the leukemic T cell line Jurkat compared to human naïve CD4+ T 
lymphocytes, this may be, in part, due to the absence of PTEN expression; 
restoration of PTEN expression increases CD62L expression on Jurkats (133). 
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What is clear however, is that down-regulation of cell surface CD62L on naïve 
CD4+ T lymphocytes in response to ATP does not require PKC and the leukemic T 
cell line Jurkat down-regulates surface CD62L in response to PMA. The 
concentration dependence of PMA for CD62L down-regulation is similar to that 
observed in a mouse B cell line expressing CD62L (130). These observations 
suggest that a pathway other than PKC is responsible for the differences between 
the action of ATP on the leukemic T cell line Jurkat and naïve CD4+ T 
lymphocytes. 
Previous studies involving CD62L down-regulation from T lymphocytes have 
focussed on mouse CD4+ T lymphocytes and subpopulations of human PBMC 
cells including naïve CD4+ T lymphocytes; here CD62L down-regulation in 
response to ATP is confirmed in isolated human naïve CD4+ T lymphocytes (245, 
284, 395). The kinetics of CD62L down-regulation in naïve CD4+ T lymphocytes 
showed rapid down-regulation, however this was not as rapid as for B 
lymphocytes from patients with BCLL. These cells down-regulate almost 95% of 
CD62L within 5 minutes, however BCLL cells have enhanced P2X7R expression 
(208, 254). ATP was more potent in BCLL cells with an EC50 of 31.3 ± μM (7 
minute treatment) (208) compared to 877 μM (5 minute treatment) for naïve CD4+ 
T lymphocytes for data presented in this thesis.  
Previous studies have used first generation P2X7R inhibitors such as oATP and 
KN62 to show that P2X7R is involved in ATP induced down-regulation of cell 
surface CD62L (208, 245). This study utilised the second generation P2X7R 
antagonists A438079 and AZ116453743 to confirm P2X7R activation is indeed 
responsible for CD62L down-regulation in response to ATP. However, other 
purinergic receptors could also be involved in this process. This study did not 
investigate the expression of P2Y receptors on naïve CD4+ T lymphocytes; 
however electrophysiology indicated a small outward current in response to 0.1 
mM ATP which could be mediated by P2Y receptors. Indeed, P2Y2 receptors 
have been shown to affect ADAM17 substrate processing and this receptor 
subtype is expressed in T lymphocytes (422, 439, 440). A reduction in the 
concentration of exogenously applied ATP could lead to reduced P2X receptor 
activation and enhanced P2Y receptor activation. The lack of CD39 expression on 
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naïve CD4+ T lymphocytes suggests that exogenous ATP degradation would not 
occur rapidly with these cells in vitro; however in vivo bystander cells could 
express high levels of CD39 and CD73. As shown in Figure 4.10, within PMBC 
there are populations of cells which are CD4+CD39+ which are likely to be Treg 
cells (172). Exogenous application of apyrase significantly inhibited loss of cell 
surface CD62L expression, therefore in vivo Treg cells may be able to inhibit ATP 
induced CD62L down-regulation from the surface of other cells. 
4.3.3. Signalling mechanisms involved in ATP induced loss of cell 
surface CD62L 
Having established that P2X7R activation couples to CD62L down-regulation from 
naïve CD4+ T lymphocytes, it was possible to address the third aim of this project 
and assess the involvement of PI3K signalling in this process.  
Firstly calcium mobilisation was investigated as a mechanism; this is because 
previous studies have shown that calcium can promote down-regulation of CD62L 
from the cell surface. The calcium ionophore Ionomycin (2.5 µM) has been shown 
to cause loss of cell surface CD62L processing from mouse T and B lymphocytes 
through ADAM10 and 17 (122). However, 10 µm Ionomycin was only able to 
cause a 14% loss of cell surface CD62L in lymphocytes from human patients with 
B-CLL (207). This thesis demonstrated that treatment with 1.3 µM Ionomycin was 
insufficient to cause CD62L down-regulation; however, higher concentrations were 
not explored. Un-expectedly treatment of naïve CD4+ T lymphocytes with U73122 
caused loss of cell surface CD62L expression; this appears to be a specific effect 
because the inactive analogue U73433 had no effect on CD62L levels. This could 
be explained by the observation that U73122 can release Ca2+ from intracellular 
store in permeabilised mouse pancreatic acinar cells (441). Indeed, the use of 
Thapsigargin in this thesis caused significant down-regulation of CD62L from the 
cell surface of naïve CD4+ T lymphocytes. The fact that ATP induced CD62L 
down-regulation was not significantly affected by removal of extracellular Ca2+ is in 
agreement with Jamieson et al (207).  
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A number of previous studies have investigated the activation of signalling 
proteins down-stream of P2X7R; here activation of the PI3K/mTOR and Erk1/2 
pathways was investigated (205, 238, 255, 330, 334–336, 426–428). For 
immunoblotting, T lymphocytes activated by SEB were used because they are 
easier to isolate in large numbers and contain more protein than naïve CD4+ T 
lymphocytes.  Treatment with 1 mM ATP led only to small increases in the 
phosphorylation of components of these signalling pathways, whereas other 
experiments have shown this concentration to be sufficient for significant 
responses. In addition, A438079 only partially reduced ATP induced 
phosphorylation of Erk1/2. Electrophysiological experiments confirmed that 10 μM 
A438079 significantly inhibited ATP induced currents in naïve CD4+ T 
lymphocytes. These experiments did, however provide a hint that the PI3K/mTOR 
and Erk1/2 pathways may be activated in T lymphocytes by ATP.  
This study demonstrates that although ATP induced loss of cell surface CD62L 
expression requires the action of MMPs; remarkably it is independent of the PI3K, 
Erk1/2, p38 MAPK and PKC signalling pathways. Although initially unexpected, 
this finding correlates with data for ATP induced CD27 loss from mouse 
splenocytes (313). Another study also showed that ATP induced TGFα release 
from AP-TGFα transfected CHO cells through P2Y receptors was Erk1/2 and PKC 
independent (422). Recent data have revealed that Akt can be activated 
independently of PI3K, therefore P2X7R may activate Akt to induce CD62L in a 
manner independent of PI3K (429). Additionally, the lack of PI3K/mTOR and 
Erk1/2 involvement in down-regulation of surface CD62L expression in response 
to CD3/CD28 ligation of T lymphocytes was also not reconciled with mouse 
studies here (114).  
Several other mechanisms could be responsible for CD62L processing in 
response to ATP. Neutrophils down-regulate CD62L from their cell surface in 
response to osmotic stress, the mechanism for this involves shrinkage of cells and 
the action of p38 MAPK and MMPs (442). Although cell shrinkage has previously 
been reported in response to ATP, data from this thesis suggests that this is not 
the case for human naïve CD4+ T lymphocytes (206, 278). Additionally, the p38 
MPAK inhibitor SB203580 had no effect on ATP induced down-regulation of cell 
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surface CD62L expression. During apoptosis, the mitochondria changes the lipid 
composition of its membrane and de novo synthesis of the lipid ceramide is 
promoted by BzATP and ATP through P2X7R in mouse thymocytes (279). This 
increased ceramide synthesis is required for activation of the apoptotic caspases 3 
and 7 in macrophages (443). Streptolysin O is a pore forming toxic from bacteria 
which causes an increase in ceramide production in human granulocytes (444). 
This ceramide increase following Streptolysin O treatment was responsible for loss 
of cell surface CD62L expression from these cells. This effect was recapitulated by 
exogenous application of ceramide. However, ceramide production in response to 
ATP was not measured in this thesis and as other markers of apoptosis were not 
induced, it is unlikely that ceramide is responsible for CD62L down-regulation in 
human naïve CD4+ T lymphocytes. 
 





5. Chapter 5: Modulation of 




















5.1.  Reactive Oxygen Species (ROS) Generation in Human 
Naive CD4+ T Lymphocytes 
5.1.1. Rational 
The previous chapter established that CD62L down-regulation from the surface of 
human naïve CD4+ T lymphocytes is dependent upon the activation of P2X7R and 
the action of MMPs. Experiments using small molecule inhibitors of signalling 
proteins of the PI3K and MAPK pathways showed that unexpectedly these did not 
transduce P2X7R activation to CD62L processing. An interesting observation was 
made when two of these compounds (LY294002 and Rottlerin) were used at 
concentrations above the published IC50 values for inhibition of their intended 
targets (PI3K and PKC respectively). At these higher concentrations, LY294002 
and Rottlerin enhanced anti-CD3 antibody coated bead and ATP induced CD62L 
cell surface down-regulation respectively. One off target effect of these 
compounds is the enhanced production of reactive oxygen species (ROS). 
LY294002 is a potent anti-cancer agent through its inhibition of PI3K and DNA-PK, 
however, recent data suggests that it may also increase production of H2O2 (59). 
Rottlerin, when used at relatively high concentrations (e.g. 10 μM) can increase 
the consumption of O2 in cells, and this effect is thought to be through increased 
ROS generation by modulation of the mitochondrial electron transport chain. 
Additionally, P2X7R activation can cause the increased production of ROS in 
cells; this can drive a number of biochemical processes including the processing 
of IL-1β by macrophages. ROS can act as second messengers through their 
ability to oxidise cysteine residues in target proteins (445, 446). Indeed, ROS can 
cause increased processing of ADAM17 substrates through a mechanism 
involving either direct reduction of cysteine residues in ADAM17 or down-
regulation of ADAM17 stabilising protein disulfide isomerases (PDIs) (421, 447). 
MMP1 and MMP9 can also be activated by ROS (448). 
The observations that: 
 ATP, through P2X7R, can increase intracellular ROS production 
 Off target ROS enhancing effects of LY294002 and Rottlerin may enhance 
CD62L down-regulation  
 ADAM17 and MMPs can be activated by ROS to cleave their substrates 




Led to formation of the hypothesis that: 
1. ATP activates P2X7R 
2. P2X7R couples to increased ROS generation 
3. ROS activates MMPs such as ADAM17 
4. This causes CD62L processing 
 
5.1.2. Aim 
Firstly, using intracellular ROS sensing dyes and pharmacological tools, the role of 
ATP in ROS generation in naïve CD4+ T lymphocytes was explored. This was 
followed by a strategy to determine if ROS mediates P2X7R dependent CD62L 



















5.1.3. ROS generation in the acute monocytic leukaemia cell line THP-
1 
Previous work established that in macrophages activation of NADPH oxidase by 
P2X7R was required for ATP induced IL-1β processing (246), however little is 
known about the role of P2X7R in ROS generation in T lymphocytes (449). A 2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA “DCF”) based fluorescence assay 
was used to measure ROS generation in freshly isolated naïve CD4+ T 
lymphocytes, SEB activated T lymphocytes and the leukemic cell lines Jurkat and 
THP-1. The acute monocytic leukaemia cell line THP-1 was previously used to 
establish an assay for ethidium bromide uptake (Figure 3.6), therefore this cell 
type was also assessed for its ability to generate ROS in response to ATP. 
Unexpectedly, undifferentiated THP-1 monocytes (Figure 5.1 A and B) and 
macrophage-like IFNγ and LPS differentiated cells (Figure 5.1 C and D) did not 





Figure 5.1: ATP does not induce significant ROS generation in the acute 
monocytic leukaemia cell line THP-1. Un-differentiated THP-1 cells were 
removed from culture A and B (n=3 ± SEM) or differentiated overnight with IFNγ 
and LPS C and D (n=2 ± range). Cells were loaded with DCF as described, treated 
with agonist and fluorescence recorded. Example kinetics of ATP induced ROS 
generation are given in A and C. Changes in DCF fluorescence were recorded 
over 1 hour of agonist stimulation and the fold changes above vehicle treatment 
are displayed in B and D. One Way ANOVA followed by Tukey’s post-test used to 
determine significance. 




5.1.4. ROS generation in SEB activated T lymphocytes and the 
leukemic T cell line Jurkat 
ROS has been investigated as a mediator of cellular signalling following activation 
of T lymphocytes. Therefore, human T lymphocytes activated ex vivo with SEB 
and the leukemic T cell line Jurkat were assessed for ROS generation in response 
to ATP. SEB activated T lymphocytes show a significant increase in their ROS 
generation after 1 hour 5 mM ATP treatment (Figure 5.2 A and B), this was 
independent of extracellular CaCl2 and MgCl2 (Figure 5.2 C). The leukemic T cell 
line Jurkat also showed increased ROS generation in response to ATP, with 3 and 
5 mM ATP evoking significant increases in ROS (Figure 5.2 D and E). Similarly to 
SEB activated T cells there was no significant difference in the effect of ATP 








Figure 5.2: ATP induces ROS generation in SEB activated T lymphocytes and 
the leukemic T cell line Jurkat. T lymphocytes activated with SEB ex vivo 
(Removed from culture 9 days post activation) and the leukemic T cell line Jurkat 
were removed from culture. Cells were loaded with DCF as described, treated with 
agonist and fluorescence recorded. A and D. Example kinetics of ATP induced 
ROS generation. B and E. After 1 hour a final reading was recorded and expressed 
as a fold change over vehicle control (n=3). C and D. After loading with DCF cells 
were placed in buffer containing or free of CaCl2 and MgCl2 and treated with 
increasing concentrations of ATP (n=3). Histograms represent fold change in DCF 
generation over 1 hour normalised to vehicle control. One Way ANOVA followed by 
Tukey’s post-test used to determine significance *p<0.05, **p<0.01 and ***p<0.001 




5.1.5. ROS generation in naïve CD4+ T lymphocytes 
ROS generated in response to PMA is involved in activation of ADAM17 and 
subsequent processing of TNF p75 receptor from a human monocytic cell line 
(125). In chapter 4 PMA induced down-regulation of surface CD62L expression 
through PKC activation was demonstrated, here 100 nM PMA is also shown to 
induce a small but insignificant increase in DCF fluorescence in naïve CD4+ T 
lymphocytes (Figure 5.3 A).  
Activation of T lymphocytes leads to an increase in ROS production. Anti-CD3 
antibody induces an increase in DCF fluorescence in murine T lymphocytes; as 
well as an increase in DHE fluorescence (a dye used to measure superoxide (O2
-) 
production) (450). Here, treatment of freshly isolated human naïve CD4+ T 
lymphocytes with 10 μg/ml anti-CD3 antibody UCHT1 for 1 hour caused a small 
non-significant increase in DCF fluorescence (Figure 5.3 B). Data from other 
groups (but not supported by data from chapter 3 here) suggest that P2X7R is 
required for T lymphocyte activation (259, 261, 268). It was hypothesised that 
P2X7R could still have a role in ROS generation following T lymphocyte activation; 
however pre-treatment with 10 μM A438079 did not inhibit ROS generation in 
response to UHCT1 treatment (Figure 5.3 B). 
Exogenous ATP could still activate P2X7R and lead to ROS generation 
independent of T lymphocyte activation, therefore this was investigated next. 
Treatment of freshly isolated naïve CD4+ T lymphocytes with ATP resulted in a 
concentration dependent increase in DCF fluorescence. Following 1 hour 5 mM 
ATP treatment, naïve CD4+ cells show a significant increase in the rate of ROS 
generation compared to vehicle treatment (Figure 5.3 C and D).  
5.1.6. Mechanisms of ROS generation 
As ATP induced CD62L down-regulation is P2X7R dependent, P2X7R was 
assessed for its involvement in ATP induced ROS formation using A438079. 
Surprisingly A438079 did not inhibit 5 mM ATP induced increase in DCF 
fluorescence (Figure 5.3 E). The cellular components responsible for ROS 
generation in response to ATP were next investigated, as ATP can modulate 
NADPH oxidase (246, 451). DPI is an inhibitor of flavocytochrome containing 
enzymes, which include: flavocytochrome P450, nitric oxide synthase, NADPH 




oxidase and complex I of the mitochondrial electron transport chain (Table 5.1). 
The increase in DCF fluorescence in response to 5 mM ATP was not inhibited by 
1 hour pre-treatment with 100 μM DPI (Figure 5.3 F). Treatment with the complex I 
inhibitor rotenone had no effect on ATP induced increase in DCF fluorescence, 
suggesting that ATP does not increase ROS through mitochondrial complex I 














Figure 5.3: Mitogen and ATP induced ROS generation in naïve CD4+ T 
lymphocytes. ROS in response to ATP is independent of P2X7R and 
unaffected by Rotenone or DPI. A. Freshly isolated naïve CD4+ T lymphocytes 
were loaded with DCF as described, treated with agonist and fluorescence 
recorded. After 1 hour a final reading was recorded and expressed as a fold change 
over vehicle control. A. Effect of PMA on ROS (n=4). B. Cells were pre-treated with 
vehicle or A438079 for 30 minutes then effect of UCHT1 (anti-CD3 antibody) on 
ROS measured (n=5). C. Example kinetic of ATP induced ROS generation. D. 
Effect of ATP on ROS (n=5). Cells were pre-treated with E. A438079 or F. 
Rotenone for 30 minutes or G. DPI for 1 hour before ATP treatment (n=3). One 
Way ANOVA followed by Tukey’s post-test used to determine significance *p<0.05 




5.1.7. Exogenous application of hydrogen peroxide (H2O2) causes 
down-regulation of cell surface CD62L expression 
Use of DCF detects generation of ROS which include H2O2. Exogenous H2O2 has 
previously been shown to cause loss of cell surface CD62L expression (421). 
Results here confirm that exogenous application of 100 µM H2O2 rapidly causes 
significant loss of cell surface CD62L expression (Figure 5.4 A). Peak CD62L loss 
was observed after 15 minutes H2O2 treatment. ROS generated in response to 
ATP treatment could potentially cause loss of CD62L surface expression, 
therefore inhibitors of ROS generating proteins were used to explore this 
possibility (Table 5.1). 
 
Compound Target Source IC50 Values 
Apocynin NADPH Oxidase 
(NOX2) 
Sigma NOX2 = 10 μM 
DPI Flavin containing 
enzymes. 
(flavocytochrome 
P450, nitric oxide 
synthase, NADPH 
Oxidase and Complex 
I) 
Sigma NOX2 = 0.9 μM 
Respiration = 13 μM 
Rotenone Complex I of 
mitochondrial electron 
transport chain 






Antimycin A Complex III of 
mitochondrial electron 
transport chain 







Table 5.1 Table of inhibitors of ROS generating proteins 
Inhibitors and uncouplers of ROS generating proteins used in this study are given 
in this table along with a range of their IC50 values. 
aBlockage of NADH oxidation 
by cardiac SR and bInhibition of oxygen consumption in middle aged rats. 




5.1.8. DPI enhances ATP induced down-regulation of cell surface 
CD62L expression independently of NADPH oxidase 
DPI inhibits flavin containing enzymes including NADPH oxidase and complex I of 
the mitochondrial electron transport chain. Unexpectedly, DPI significantly 
enhanced ATP induced CD62L loss (Figure 5.4 B); however inhibition of NAPDH 
oxidase (NOX2) with apocynin did not replicate the enhancing effect on CD62L 
down-regulation (Figure 5.4 C). This observation suggested that complex I of the 
mitochondrial electron transport chain might be responsible for this enhancement. 
Inhibition of electron transport through complexes in the respiratory chain can lead 
to the leaking of electrons and generation of ROS including O2
-. As mentioned 
previously, Rottlerin pre-treatment also enhances ATP induced CD62L loss and 
studies suggest Rottlerin may enhance ROS generation by mitochondria at 10 µM 
(418, 453). The mitochondrial electron transport chain was therefore investigated 
as a possible mechanism for enhanced ATP induced down-regulation of cell 








Figure 5.4: Exogenous H2O2 causes CD62L loss from naïve CD4
+ T 
lymphocytes. DPI but not apocynin enhances ATP induced CD62L loss. A. 
Freshly isolated naïve CD4+ T lymphocytes were treated with 100 μM H2O2 for 
increasing periods of time (n=3). Cells were pre-treated with vehicle (DMSO), or 
B. 100 µM DPI for 1 hour or C. increasing concentrations of apocynin for 30 
minutes, then treated with vehicle or 3 mM ATP for 1 hour (n=3). CD62L 
expression was measured using flow cytometry as described. One Way ANOVA 
followed by Tukey’s post-test was used to determine significance *p<0.05 




5.1.9. Uncoupling of mitochondrial electron transport at complex I or 
III causes enhanced ATP dependent down-regulation of cell 
surface CD62L expression via P2X7R 
Rotenone and antimycin A, small molecule inhibitors of complex I and complex III 
of the mitochondrial electron transport chain respectively, were used to investigate 
the role of mitochondrial ROS in ATP induced CD62L down-regulation through 
P2X7R. Before ATP treatment, cells were pre-treated with a range of 
concentrations of rotenone or antimycin A close to published IC50 values for these 
compounds (Table 5.1). Both rotenone and antimycin A had no effect on basal 
levels of cell surface CD62L expression (Figure 5.5 A and B), but significantly 
enhanced CD62L down-regulation in response to ATP treatment (Figure 5.5 C 
and D). An additional 50.27 ± 2.25 % (n=8 ± SEM) loss of CD62L expression was 
observed with 5 μM rotenone pre-treatment when compared with DMSO. For pre-
treatment with 1 μM antimycin A, an additional 41.57 ± 4.08 % (n=3 ± SEM) loss 
of CD62L expression was observed compared with DMSO. As the effect of 
rotenone and antimycin A on CD62L expression was only observed when cells 
were subsequently treated with 3 mM ATP, P2X7R was most likely involved in this 
process. Cells were pre-treated with 5 μM rotenone (Figure 5.5 E) or 1 μM 
antimycin A (Figure 5.5 F) in the presence or absence of 10 μM A438079 before 3 
mM ATP was applied for 1 hour. Pre-treatment with A438079 significantly inhibited 
not only the CD62L loss induced by ATP alone, but also when cells were pre-
treated with rotenone or antimycin A. The enhancement effect of rotenone and 
antimycin A therefore involves P2X7R and evidence exists for the regulation of ion 
channels including P2X2 by ROS (454, 455). The effect of these compounds on 
the concentration of ATP required to elicit CD62L down-regulation through P2X7R 
was next investigated. ATP was applied in increasing concentrations to naïve 
CD4+ T lymphocytes pre-treated with vehicle (DMSO), 5 μM rotenone A or 1 μM 
antimycin A (Figure 5.6 A). For down-regulation of cell surface CD62L expression 
in response to ATP, the EC50 value was decreased from 1.58 mM (DMSO) to 0.43 
mM when cells were pre-treated with either rotenone or antimycin A (Figure 5.6 
B). However, pre-treatment of cells with increasing concentrations of antimycin A 
(Figure 5.7 A) or rotenone (Figure 5.7 B) did not significantly enhance anti-
CD3/CD28 antibody induced CD62L down-regulation. 









Figure 5.5: Antimycin A and rotenone enhance ATP induced CD62L down-
regulation in a P2X7R dependent manner. Freshly isolated naïve CD4+ T 
lymphocytes were pre-treated with vehicle (DMSO), or increasing concentrations of 
A and C: Rotenone (n=8) or B and D: Antimycin A (n=3) for 30 minutes. Cells were 
then treated with vehicle (A and B) or 3 mM ATP for 1 hour (C and D). E. Cells 
were pre-treated with DMSO, 10 μM A438079, 5 μM rotenone or both A438079 and 
rotenone for 30 minutes before treatment with 3 mM ATP for 1 hour (n=3). F. Cells 
were pre-treated with DMSO, 10 μM A438079, 1 μM antimycin A or both A438079 
and antimycin A for 30 minutes before treatment with 3 mM ATP for 1 hour (n=3). 
One Way ANOVA followed by Tukey’s post-test or Two Way ANOVA followed by 
post-test were used to determine significance */#p<0.05, **/##p<0.01 and 
***/###p<0.001 













Figure 5.7: Antimycin A and rotenone do not affect CD62L down-regulation in 
response to 18 hour anti-CD3/CD28 antibody treatment. Freshly isolated naive 
CD4+ T lymphocytes were pre-treated with DMSO, or increasing concentrations of 
A. Antimycin A or B. Rotenone for 30 minutes. Cells were then treated with anti-
CD3/CD28 antibody coated beads for 18 hours and CD62L expression levels 
measured and analysed as described (n=3). One Way ANOVA followed by Tukey’s 
post-test used to determine significance ***p<0.001 
 
Figure 5.6: Antimycin A and rotenone increase potency for ATP induced 
CD62L down-regulation. A. Freshly isolated naive CD4+ T lymphocytes were pre-
treated with vehicle (DMSO), 5 μM rotenone or 1 μM antimycin A (n=3). Cells were 
then treated with increasing concentrations of ATP from 0.01-5 mM for 1 hour and 
CD62L expression measured as described. B. GraphPad Prism 4 was used to 
concentration response curves, pEC50 values for ATP for each of the pre-
treatments are given in the corresponding table. 




5.1.10. Rotenone and antimycin A enhance basal mitochondrial 
O2
- 
Previous work has demonstrated that uncoupling of the mitochondrial electron 
transport chain at complex I and III by rotenone or antimycin A respectively can 
increase the basal levels of O2
- (158–160). In isolated mouse liver mitochondria 
antimycin A induced O2
- generation (measured using MitoSOX Red) with an EC50 
value of 11.4 ± 1.8 μM (159). Here it was confirmed that rotenone and antimycin A 
significantly increase basal levels of mitochondrial O2
- in naïve CD4+ T 
lymphocytes (Figure 5.8 A-C). This process was dependent on the concentration 
of each compound used. When cells were pre-treated with rotenone or antimycin 
A at the same concentrations, then treated with 3 mM ATP for 1 hour there was no 
significant enhancement of mitochondrial O2
- above basal levels. 
As previously mentioned, small amounts of ROS are generated after treatment of 
naïve CD4+ T lymphocytes with anti-CD3 antibody (UCHT1) or PMA. O2
- 
generation in activated T lymphocytes has also been reported (450); therefore 
MitoSOX Red was used to investigate if mitochondrial O2
- increased after UCHT1 
or PMA treatment. No significant increase in MitoSOX Red fluorescence was 
observed after UCHT1 or PMA treatment, suggesting O2
- is not produced in the 
mitochondria following ligation of CD3 with anti-CD3 antibody (Figure 5.8 D).  









Figure 5.8: Antimycin A and rotenone significantly increase mitochondrial O2
- 
levels independent of ATP. Freshly isolated naïve CD4+ T lymphocytes were 
loaded with MitoSOX Red as described, pre-treated with vehicle (DMSO), rotenone 
or antimycin A for 30 minutes then vehicle or 3 mM ATP for 1 hour. MitoSOX Red 
Fluorescence was measured using Flow cytometry. A. Example flow cytometry 
histograms. B. Cells were treated with DMSO or rotenone and then vehicle or 3 mM 
ATP for 1 hour (n=3). C. Cells were treated with DMSO or antimycin A and then 
vehicle or 3 mM ATP for 1 hour (n=3). D. Effect of UCHT1 and PMA on 
mitochondrial O2
- levels (n=3). One Way or Two Way ANOVA followed by Tukey’s 
post-test used to determine significance #/^p<0.05, ***/###p<0.001 




5.1.11. Effect of SOD mimetic Mn-cpx 3 on ROS generation and 
CD62L down-regulation 
In cells O2
- can be converted into H2O2 by the enzyme superoxide dismutase 
(SOD). SOD is just one component of a complex antioxidant system within cells 
that reduces damage to cellular components by ROS, or terminates ROS 
mediated signalling. H2O2 can be rapidly converted to H2O by catalase and its 
reactivity with intracellular proteins such as ADAM17 is lost. The ability of H2O2 to 
induce CD62L down-regulation has been reported before and was confirmed for 
naïve CD4+ T lymphocytes in this study (421) (Figure 5.4 A). Therefore, it is 
possible that mitochondrial O2
- produced by rotenone and antimycin A is 
converted to H2O2 by SOD, and this is the ROS required for enhanced CD62L 
down-regulation by ATP. To investigate this, a cell permeable mimetic of SOD, 
Mn-cpx 3, was employed. The rational was that if O2
- was required for enhanced 
CD62L loss, Mn-cpx 3 would inhibit CD62L down-regulation, whereas if H2O2 was 
required then Mn-cpx 3 would enhance CD62L down-regulation. 
Mn-cpx 3 was first tested for its ability to enhance H2O2 production in naïve CD4
+ 
T lymphocytes. Indeed, while 30 minute pre-incubation with 30 μM Mn-cpx 3 had 
no effect on the basal rate of DCF fluorescence increase over 1 hour, it markedly 
enhanced DCF fluorescence when 3 mM ATP was applied (Figure 5.9 A and B). 
When cells were pre-treated with both Mn-cpx 3 and rotenone or antimycin A there 
did not appear to be an increase in DCF fluorescence compared to Mn-cpx 3 plus 
DMSO. This indicated that mitochondrial O2
- generated by rotenone and antimycin 
A does not lead to enhanced cellular ROS detected by DCF. Mn-cpx 3 had no 
effect on basal CD62L expression levels, it did not enhance CD62L down-
regulation induced by ATP alone, and unexpectedly had no effect on the 
















Figure 5.9: A SOD mimetic Mn-cpx 3 increases ATP induced DCF 
fluorescence, but has no effect on ATP or ATP + antimycin A induced CD62L 
down-regulation. Freshly isolated naïve CD4+ T lymphocytes were loaded with 
DCF and pre-treated with vehicle (DMSO) or 30 μM Mn-cpx 3 for 30 minutes. DCF 
fluorescence was measured as described and vehicle or 3 mM ATP applied for 1 
hour. A. Example kinetic of DCF fluorescence over 1 hour. B. Cells were pre-
treated with DMSO or 30 μM Mn-cpx +/- DMSO, 5 μM rotenone or 1 μM antimycin 
A for 30 minutes then vehicle or 3 mM ATP applied for 1 hour  (n=2 ± STDEV). C. 
Cells were pre-treated with DMSO or 30 μM Mn-cpx +/- increasing concentrations 
of antimycin A for 30 minutes, followed by 3 mM ATP for 1 hour and CD62L 
expression was measured using flow cytometry as described (n=3). Two Way 
ANOVA followed by post-test were used to determine significance. 




5.1.12. Comparison of effects of antimycin A and rotenone 
between naive CD4+ and SEB activated T lymphocytes 
 
Naive CD4+ T lymphocytes and effector Th cells demonstrate differential 
sensitivity to ROS such as H2O2 (456), therefore it was hypothesised that the 
ability of antimycin A and rotenone to enhance loss of cell surface CD62L 
expression through P2X7R may differ between these cell types. 
Naïve CD4+ T lymphocytes were isolated, and T lymphocytes from the same 
donor activated ex vivo from PBMCs using SEB. Cells were used on the day of 
isolation (naïve CD4+) or 7 days post activation (SEB T cells) and experiment 
paired for each donor. SEB activated T cells show higher basal MitoSOX red 
fluorescence than naïve CD4+ T lymphocytes (Figure 5.10 A). As shown in Figure 
5.8, 1 μM antimycin A and 5 μM rotenone significantly enhance mitochondrial O2
- 
generation. SEB activated T lymphocytes are significantly less sensitive to 
enhanced mitochondrial O2
- generation in response to antimycin A, when 
compared to naïve CD4+ T lymphocytes (Figure 5.10 B).  However, this effect was 
not observed for rotenone pre-treatment. 
When naïve CD4+ T lymphocytes are activated they down-regulate CD62L, 
however central memory T lymphocytes re-express high levels of CD62L, this 
allows migration into the lymphatic system. Therefore, SEB activated T 
lymphocytes have biphasic CD62L expression but still respond to ATP by down-
regulating CD62L expression in a P2X7R dependent manner, with an EC50 value 
of 804.2 μM (Figure 5.10 C and D).  
When naïve CD4+ T lymphocytes are compared to SEB activated T lymphocytes 
from the same donors, there is a small difference between the effect of antimycin 
A and rotenone on ATP induced CD62L down-regulation, but this was statistically 
insignificant (Figure 5.10 E and F). 
 
 












Figure 5.10: Comparison of effects of antimycin A and rotenone on 
mitochondrial superoxide generation and CD62L expression between naïve 
CD4+ and SEB activated T lymphocytes. Freshly isolated naïve CD4+ T or SEB T 
lymphocytes (Day 9 post activation) were loaded with MitoSOX Red as described. 
MitoSOX Red Fluorescence was measured using Flow cytometry. A. Histograms 
representing basal MitoSOX Red Fluorescence B. Cells were treated with vehicle 
(DMSO), rotenone or antimycin A for 90 minutes (n=3). C and D. T lymphocytes 
were activated ex vivo by SEB and removed from culture 9 days post activation. 
Cells were treated with increasing concentrations of ATP and cell surface CD62L 
expression measured as described (n=3). E. Cells were pre-treated with increasing 
concentrations of rotenone for 30 minutes before 1 hour 3 mM ATP treatment. 
CD62L expression was measured by flow cytometry as described (n=3). F. Cells 
were pre-treated with increasing concentrations of antimycin A for 30 minutes 
before 1 hour 3 mM ATP treatment (n=3). CD62L expression was measured by flow 
cytometry as described. Two Way ANOVA followed by post-test was used to 
determine significance between groups *p<0.05 




5.1.13. Effect of rotenone and antimycin A on naïve CD4+ T 
lymphocyte proliferation 
Having demonstrated enhancement of ATP induced CD62L down-regulation by 
rotenone and antimycin A, other T lymphocyte processes were investigated for 
sensitivity to these compounds. If, like with CD62L expression, these compounds 
alone have no effect they may still enhance ATP responses through P2X7R. 
Although in chapter 3 inhibition of P2X7R by A438079 was shown to have no 
effect on proliferation, it was hypothesised that rotenone and antimycin A could 
potentially increase sensitivity of P2X7R to ATP and reveal a role for the receptor 
in proliferation. In a CFSE assay of proliferation, both rotenone and antimycin A 
significantly inhibited proliferation of naïve CD4+ T lymphocytes after 7 days ex 
vivo culture (Figure 5.12 A-C). As this effect occurred in the absence of ATP, the 
role of mitochondrial uncoupling and P2X7R in proliferation was not explored 
further. 











Figure 5.11: Antimycin A and rotenone significantly inhibit proliferation of 
human T lymphocytes. Freshly isolated naïve CD4+ T lymphocytes were labelled 
with CFSE as described. Cells were analysed on the same day (Day 0) or pre-
treated with vehicle (DMSO), 5 μM rotenone or 1 μM antimycin A for 30 minutes 
followed by addition of anti-CD3/ CD28 antibody coated beads to cells at a ratio of 
3:1. IL2 was added at a final concentration of 36 Units/ml and cells cultured for 7 
days before analysis for CFSE fluorescence. A. Representative flow cytometry 
histograms displaying population divisions 0-6. B. Comparison of the effect of 
rotenone and antimycin A on percentage of cells in each division (n=3). C. 
Statistical analysis of percentage of cells in final division 6 (minimum CFSE 
fluorescence) (n=3). Two Way ANOVA followed by post-test used to determine 
significance ***p<0.001 




5.1.14. Effect of rotenone and antimycin A on naïve CD4+ T 
lymphocyte migration 
Purinergic receptors, particularly P1 adenosine and P2Y receptors have been 
studied for their role in cell migration, however little work on the role of P2X7R has 
been undertaken to date. Here the P2X7R antagonist A438079 suggested a small 
but insignificant inhibitory effect on migration of naïve CD4+ T lymphocytes 
towards the chemokine CXCL12 (Figure 5.12 A). Using the Neuroprobe Boyden 
Chamber-like assay, migration of T lymphocytes activated by SEB appears to be 
unaffected by A438079 pre-treatment (Figure 5.12 B). However, a more detailed 
analysis of migration during live cell imaging using IBIDI µslides suggests that 1 
µM A438079 may enhance basal motility while decreasing directed migration of 
SEB activated T lymphocytes (Figure 5.12 C). Indeed, basal velocity, accumulated 
and euclidean distance were all increased following 1 µM A438079 treatment; 
whereas, these parameters were all reduced compared to vehicle treated control 
cells when a CXCL-11 gradient was present. Migration of naïve CD4+ T 
lymphocytes towards CXCL12 or basally (without chemokine) was therefore 
investigated with rotenone and antimycin A. As with proliferation both compounds 
caused a marked decrease in migration in the absence of ATP (Figure 5.13). 
Therefore, the combined effect of ATP and rotenone or antimycin A was not 














Figure 5.12: Effect of P2X7R inhibition on naive CD4+ and SEB activated 
human T lymphocyte migration. A. Naïve CD4+ T lymphocytes were freshly 
isolated and pre-treated with vehicle or 1 µM A438079 for 30 minutes. The in vitro 
basal migration of cells and migration towards the chemokine CXCL-12 was then 
assessed by a Neuroprobe assay (n=3). B and C. T lymphocytes activated ex vivo 
by SEB were removed from culture after 9 days, and pre-treated with vehicle or 
0.01 – 10 µM A438079 (B) or 1 µM A438079 (C) for 30 minutes. The in vitro basal 
migration of cells and migration towards the chemokine CXCL-11 was then 
assessed by a Neuroprobe assay (n=3). C and D. IBIDI µslides were briefly used to 
assess in vitro basal migration or migration towards CXCL-11 (n=1). 
















Figure 5.13: Antimycin A and rotenone reduce migration of naive CD4+ human 
T lymphocytes. Freshly isolated naïve CD4+ T lymphocytes were pre-treated with 
DMSO or increasing concentrations of rotenone or antimycin A. Cells were then 
assessed for their ability to migrate independent of chemokine (Basal) or towards 
the chemokine CXCL-12 using the previously described Neuroprobe migration 
assay. A. Effect of antimycin A on basal migration (n=3) B. Effect of antimycin A on 
CXCL-12 directed migration (n=3). C. Effect of rotenone on basal migration (n=3). 
D. Effect of rotenone on CXCL-12 directed migration (n=3). One Way ANOVA 
followed by Tukey’s post-test used to determine significance *p<0.05 




5.1.15. Effect of rotenone and antimycin A on naïve CD4+ T 
lymphocyte apoptosis 
Next the effect of rotenone and antimycin A on apoptosis was investigated; neither 
compound alone had significant effect on PS translocation or PI uptake. 
Treatment with 3 mM ATP for 1 hour had no effect on annexin V binding, however 
when cells were pre-treated with rotenone or antimycin A significant annexin V 
binding was revealed (Figure 5.14 A). Staining for PI was very weak, however the 
percentage of cells staining positive for PS translocation and for PI uptake 
following ATP treatment was significantly enhanced by pre-treatment with 
rotenone and antimycin A (Figure 5.14 B). Despite ATP alone having no effect, PS 
translocation observed with rotenone and antimycin A in combination with ATP 











Figure 5.14: Antimycin A and rotenone enhance PS exposure and PI uptake in 
naïve CD4+ T lymphocytes. Naïve CD4+ T lymphocytes were freshly isolated from 
peripheral human blood and re-suspended in complete RMPI-1640. Cells were pre-
treated with vehicle (DMSO), 5 µM rotenone or 1 µM antimycin A and/or 10 µM 
A438079 for 30 minutes then treated with 3 mM ATP for 1 hour. Cells were stained 
with annexin V and PI as described in materials and methods. A. The percentage of 
cells positive for annexin V is given for each treatment condition (n=3). B. The 
percentage of cell positive for both annexin V and PI is given for each treatment 
condition (n=3). Two way ANOVA followed by post hoc test was used to determine 
significance between groups **p<0.01, ***p<0.001. 




5.1.16. Results Section 5 Summary 
 T lymphocyte activation by anti-CD3 antibody or PMA cause small 
insignificant increases in ROS generation in naïve CD4+ T lymphocytes 
 ATP causes significant increases in ROS in naïve CD4+, SEB activated T 
lymphocytes and the leukemic T cell line Jurkat independent of extracellular 
CaCl2 or MgCl2 
 The P2X7R inhibitor A438079 did not inhibit ROS generation 
 The source of ROS was not determined 
 ROS machinery inhibitors do not affect basal CD62L levels 
 DPI, rotenone and antimycin A, but not apocynin, significantly enhance ATP 
induced CD62L down-regulation suggesting mitochondrial ROS 
involvement 
 This increase was P2X7R dependent, and rotenone and antimycin A 
enhance ATP sensitivity 
 Rotenone and antimycin A treatment enhance mitochondrial O2
- levels 
independent of ATP 
 It is unclear whether conversion of O2
- to H2O2 is required 
 Exposure of PS is also be enhanced by rotenone and antimycin A, through 




















Figure 5.15: Effect of uncouplers of complex I and III of the mitochondrial 
electron transport on ATP induced loss of cell surface CD62L expression. 1. 
ATP induces loss of cell surface CD62L expression through P2X7R. 2. Rotenone 
and Antimycin A are uncouplers of complex I and complex III of the mitochondrial 
electron transport chain respectively. 3. Rotenone and Antimycin A significantly 
increase mitochondrial superoxide levels. 4. Pre-treatment with these compounds 
or DPI, an inhibitor of flavin containing enzymes such as complex I, but not 
Apocynin (5), an NADPH oxidase inhibitor, significantly enhance ATP induced 
CD62L down-regulation. 6. Pre-treatment with Rotenone or Antimycin A reveals 
P2X7R dependent externalisation of Phosphatidyl serine. 




5.2. Results Chapter 5 Discussion 
5.2.1. Modulation of mitochondrial ROS enhances P2X7R function 
Several lines of evidence led to the formation of a hypothesis that ROS were 
involved in the mechanism responsible for CD62L down-regulation through 
P2X7R. Firstly, LY294002 enhanced CD62L down-regulation in response to anti-
CD3/CD28 antibody coated beads. This observation may be explained by the 
ability of this PI3K inhibitor to cause increased H2O2 production (59). H2O2 is a 
known activator of ADAM17 and leads to enhanced ADAM17 substrate cleavage 
(421), CD62L loss in response to H2O2 was confirmed by data presented in this 
thesis. Secondly, the PKC inhibitor Rottlerin enhanced down-regulation of cell 
surface CD62L induced by ATP. Rottlerin has been shown to increase O2 
consumption by mitochondria in a PKC independent manner, suggesting it is a 
mitochondrial uncoupling agent (418). 
ROS generation is an important part of T lymphocyte activation and differentiation 
(294, 457, 458), however in this study significant cytosolic or mitochondrial ROS 
could not be detected in response to anti-CD3 antibody or PMA (450, 459). ATP 
induced significant generation of cytosolic ROS; however the source of this ROS 
was not confirmed here. Unexpectedly, A438079 did not inhibit ATP induced ROS 
generation; as ATP induced CD62L was inhibited by A438079, ROS was therefore 
unlikely to be the mechanism connecting ATP to down-regulation of cell surface 
CD62L.  
Nevertheless, the involvement of ROS in ATP induced down-regulation of cell 
surface CD62L was explored using inhibitors of ROS generating proteins. 
Unexpectedly, DPI caused an enhancement of ATP induced loss of cell surface 
CD62L expression independently of NADPH oxidase. Inhibitors of the 
mitochondrial electron transport chain complex I and III, rotenone and antimycin A 
also enhanced ATP induced CD62L processing. This observation is in contrast to 
the effect of these compounds on P2Y2 mediated TGF-α shedding (422). A 
decrease in the ATP EC50 indicates that these compounds enhance the potency 
for ATP in the process of CD62L down-regulation; although the threshold 
concentration of 1mM remained unaltered. The fact that the threshold did not 




change suggests that P2X receptors other than P2X7 were not involved in this 
effect. 
Increased mitochondrial O2
- generation was recently observed in the acute 
monocytic leukaemia cell line THP-1 following treatment with rotenone and 
antimycin A (160). This study by Zhou et al. also employed MitoSOX Red to 
measure O2
- levels; however, higher concentrations of rotenone and antimycin A 
were used than those presented in this thesis (10 and 73 µM respectively (160), 
compared to 5 and 1 µM here). Rotenone and antimycin A also promoted IL-1β 
processing in THP-1 cells through activation of caspase 1 by the NLRP3 
inflammasome (160). 
In this thesis, it was also investigated if mitochondrial uncoupling by rotenone and 
antimycin A would influence the ability of ATP, through P2X7R, to bring about 
cellular changes other than CD62L processing. However, it was observed that 
rotenone significantly inhibited basal and CXCL-12 directed migration of naïve 
CD4+ T lymphocytes. The polarisation of mitochondria to the uropod of cells is 
critical for migration; therefore, Rotenone and antimycin A would indeed be 
expected to inhibit T lymphocyte migration (460). Both rotenone and antimycin A 
significantly inhibited proliferation of naïve CD4+ T lymphocytes activated with anti-
CD3/CD28 antibody coated beads and IL-2. This is in agreement with the 
inhibition of CD8+ T lymphocyte proliferation by rotenone (461). In this study by Yi 
et al. 0.01 – 5 µM rotenone cause significant inhibition of proliferation in response 
to plate bound anti-CD3 and anti-CD28 antibodies (461).  
Un-expectedly, rotenone and antimycin A did not significantly enhance apoptosis 
of naïve CD4+ T lymphocytes, despite causing production of significant amounts of 
O2
- over the same time period. Rotenone has been shown to cause apoptosis of a 
breast cancer cell line through enhanced ROS generation and activation of the 
stress kinases JNK and p38 MAPK (164). In another study, treatment of the 
leukemic T cell line Jurkat with antimycin A alone was insufficient to induce 
apoptosis (462), however, combination of antimycin A with the adenine nucleotide 
translocator (ANT) inhibitor bongkrekic acid (BA) did cause significant apoptosis of 
cells. It is important to note that the concentration used in the study by Wang et al. 
was lower than in this thesis, 0.02 compared to 1 µM. 





- as a modulator of P2XRs 
Uncoupling of mitochondrial electron transport can lead to the increased leakage 
of mitochondrial ROS such as O2
-, indeed increased mitochondrial O2
- generation 
for Rotenone and antimycin A treated naïve CD4+ T lymphocytes was observed. 
Increased mitochondrial O2
- generation may therefore represent a novel 
mechanism of P2X7R modulation. The conversion of O2
- to H2O2 by SOD does not 
appear to be responsible, as Mn-cpx 3 had no effect on CD62L down-regulation.  
P2X receptors can be modulated by a number of cellular mechanisms including 
direct post translational modifications such as phosphorylation, or by interaction 
with second messengers such as lipids including PIP2 (463–465). ROS can 
promote lipid raft formation in T lymphocytes (449) and a number of P2XRs 
including P2X7R have been reported to associate in lipid rafts (383, 466–469). 
Association of P2X7R with lipid rafts is mediated by palmitoylation: the covalent 
attachment of palmitate (a 16-carbon fatty acid) to cysteine residues (383). 
However, it is unlikely that rotenone and antimycin A treatment enhances 
palmitoylation of P2X7 as data suggest that palmitoylation is in fact inhibited by 
ROS (470, 471).  
ROS have been implicated in direct modulation of ion channels including P2X2R 
(454, 455). Interestingly both of these studies demonstrated that inhibition of 
Complex I or III by rotenone and antimycin A/Myxothiazol could enhance P2X2R 
activation, which agrees with data presented in this thesis for the first time in 
P2X7R. One study suggests that the Cys430 residue is responsible for this and 
the effect can be mimicked by exogenous application of H2O2. P2X2R has the 
second largest C-terminal region of P2XRs; P2X7R has the largest P2X C-
terminus and this contains a number of cysteine residues which could act to 
potentiate receptor activation in a similar manner (173).  
Here, SEB activated T lymphocytes did not produce significant mitochondrial O2
- 
in response to rotenone and antimycin A treatment. It has been reported that 
channels expressed by activated T lymphocytes are less sensitive to modulation 
by ROS (456). Taken together these observations could explain why ATP 
mediated CD62L down-regulation from the surface of SEB activated T 
lymphocytes is not enhanced by rotenone or antimycin A. 




























This thesis began by confirming expression of P2X7R in human T lymphocytes 
and leukemic cell lines using immunoblotting and voltage clamp electrophysiology. 
This was followed by a detailed analysis of its function in human naïve CD4+ T 
lymphocytes. This project aimed to explore whether PI3K signalling was 
responsible for integrating P2X7R activation with T lymphocyte function.  
ATP was shown to couple to uptake of the dye ethidium bromide, although this 
process was insensitive to inhibition by the P2X7R antagonist A438079. However, 
pore formation did not result in subsequent death of these cells by apoptosis or 
necrosis. P2X7R was shown to be dispensable for the proliferation of these cells 
following activation by anti-CD3/CD28 antibody coated beads. This two-signal 
system of T lymphocyte activation was used initially to set up an assay to explore 
regulation of cell surface expression of CD62L by ATP. Unlike in mouse CD4+ T 
lymphocytes, CD62L down-regulation from the surface of human CD4+ T 
lymphocytes was insensitive to inhibitors of the PI3K/mTOR and Erk1/2 signalling 
pathways.  
Interestingly, while naïve CD4+ T lymphocytes down-regulated cell surface CD62L 
in response to PMA and ATP, the leukemic T cell line Jurkat was un-responsive to 
ATP. The pharmacology of ATP induced surface CD62L down-regulation was 
explored in naïve CD4+ T lymphocytes and was shown to require P2X7R. Again, 
inhibitors of PI3K/mTOR and Erk1/2 pathways could not prevent this down-
regulation, PKC and p38 MAPK inhibition were also ineffectual. While investigating 
ROS as a component of ATP induced CD62L down-regulation, a novel 
mechanism whereby uncoupling of complex I or III of the mitochondrial electron 
transport chain caused enhanced CD62L down-regulation through P2X7R was 
discovered. This uncoupling also revealed P2X7R dependent PS translocation, 
which was absent in cells where mitochondrial function was not altered.  
Although specific results have already been discussed in previous sections, a 
more detailed discussion of the implications of these findings will now follow. This 
will focus on the role of P2X7R and mitochondrial ROS in disease, present a 
model for a novel protective P2X7R mechanism and conclude by highlighting 
questions raised by the data and discussion in this thesis. 




6.2. P2X7R and mitochondrial ROS in disease 
Increased reactive oxygen and nitrogen species, including O2
-, generation and 
mutated mtDNA or damaged mitochondrial electron chain components are 
implicated in the pathology of a number autoimmune of diseases including SLE, 
RA, MS and ALS. 
In RA hypoxic synovial tissue undergoes mtDNA damage, which is reversible by 
the antioxidant SOD. Although SOD levels are significantly higher in PBMCs of RA 
patients, the overall trapping antioxidant capacity (TRAP) was lower in these cells 
(472). The lymphocytes of RA patients also produce increased ROS and this could 
potentially affect P2X7R activity (473); indeed P2X7R is implicated in RA (411, 
474). SLE is associated with mitochondrial hyperpolarisation, enhanced ROS 
generation (475, 476) and increased soluble CD62L (477), in addition mtDNA is 
associated with SLE (478). As in RA, the activity of antioxidant enzymes including 
SOD are significantly lower in patients with SLE (479).  
Mutation of SOD1 can cause amyotrophic lateral sclerosis (ALS), a paralysing 
disease involving degeneration of the motor neurones (480). In mice this disease 
can be modelled by introducing a G93A mutation into mSOD1 and the pathology 
of the disease involves the mitochondrial permeability transition pore (mPTP). The 
majority of the pathology of this disease is driven by damage to motor neurones, 
however T lymphocytes play an important role in endogenous neuro-protection 
and numbers of CD4+ T lymphocytes from the blood of patients with ALS are 
increased (481, 482). Increased numbers of NKT cells are found in the spinal 
cord, spleen and liver in G93AmSOD1 mice compared to WT mice (483). 
Interestingly the levels of all T cells in the spleen compared to WT were 
significantly increased in G93AmSOD1 compared to WT mice. This suggests that 
there are T lymphocyte circulation defects in G93AmSOD1 mice. Re-introduction 
of wild type SOD1 may be a route of therapeutic intervention in ALS (484).  
Mutations in SOD would be expected to cause increased O2
- levels and data from 
this thesis suggest that this would potentially make naïve CD4+ T lymphocytes 
more susceptible to ATP. Indeed, P2X7R has been implicated in ALS and 
extracellular ATP in released by lesions in ALS (351, 485). P2X7R in ALS may 
lead to enhanced CD62L down-regulation, causing the retention of cells in the 




spleen as seen in the CD62L-/- mouse (483). However, fewer T lymphocytes are 
observed in the spleen of older mice, this may be due to enhanced ability of CD4+ 
cells to undergo apoptosis (486). Apoptosis of these cells would prevent them 
protecting against ALS and potentially exacerbate the condition. The observation 
from this thesis that modulation of the mitochondrial electron transport reveals 
P2X7R dependent PS exposure, could potentially explain enhanced apoptosis of 
these naïve CD4+ T lymphocytes. 
EAE is a mouse model of MS and P2X7R expression was increased after EAE 
induction in brain homogonies (350). Indeed, a study showed that mice lacking 
P2X7R developed an increased incidence and greater severity of EAE when 
immunised with MOG35-55 peptide (348). This second study by Chen et al. 
observed that following induction of EAE in P2X7R-/- mice there was a marked 
reduction in the ability of lymphocytes to undergo apoptosis. Indeed, increased 
number of CD3+ cells were observed in the CNS of P2X7R-/- mice. In EAE, antigen 
induced cell death (AICD) is important for recovery from the acute phase of the 
disease. P2X7R induced cell death may also be important for protecting from EAE 
and the loss of this protective mechanism in the P2X7R-/- mouse may account for 
the increased disease incidence and/or severity.  
However a second study reported that P2X7R deficiency was in fact associated 
with decreased disease incidence and clinical score in mice lacking P2X7R in a 
MOG35-55 peptide model of MS (349). The discrepancies in these studies could be 
explained by the fact that this second study by Sharp et al. (349) used P2X7-/- 
mice provided by GSK, whereas, Chen et al. used P2X7R-/- mice provided by 
Pfizer (348). As mentioned in section 1.10, GSK P2X7R-/- mice contain a 
functional splice variant with an alternative TMD1 that escapes inactivation and in 
fact leads to hyper responsive T lymphocytes (365, 366). While Pfizer mice do 
express splice variants with the truncated exon 13 as well as a novel hybrid 
isoform, these were shown to be non-functional (367). If cell death through P2X7R 
is indeed and important protective mechanism for the resolution of EAE, then 
hyper-responsive T lymphocytes from GSK P2X7-/- mice would be expected to 
undergo enhanced apoptosis and could explain the reduced indicdence and 
clinical score observed by Sharp et al (349). 




Taken together, these studies suggest that P2X7R induced cell death involving 
the externalisation of PS (measured by annexin V binding by Chen et al. (348)) 
may act as a protective mechanism against EAE. Recently, increased survival of 
naïve CD4+ T lymphocytes has been demonstrated in EAE/MS, this could 
potentially occur through an absence of P2X7R induced apoptosis of cells due to 
expression of SNPs or non-functional P2X7R splice variants (487, 488). 
 
6.3. ATP and PS as “find me” and “eat me” signals  
ATP was chosen as the agonist for P2X7R activation in this study because it is the 
endogenous P2X7R ligand and no selective P2X7R agonists exist; while BzATP is 
more potent than ATP at P2X7R it also activates other P2XRs. It is important 
when analysing the results of experiments involving ATP as an agonist, to 
consider the source and stability of ATP in the environment around the cell. 
Possible sources of ATP include: autocrine/pancrine release and release from 
cells undergoing necrosis. Autocrine release occurs through Pannexin-1 
hemichannels, is involved in activation of P2X7R during T lymphocyte activation 
and can also activate P2YRs (261, 268). While necrosis would result in the un-
restrained release of cellular contents including ATP into the extracellular 
environment, cells undergoing apoptosis release ATP through Pannexin-1 
hemichannels (280, 489, 490). Purines can act as chemoattractant for 
phagocytes, therefore ATP release from apoptotic cells may enhance their own 
phagocytic clearance (318, 320, 325, 326, 491). Other soluble pro- and anti-
inflammatory factors can also influence the phagocytosis of apoptotic cells, such 
as LPS, TNF-α and IFN-γ (492, 493). 
Once phagocytes encounter apoptotic cells they require specific signals to 
recognise, engage and eventually opsonise these cells. These “Eat me” signals 
are an established concept and involve a wide variety of molecules expressed on 
the surface of cells undergoing apoptosis, including PS. PS is normally confined to 
the inner leaflet of the plasma membrane, however apoptotic cells rapidly 
externalise PS altering membrane A-symmetry (394, 494, 495). Indeed, PS 
expressed by lymphocytes undergoing apoptosis is required for their phagocytosis 




by macrophages (496). Phagocytes express receptors for PS, for example the 
receptor TIM4 is expressed by macrophages and administration of antibodies 
against this receptor block phagocytosis in vivo (497).  
Previous studies have shown that treatment of a number of cell types including: 
mouse thymocytes and mature T lymphocytes with ATP, causes externalisation of 
PS to the cell surface. However, data in this thesis suggest that ATP alone is not 
sufficient to cause significant PS exposure in human naïve CD4+ T lymphocytes. 
Interestingly, it was revealed that cells could be primed using rotenone or 
antimycin A pre-treatment to significantly externalise PS through P2X7R. This may 
present a novel P2X7R dependent mechanism for the increased phagocytosis of 
cells with damaged mitochondria. Although this study used pharmacological 
uncoupling of mitochondrial electron transport, damaged mitochondria also display 
enhanced ROS generation and can promote inflammation (Section 6.2). Removal 
of cells with damaged mitochondria would be desirable to prevent un-restrained 
inflammation. Individuals with reduced P2X7R function, through SNPs or 
expression of inactive and inactivating splice variants could potentially lack a novel 
mechanism of T lymphocyte clearance (Figure 6.1). This highlights the need for 
further research into the modulation of P2X7R by ROS and how this, coupled with 
the emergent role of P2X7R splice variants in human immune cells, may 





















Figure 6.1: Model of the potential role of enhanced P2X7R function in naïve 
CD4+ T lymphocytes. A. ATP induces CD62L down-regulation from the surface of 
naïve CD4+ T lymphocytes in an MMP dependent manner. Upon damage to 
mitochondria, this CD62L down-regulation may be enhanced and PS exposure 
through P2X7R revealed (shown here by uncoupling of mitochondrial electron 
transport). sCD62L in the supernatant may have potential biological function, 
including blocking TEM of cells. Exposed PS may act as a “find me” signal for 
phagocytes to opsonise naïve CD4+ T lymphocytes with damaged mitochondria. B. 
If expression of functional P2X7R is altered, for example by the expression of a 
non-functional P2X7R slice variant, then CD62L processing in response to ATP 
would be expected to be inhibited. When mitochondrial damage occurs PS 
exposure through P2X7R would not occur, cells would escape phagocytosis and 
potentially enhance inflammation. 





6.4. Summary and Future direction 
This thesis confirms P2X7R expression by leukemic cell lines, SEB activated T 
lymphocytes and human naïve CD4+ T lymphocytes. It also makes novel findings 
which expand our understanding about the role of P2X7R in T lymphocyte 
function. PI3K signalling, as well as the PKC, Erk1/2 and p38 MAPK pathways 
were not involved in ATP induced CD62L down-regulation. Additionally, a species 
difference between the signalling pathways involved in CD3 and CD3/CD28 
induced down-regulation of cell surface CD62L expression was revealed. Finally, 
uncoupling of mitochondrial electron transport positively regulates P2X7R induced 
CD62L down-regulation and reveals ATP induced PS exposure through P2X7R. 
Whilst the implication of this has been discussed in detail above, several questions 
are raised: 
 What is responsible for the differences between down-regulation of cell 
surface CD62L in mouse and human naïve CD4+ T lymphocytes? 
 What mechanism links P2X7R activation to MMP induced CD62L down-
regulation in the absence of mitochondrial perturbation? 
 In diseases which have a mitochondrial component, is enhanced P2X7R 
activity responsible for disease pathophysiology? 
 Are there other P2X7R dependent processes in naïve CD4+ T lymphocytes 
which are enhanced by uncoupling of mitochondrial electron transport? 
 Does the increased PS exposure on naïve CD4+ T lymphocytes result in 
enhanced phagocytosis? 
 Which P2X7R splice variants are expressed by naïve CD4+ T lymphocytes?  
 Does the expression of non-functional P2X7R splice variants inhibit ATP 
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8.1. Expression of cell surface markers on freshly isolated 
human naïve CD4+ T lymphocytes 
To confirm that high purity naïve CD4+ T lymphocytes were isolated from whole 
blood as described in material and methods 2.2.4, levels of the cell surface 
markers CD4, CD62L and CCR7 were measured. Cells isolated from three 
independent donors on three separate occasions showed high levels of cell 
surface CD4 (98.33 ± 0.38 %) and CD62L (98.5 ± 0.4 %) (Figure 8.1). Additionally 
when the adhesion molecule CD62L was analysed alongside the chemokine 
receptor CCR7, cells isolated from five donors showed 91.88 ± 2.87 % cells 





















Figure 8.1: Expression of CD4 and CD62L on the surface of freshly isolated  
human naïve CD4+ T lymphocytes. Naïve CD4+ T lymphcoytes were freshly 
isolated from human PBMC, as described in materials and methods. Cells were 
washed twice in ice cold PBS + 2% FCS and incubated for 1 hour with Isotype 
control (IgGκ1-FITC), CD62L-FITC or CD4-FITC Cell surface expression of 
molecules were measured using flow cytometry. A gate was set around 1% of the 
isotype control and the percentage of CD62L and CD4 positive cells are recorded 
along with example histograms for three independent donors. 








Figure 8.2: Expression of CD62L and CCR7 on the surface of freshly isolated  
human naïve CD4+ T lymphocytes. Naïve CD4+ T lymphcoytes were freshly 
isolated from human PBMC, as described in materials and methods. Cells were 
washed twice in ice cold PBS + 2% FCS and incubated for 1 hour with Isotype 
control (IgGκ1-FITC and IgG2a) or CD62L-FITC and CCR7-APC. Cell surface 
expression of molecules were measured using flow cytometry. A. A gate was set 
around 1% of the isotype control and the percentage of CD62L-CCR7-, 
CD62L+CCR7-, CD62L+CCR7+ and CD62L-CCR7+ positive cells are recorded. B. 
The percentage of cells (from three independent donors) in each quadratic are 
complied in a bar graph. 
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